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N-methyl-D-Aspartate receptors (NMDARs) play a key role in memory formation 
and learning, and modulate gamma-frequency oscillations (-: 30-80Hz). 
Gamma-oscillations are important in perception, cognition and memory 
formation. They are disrupted in patients with schizophrenia, in whom NMDAR 
hypofunction has been posited, and in animal models of schizophrenia. 
Furthermore, NMDAR antagonists reduce -oscillation power and frequency in 
vitro.  
NMDA receptor antibody (NMDAR-Ab) encephalitis recapitulates some of the 
features seen with blockade or ablation of NMDARs, including anterograde 
memory loss and psychiatric symptoms. 
We hypothesised that patients’ autoantibodies against NMDARs could disrupt 
neuronal network activity and that this may be responsible for the 
neuropsychiatric symptoms experienced by patients. We examined the effect of 
acute and subacute NMDAR-Ab exposure on -frequency oscillations in the 
medial entorhinal cortex (mEC), using an in vitro rat brain slice preparation. We 
also performed the first comparison of four different diagnostic assays used for 
the detection of NMDAR-Abs. 
We found that: 
1. Cell-based assay using live cells was 100% sensitive but poorly specific 
in the detection of NMDAR-Abs. Immunohistochemistry was 100% 
specific and also sensitive (85%). Two cell-based assays using fixed 
cells produced significant non-specific staining and had intermediate 
sensitivity and specificity values. 
2. Acute exposure to purified IgG from patients with NMDAR-Ab 
encephalitis reduced the power of -frequency oscillations in the mEC 
but not in the hippocampus. 
3. Immunoglobulin deposition was not found in the slices acutely exposed 
to patient or control IgG. 
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4. Subacute exposure to IgG by single intracerebral injection of either 
patient or control IgG did not alter mEC -oscillations ex vivo. No change 
in NMDAR-mediated responses was detected. 
5. IgG uptake into presumed neurons was detected in slices from these 
animals, but it was not possible to co-localise the IgG to either excitatory 
neurones or inhibitory interneurones with certainty.
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1.1 Antibody-mediated diseases of the central nervous system 
Some diseases of the peripheral nervous system are antibody-mediated, and 
this has been recognised for some time. The role of autoantibodies against 
acetylcholine receptors (AChR) in myasthenia gravis was established in the 
1970’s (reviewed in Vincent (2002)), and the experimental approaches used still 
define the paradigm used to determine the autoimmune basis of a disease. In 
the 1980’s and 90’s, pathogenic antibodies to voltage-gated calcium channels 
(VGCC) and voltage-gated potassium channels (VGKC) and their effects at the 
neuromuscular junction in Lambert-Eaton myasthenic syndrome and acquired 
neuromyotonia respectively were described, and similar approaches were used 
to demonstrate their pathogenicity. 
The association of cancer and central nervous system (CNS) syndromes such 
as encephalomyelitis, cerebellar degeneration or sensory neuronopathy, had 
been observed since the 1960s and it was clear that they were not related to 
the primary tumour itself or to its metastases but rather to an as yet unexplained 
immune response (reviewed in Voltz (2002); and Dalmau and Rosenfeld 
(2008)). In 1985, Posner and colleagues (Graus et al., 1985) defined the first 
paraneoplastic antibody, named anti-Hu, directed against a neuronal nuclear 
antigen. Since then many more paraneoplastic antibodies have been described. 
Most are directed against intracellular nuclear targets that are ectopically 
expressed by the patients’ tumour. Several lines of evidence, including the 
intracellular location of the antigen, the failure of passive transfer or active 
immunisation experiments, and the lack of efficacy of treatments that reduce 
circulating antibody concentration, counter a pathogenic role for these 
antibodies. Instead, these antibodies are useful diagnostic markers for 
paraneoplastic disorders that are felt to be T-cell-mediated (see Dalmau and 
Rosenfeld (2008) for review). Paraneoplastic limbic encephalitis has been 
linked in particular with lung cancer (usually small cell lung carcinoma), 
testicular cancer and breast cancer. The usual paraneoplastic antibodies found 
in such patients are anti-Hu (mainly lung cancer), anti-Ma/Ta (mainly in 
testicular cancer patients), ANNA-3 and CRMP-5 (Voltz, 2002). 
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The recognition of antibody-mediated CNS diseases lagged behind, however, 
and such disorders were felt to be less common partly because of the immune 
privilege accorded to the CNS by the blood-brain-barrier (BBB). Up to the 
beginning of the 21st century subacute non-viral limbic encephalitis (LE) was 
thought to represent a paraneoplastic syndrome with poor prognosis. However, 
by then, it was becoming clear that there were cases of non-infectious immune-
mediated limbic encephalitis not associated with neoplasms. Bien et al. (2000) 
published a series of four patients with intractable temporal lobe seizures, 
cognitive and memory deficits, and psychiatric symptoms. They all had changes 
in one or both medial temporal lobe on MRI as well as lymphocytic infiltrates 
and astrogliosis on brain biopsy histology. They were hence clinically 
indistinguishable from paraneoplastic LE. However, they did not have 
paraneoplastic antibodies and repeated detailed tumour searches were 
negative. Also, all four improved significantly with immunomodulatory treatment 
with steroids and/or intravenous immunoglobulin, leading the authors to 
speculate that a primary or secondary autoimmune mechanism may have 
caused this non-paraneoplastic LE. The symptoms of LE are summarised in 
Table 1.1. 
Simultaneously, Vincent’s team in Oxford in collaboration with neurologists in 
Bologna asked whether VGKC antibodies were present in Morvan’s syndrome 
(Liguori et al., 2001). This is a condition characterized by peripheral nerve 
hyperexcitability and consequent neuromyotonia, but also associated with CNS 
features such as insomnia, hallucinations, confusion and memory loss. As in 
isolated acquired neuromyotonia, antibodies to voltage-gated potassium 
channels (VGKC-Abs) are present in some patients with Morvan’s syndrome 
and are thought to be pathogenic (Liguori et al., 2001; Irani et al., 2012). 
Following the success of plasma exchange in the first patient, and some 
similarities between symptoms of Morvan’s syndrome and LE, they examined 
whether VGKC antibodies were also present in LE, identifying two patients with 
high serum VGKC Ab titres. In both cases, improvement in LE symptoms 
correlated with a decrease in VGKC Ab titre, which resulted from treatment with 
plasmapheresis in the first patient and occurred spontaneously in the second 
patient (Buckley et al., 2001). 
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Shortly thereafter, the same group published a case series of fifteen patients 
with LE (Pozo-Rosich et al., 2003). Of these, 4 had VGKC Abs, 8 had either 
anti-Hu or anti-Ma Abs and three had no detectable antibody. Of the 4 patients 
with VGKC Abs, two had tumours (both lung) and two did not. All the other 
patients in that study had cancer. Again, the authors found that symptomatology 
as well as MRI appearances were more likely to improve after 
immunomodulating treatment if the patient harboured VGKC Ab, particularly in 
the two patients with non-paraneoplastic LE. 
Unlike intracellularly directed onconeuronal antibodies such as anti-Hu or anti-
Ma/Ta, the pathogenic potential of VGKC Abs, which were at that time thought 
to target the VGKC itself, expressed on the cell membrane of neurons, was 
easier to envisage. Furthermore the reduction in VGKC Ab titre achieved by 
steroids, plasmapheresis and intravenous immunoglobulin treatments with 
concurrent improvement in all symptoms of LE suggested a direct role for this 
autoantibody in the causation of symptoms. 
Two further case series confirmed the treatment-responsiveness of VGKC-Ab 
LE (Thieben et al., 2004; Vincent et al., 2004). In Vincent’s (2004) series, the 
ten cases were non-paraneoplastic. Again, there was improvement in 
neuropsychological function in line with reductions in Ab titre following 
treatment. 
More recently, it has become clear that most VGKC-Abs are in fact directed 
against proteins that complex with VGKC in situ, most commonly Leucine-rich 
glioma inactivated 1 (LGI1) and contactin-associated protein 2 (CASPR2) (Irani 
et al., 2010a). LGI1 antibodies are found predominantly in patients with LE, 
whilst CASPR2 and Contactin-2 antibodies prevail in neuromyotonia and 
Morvan’s syndrome, although there is some overlap (Irani et al., 2010a). 
Subsequently, a number of different antibodies directed against cell-surface 
antigens have been reported in patients with autoimmune forms of encephalitis, 
including antibodies against the N-methyl-D-aspartate receptor (NMDAR), the 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPAR), the 
-aminobutyric acid B and A receptors (GABABR, GABAAR), and glycine 
receptors. Tumours are found in some of these patients, but much less 
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frequently than in the classical onconeural paraneoplastic antibodies and the 
proportions vary for each antibody (Leypoldt et al., 2015). 
1.2 Pathogenic mechanisms in autoantibody-mediated 
diseases 
Antibodies, or secreted immunoglobulins (Igs), are produced by plasma cells, B-
lymphocytes that have to be activated by exposure to a specific antigen within a 
pro-inflammatory milieu. They are Y-shaped structures that consist of two 
identical polypeptide heavy chains (named , , , , and  in mammals) and 
two identical light chains (see Figure 1.1). There are therefore five Ig isotypes 
with differing biological properties and named according to the heavy chain they 
contain (IgA, IgD, IgE, IgG and IgM). IgG is the most abundant Ig molecule and 
exists as four different subclasses (IgG1-4) numbered after their relative 
abundance in serum. The different IgG subclasses have different complement 
activating properties and Fc receptor binding affinities. IgM and IgD (which is 
bound to B-cells) are important in the initial immune response. After B-cell 
activation, heavy-chain class-switching occurs, allowing production of IgA 
(mucosal regions), IgE (involved in allergic reactions and parasitic infections) or 
IgG (serum) without affecting the antigen-specificity. 
The heavy and light chains consist of a constant and variable region each. The 
two antigen binding sites are formed by the combination of the variable regions 
of the heavy and light chains. Together, they are known as the Fragment 
antigen-binding region (Fab). The stem of the Y-shaped Ig molecule, consisting 
only of two heavy chains, is called the Fragment crystallisable region (Fc) and is 
responsible for triggering effector mechanisms of the immune response, for 
example by binding to Fc receptors on effector cells or triggering the 
complement system. 
Autoantibodies can cause tissue damage and functional changes by several 
different mechanisms, some of which are related to the normal function of 
antibodies in the presence of a pathogen, such as cell-mediated cytotoxicity 
and complement-mediated lysis. In antibody-dependent cell-mediated 
cytotoxicity, natural killer cells (NK cells) are activated by interaction of the Ig 
molecule with their Fc receptors. Other immune effector cells can also be 
activated by antibody binding to Fc receptors. Activation of the complement 
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cascade, eventually leading to osmotic lysis of the targeted cell(s), occurs 
through binding of the first protein complex of the cascade to the Fc-region of 
antigen-bound antibodies. 
Antibodies do not only cause cellular damage. Other mechanisms include 
internalisation after cross-linking of the antigen (see Figure 1.2) and direct 
effects on the target protein or target-expressing tissue. The two antigen-
binding sites on the arms of the Y-shaped antibody molecules allow binding of 
two adjacent antigens. If the antigenic sites for any antibody are present in 
multiple copies on each macromolecule, cross-linking between antigens can be 
substantial. This promotes clustering of the antigen resulting in internalisation 
and degradation of the antigen-antibody complexes and therefore reduces 
surface availability of the protein. This has been shown to take place with AChR 
in myasthenia gravis (Vincent, 2002). The requirement for divalency for 
internalisation is demonstrated by the fact that single Fab fragments do not 
cause internalisation unless the Fabs are cross-linked by an anti-Fab antibody. 
In addition, some antibodies have been shown to have direct effects on their 
targets: for example, thyroid-stimulating immunoglobulins activate thyroid-
stimulating hormone receptors in the thyroid gland, causing excessive thyroid 
hormone synthesis and hyperthyroidism in Grave’s disease. 
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Table 1.1 Symptoms of limbic encephalitis 
Amnesia Seizures Affective disturbance 
Anterograde amnesia 
Can present initially as 
confusion 
Complex partial and 
secondarily generalised 
seizures of limbic origin 
Change in behaviour or 
personality 
Agitation 
Anxiety or change in mood 
Psychotic features 
including delusions and 
hallucinations 
 
 
Figure 1.1 Schematic representation of an IgG molecule. 
IgG molecules consist of two heavy (blue) and two light (orange) chains connected by 
disulphide bonds. The antigen binding sites are in the antigen-binding fragment (Fab), 
which can be cleaved enzymatically from the crystallisable fragment (Fc), which binds 
to effector cells and complement factors to mediate the effect of IgG. 
 
 
Figure 1.2 Cross-linking of antigen by antibodies and internalisation followed by 
degradation. 
NMDAR-Abs cause the internalisation of NMDAR, reducing their surface density. This 
effect is specific to the full divalent IgG molecules as incubation with NMDAR-Fab, 
which is monovalent, does not cause internalisation of NMDAR. The requirement of 
divalency for this mechanism of action has been demonstrated by rendering the 
NMDAR-Fab divalent by adding anti-Fab antibody. In that situation, NMDAR are 
internalised.
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1.3 Anti-NMDA Receptor antibody encephalitis (NMDAR-Ab 
encephalitis) 
1.3.1 First description of NMDAR-Ab encephalitis 
The description of VGKC-complex LE prompted the recognition of other cell 
membrane antigen-directed treatment-responsive LE syndromes. In the 1990’s, 
a number of case reports described treatable limbic encephalitis in young 
women with ovarian teratomas (Nokura et al., 1997; Okamura et al., 1997; 
Taylor et al., 1999), but it was not until 2005 that the remarkable similarity in 
presenting symptoms - marked psychiatric features resembling acute psychosis 
- and the presence in each patient of an antibody in serum and CSF that bound 
to the molecular layers of the hippocampus, that the idea of a separate 
treatable paraneoplastic syndrome associated with teratoma took form (Vitaliani 
et al., 2005). Another remarkable feature of this syndrome was the involvement 
of extra-limbic areas: abnormal choreiform and dystonic movements developed 
in most of these patients, as did central hypoventilation. The patients also 
manifested a broad range of seizure types, some of which localised to non-
temporal lobe structures. Although the target of the antibodies was not found, 
the authors demonstrated that this was a cell-surface antigen by showing 
binding to the cell membrane and dendrites of live cultured hippocampal 
neurons. A prospective study then showed that 44% of 39 patients with limbic 
encephalitis investigated at a single institution had this same novel antibody, 
and presented with a similar multi-focal encephalitic syndrome (Bataller et al., 
2007). They were overwhelmingly women, and in the majority of cases, had 
teratoma of the ovaries or thymus. Marked improvement was seen in most of 
these patients with steroids, plasma exchange, immunoglobulin infusion or a 
combination of these. 
Later in the same year, Dalmau and his colleagues (2007) were able to 
determine that the antigen in this condition was a subunit of the NMDA receptor 
(NMDAR) expressed most strongly in the molecular layer of the hippocampus 
but also present in forebrain cortical areas. The epitope was likely to be 
conformational as patients’ sera and CSF did not react with immunoblots 
prepared from cultured hippocampal neurons or cell lines recombinantly 
expressing subunits of the NMDAR, which present linear epitopes. The epitope 
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was eventually shown to be in the extracellular region of the NR1 subunit of 
NMDARs (Dalmau et al., 2008). More recent studies using mutant NR1 subunits 
demonstrated that the NMDAR antibody epitope is within the amino terminal 
domain (ATD) of NR1 (Gleichman et al., 2012). This region is important 
functionally as it provides the binding sites for NMDAR allosteric modulators. 
Within the ATD, a small region in the vicinity of the hinge between the two lobes 
of the ATD was found to be important for antibody binding. Mutations that 
increased the size of this region progressively reduced the intensity of antibody 
binding and also pushed the receptor into a closed conformation, suggesting 
that the antibodies bind preferentially to receptors in an open-cleft configuration. 
Binding of patient NMDAR-Abs to the wild-type NR1 subunit after brief exposure 
(six minutes) to patient CSF also prolonged receptor opening time, though it did 
not increase the likelihood of channel opening, suggesting it may stabilise the 
open configuration (Gleichman et al., 2012) rather than cause it to open. The 
authors did not indicate the magnitude of the prolongation of the channel 
opening time and whether this was significant compared to baseline. 
Furthermore, the functional implications of the prolonged open time were not 
investigated. 
1.3.2 The NMDA receptor 
NMDA receptors are a subset of glutamatergic receptors. Glutamate is the main 
excitatory neurotransmitter in mammalian CNS and acts through two classes of 
receptors: ligand-gated ion channels and G-protein coupled metabotropic 
receptors. The ligand-gated ion channels, also called ionotropic receptors, are 
channels that become permeable to ions once activated by their agonist. They 
are named after the agonist they bind most strongly, i.e. AMPA, kainate or 
NMDA (for review, see Dingledine et al. (1999)). All glutamatergic ionotropic 
receptors share basic structural similarities. They are multimeric constructs 
consisting of four subunits. These subunits are formed of four hydrophobic 
transmembrane regions, one of which is re-entrant in order for the subunits to 
carry an extracellular N-terminal and an intracellular C-terminal. The ligand-
binding domain consists of the N-terminal and part of the loop between the third 
and fourth transmembrane regions. The NMDA receptor is mostly made up of 
two families of subunits, NR1 and NR2. The NR1 subunits are obligate to the 
formation of NMDA receptors, although they cannot by themselves form 
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functional receptors as they do not contain glutamate binding sites. Instead, it 
contains a glycine binding site. Functional NMDA receptors are formed by two 
NR1 subunits and two NR2 subunits. There are four subtypes of NR2 subunits 
(A-D), affording NMDA receptors pharmacological variability. 
The expression of NR2 subunits changes during foetal and neonatal 
development and varies by region in the adult brain, suggesting a role in 
functional specialisation (Monyer et al., 1992; Monyer et al., 1994). In rats, 
NR2B and D are expressed pre-natally and decrease post-natally into 
adulthood, whilst NR2A and C mRNAs appear after birth. In adulthood, NR2A 
and NR2B are expressed throughout the cortex and particularly strongly in the 
pyramidal layers of the hippocampus. NR2C is chiefly expressed in the 
cerebellum and NR2D expression declines dramatically. Interestingly, NR2A 
and NR2B subunit expression localises to hippocampal pyramidal cells and 
dentate gyrus granule cells, whilst NR2C and NR2D expression occurs in 
interneurons. Further functional differentiation is reflected in the different 
electrophysiological properties of the different NR2-subunit containing 
receptors: NR1-NR2A channels have much faster decay times than receptors 
containing either NR2B or C, and NR2D-containing receptors have very 
protracted time constants (Monyer et al., 1994). A final NMDAR subunit named 
NR3 was identified somewhat later. Like NR1, it has a glycine binding site 
rather than a glutamate binding site but its physiological role is not well 
understood at present (Low and Wee, 2010). 
There are a number of differences between NMDA receptors and AMPA and 
Kainate receptors (AMPAR and KAR), which have significant functional 
implications. AMPA and kainate receptors are involved in fast glutamatergic 
neurotransmission (Dingledine et al., 1999). They are rapidly activated by 
glutamate, but have relatively low affinity for glutamate and therefore de-
activate rapidly as well. Activation leads to Na+ influx, but most AMPAR and 
KAR are impermeable to Ca2+, which limits their involvement in excitotoxicity. 
Furthermore, AMPAR and KAR desensitise rapidly. The NMDA receptor is 
characterised by its slow kinetics (Dingledine et al., 1999). Although it has a 500 
times higher affinity for glutamate, it activates and de-activates much more 
slowly (time constants in the tens of milliseconds). Additionally, in the continued 
presence of glutamate, NMDARs desensitise slowly and by several different 
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complex mechanisms. It is also unusual in that three conditions must be fulfilled 
in order for the NMDA receptors to activate: its two co-agonists, glutamate and 
glycine, must bind and a voltage-gated block must be lifted. Glutamate binds to 
the NR2 subunits and the glycine binding site is found on NR1.  
A voltage-dependent block is imposed on the NMDAR ion channel by 
magnesium (Mg2+) ions. This renders NMDA receptors inactive at resting 
membrane potential. If the postsynaptic cell is depolarised at the same time as 
glutamate release is occurring pre-synaptically, however, the channel block is 
released and receptor activation leads to calcium-influx into the postsynaptic 
cell. This mechanism of activation ideally places the NMDA receptor as a 
coincidence detector and explains its role in synaptic response modulation. 
AMPARs and NMDARs are usually co-expressed at synapses and this 
distribution allows participation of NMDAR in synaptic transmission: 
postsynaptic cell depolarisation and displacement of the Mg2+ block in NMDAR 
channels is provided by the rapid activation of AMPARs following glutamate 
release. The slow de-activation time of NMDAR, which often exceeds the 
presence of glutamate in synaptic clefts, can then control the duration of the 
synaptic current (Dingledine et al., 1999). Various forms of activity-dependent 
synaptic plasticity, such as long-term potentiation, have been shown to be 
NMDAR-dependent (Bliss and Collingridge, 1993), and are thought to underlie 
learning and memory. 
These same mechanisms, as well as the very slow desensitisation process, 
also make the NMDA receptor a major mediator of excitotoxicity. Indeed, 
prolonged NMDA receptor activation leads to rising intracellular calcium 
concentration and eventually cell death through complex downstream steps 
including mitochondrial dysfunction and changes in kinase, protease and 
phosphatase signalling (Waxman and Lynch, 2005). 
1.3.3 Clinical course of NMDAR-Ab encephalitis 
Since 2007, there has been a cascade of case reports and case series 
describing patients with NMDAR-Abs. Initial reports suggested the condition 
was overwhelmingly paraneoplastic and affected mainly young women (Dalmau 
et al., 2007; Sansing et al., 2007; Tonomura et al., 2007; Dalmau et al., 2008; 
Iizuka et al., 2008; Kataoka et al., 2008; Seki et al., 2008). Indeed, in a case 
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series of 100 patients, Dalmau et al (2008) found that 91% of the patients were 
female and 59% had tumours. These were mainly mature ovarian teratomas, 
and all examined tumour tissue stained strongly for NMDA receptors. However, 
as recognition of the new disease grew, the phenotype widened. Irani et al. 
(2010b) described the characteristics and clinical course of 44 European 
patients with NMDAR-Abs. In this series, 70% of patients were female and only 
20% were found to have a tumour. The tumours consisted solely of ovarian 
teratomas, except for one male who suffered a recurrence of a previously 
treated Hodgkin’s lymphoma. A recent retrospective observational cohort 
consisting of all 577 patients whose serum and/or CSF tested positive for 
NMDAR-Abs in Professor Dalmau’s laboratory in Barcelona included 19% male 
patients, with greater prevalence of male patients in children under the age of 
twelve and adults over the age of 45 (Titulaer et al., 2013). In this study, 
paraneoplastic cases were in the minority again, with 38% of patients having 
underlying neoplasm. 
Recognition of NMDAR-Ab encephalitis in children has also grown. 37% of the 
patients in the Titulaer et al. (2013) cohort and 32 of 80 patients in a separate 
American cohort were under the age of 18 (Florance et al., 2009). 
The clinical course of NMDAR-Ab encephalitis evolves over two distinct stages 
(Irani et al., 2010b). The majority of patients present with symptoms of higher 
cognitive dysfunction, such as confusion and amnesia, and/or psychiatric 
symptoms (Dalmau et al., 2008; Irani et al., 2010b; Titulaer et al., 2013). The 
psychiatric symptoms described include anxiety, depressive symptoms, 
obsessive thoughts and behaviours, agitation, delusions and other psychotic 
phenomena, and visual and auditory hallucinations. Seizures, which can be 
generalised tonic-clonic, complex partial or simple partial, affect up to 82% of 
patients at initial presentation. Five to twenty days later, an increasingly sub-
cortical picture emerges, progressing to reduced levels of consciousness, 
frequently with central hypoventilation that often requires intubation and 
ventilation (Irani et al., 2010b). Abnormal movements become prominent. These 
are most often choreoathetoid but parkinsonian features with rigidity, 
myoclonus, oculogyric crises and opisthotonus have all been described. During 
this time autonomic dysfunction is also frequent, affecting up to 72% of patients 
and often requires treatment in its own right. 
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Seizures are less frequent and less persistent in NMDAR-Ab encephalitis than in other 
types of autoimmune encephalitis. Indeed, seizures are a very prominent feature of 
limbic encephalitis with antibodies to GABARs (Lancaster et al., 2010), LGI-1 (Irani et 
al., 2010a), and GAD (Malter et al., 2010). Additionally, the two published animal 
models of NMDAR-Ab encephalitis did not report spontaneous seizures even with 
prolonged administration of antibodies and strong hippocampal binding (Planagumà et 
al., 2014; Wright et al., 2015b). Whilst this could reflect a species difference in the role 
of NMDAR in epileptogenesis, it is also possible that the seizures seen in patients with 
NMDAR-Ab encephalitis are not a direct result of the effects of NMDAR-abs on 
NMDARs in limbic and cortical areas. Instead, they may be a downstream effect of 
alterations of the balance of excitation and inhibition in cortical networks as seen in 
NR1 knock-down mice (Gary E. Duncan et al., 2010; Gandal et al., 2012), or could 
result from cortical damage caused by the inflammatory reaction.  
Implicating loss of surface NMDAR in epileptogenesis is not straightforward: many 
studies point to a protective effect of NMDAR hypomorphism/antagonism in seizures 
(Kalev-Zylinska et al., 2009; Wasterlain et al., 2013), with NMDAR antagonists 
displaying anticonvulsant properties in many animal models of epilepsy (Chapman, 
1998). Furthermore, it is noteworthy that one common animal model of epilepsy is to 
use low/no magnesium aCSF to perfuse slices (for example, see Anderson et al. 
(1986). This removes the Mg2+ block of NMDARs and therefore potentiates NMDAR-
mediated glutamatergic transmission, and leads to the development of epileptiform 
activity in slices. Nevertheless, there is also evidence that NMDAR hypomorphism 
increases susceptibility to kainate-induced seizures by sensitizing kainate receptors to 
endogenous glutamate (Gary E. Duncan et al., 2010). Altering surface and synaptic 
NMDAR density is therefore associated with wide-ranging and occasionally opposing 
effects (protection from seizures as well as increasing susceptibility to seizures by 
secondary mechanisms as seen above), suggesting that individual clinical outcomes 
such as seizures, may depend on multiple factors including antibody titre, location and 
duration of exposure, and accompanying inflammation, in each patient. 
Similar arguments can be made for other characteristic features of NMDAR-Ab 
encephalitis, such as the movement disorders observed, which so far have not been 
directly linked to an NMDAR-mediated effect. 
1.3.4 Clinical investigations in NMDAR-Ab encephalitis 
CSF and scalp electroencephalogram (EEG) are abnormal in the majority of 
patients (79-95% and 90-100% respectively (Dalmau et al., 2008; Titulaer et al., 
2013)). Irani et al. (2010b) found that investigation results follow a biphasic 
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pattern that mirrors the clinical presentation. At presentation, CSF findings are 
mostly that of lymphocytic pleocytosis with leucocyte counts ranging from just 
above normal to well into the hundreds (normal range <5/ml). CSF protein is 
sometimes mildly elevated and oligoclonal bands are rarely found. In CSF 
collected later in the course of the illness however, leucocytosis is usually 
absent and oligoclonal bands unmatched in the serum are more often seen 
(Irani et al., 2010b). Epileptiform EEG changes on a normal background are 
more often seen in the early stages of the disease, whereas diffuse slowing with 
delta and theta activity is a common late feature. 
Magnetic Resonance Imaging (MRI) is surprisingly often normal in NMDAR-Ab 
encephalitis. Dalmau et al. (2008) found that 45% of patients had no imaging 
findings and this proportion was even higher in Irani et al. (2010b). The most 
common abnormalities were high signal in the medial temporal lobes on Fluid 
Attenuation Inversion Recovery (FLAIR) sequences or T2 sequences, contrast 
enhancement in the cerebral cortex and overlying meninges or basal ganglia, 
and white matter hyperintensity. 
1.3.5 Treatment and outcome in NMDAR-Ab encephalitis 
One of the features that initially differentiated NMDAR-Ab encephalitis from 
classical paraneoplastic encephalitis syndromes was the response to 
immunomodulatory treatments. Although experience with the treatment of 
NMDAR-Ab encephalitis has increased dramatically recently, the condition is 
still rare and relatively new, and no prospective trials of different 
immunomodulatory drugs or regimes exist at present. The three largest cohorts 
of NMDAR-Ab encephalitis patients (Dalmau et al., 2007; Irani et al., 2010b; 
Titulaer et al., 2013) have found that patients with paraneoplastic NMDAR-Ab 
encephalitis who undergo tumour resection tend to do better than patients with 
non-paraneoplastic NMDAR-Ab encephalitis. This is likely to be related to the 
probable role played by the teratomas in triggering the immune response. 
Indeed, all tumours examined histologically were found to contain neurons that 
expressed NMDA receptors, and these were bound by patient antibodies. 
Considerable improvement is seen after surgical resection and first-line 
immunotherapy in around 80% of patients (Seki et al., 2008; Florance et al., 
2009; Irani et al., 2010b; Alexopoulos et al., 2011; Dalmau et al., 2011). 
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In the non-paraneoplastic group of patients, various forms of 
immunomodulation and immunosuppression have been used alone or in 
combination. A combination of glucocorticoid treatment with other immune 
therapies is more successful than glucocorticoids alone (Dalmau et al., 2008; 
Irani et al., 2010b; Titulaer et al., 2013). Early treatment is also a significant 
factor in the outcome (Irani et al., 2010b; Titulaer et al., 2013). However, first-
line immunotherapies fail in nearly half of patient with non-paraneoplastic 
NMDAR-Ab encephalitis (Titulaer et al., 2013) and such patients are often 
treated with second-line agents such as rituximab or cyclophosphamide. 
Substantial improvements are seen in around 75% of patients treated with 
second-line immunotherapy (Titulaer et al., 2013). 
While cyclophosphamide is able to cross the blood-brain-barrier, it is not clear 
that rituximab can. Rituximab is a monoclonal antibody targeting CD20 positive 
B cells, that is naïve and memory B cells, but not the long-lived plasma cells 
that are likely to be responsible for the intrathecal production of NMDAR-abs. 
Cyclophosphamide reduces both B and T-cell populations. B cells are abundant 
in the perivascular infiltrates in patients with NMDAR-Ab encephalitis (Martinez-
Hernandez et al., 2011) where they may perpetuate the inflammatory 
environment required for maturation of plasma cells. Significant selective B cell 
expansion has been described in the CSF of patients with NMDAR-Ab 
encephalitis during active disease (Dale et al., 2013), but whether rituximab or 
other therapies can deplete CSF B-cell in this condition has not been studied. In 
blood, rituximab-induced CD20+ B-cell depletion at one month after treatment 
was accompanied by a reduction in CD20- plasma blasts, short-lived cells that 
are able to secrete antibodies (Hachiya et al.). Rituximab, and perhaps 
cyclophosphamide too, may therefore be useful both in terms of reducing the 
supply of B cells to the CNS and depleting short-lived plasma blasts. 
A minority of mostly non-paraneoplastic NMDAR-Ab encephalitis patients suffer 
relapses (12-25%, (Dalmau et al., 2008; Florance et al., 2009; Irani et al., 
2010b; Gabilondo et al., 2011; Titulaer et al., 2013)). Relapses may occur 
months to several years after the initial episode and are often less severe than 
the initial event. They usually occur in patients who received no or limited 
treatment for the initial episode and are rare in patients exposed to second-line 
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immunotherapy (Dalmau et al., 2008; Florance et al., 2009; Irani et al., 2010b; 
Gabilondo et al., 2011; Titulaer et al., 2013). 
The case reports and case series described above all report very encouraging 
recovery rates (75-81%), especially when the duration of coma and intensive 
care unit stay is considered. However, more careful analysis shows that up to 
85% of patients described as having fully recovered or experiencing mild 
deficits only do show signs of frontal lobe dysfunction on cognitive testing 
(Dalmau et al., 2008). Long-term cognitive outcome has only been reported in 
one small study. Patients classified as having good outcome were found to 
have deficits in executive function and memory testing, more severe in those 
with delayed treatment (Finke et al., 2012). Overall, this does suggest that the 
initial part of the illness may be critical in terms of neuronal damage and long-
term outcome. 
1.3.6 NMDA Receptor antibodies in NMDAR-Ab encephalitis 
NMDAR-abs are found in the serum and CSF of patients with NMDAR-Ab 
encephalitis and are predominantly of the IgG1 subtype (Tuzun et al., 2009; 
Irani et al., 2010b). Intrathecal production of antibodies has been demonstrated 
in most patients with CSF antibodies (Dalmau et al., 2008; Irani et al., 2010b) 
but absolute titres of NMDAR-abs are higher in serum than CSF (Irani et al., 
2010b). Serum IgG concentration is about 400 times higher than CSF IgG 
concentration. Once IgG concentration in CSF is normalised to that in serum, 
however, the relative NMDAR-Ab concentration in CSF will be higher in the 
majority patients (Dalmau et al., 2008). This explains the apparent discrepancy 
in relative serum and CSF titres reported by Dalmau’s group in their original 
study (2008) and the Oxford laboratory, as the former were expressed after 
normalisation to serum IgG concentration. 
CSF NMDAR-Ab titres, and to a lesser extent serum titres, correlate with 
disease course: one study found that CSF titres fell markedly and rapidly in 
patients with a monophasic illness and good outcome, whereas the reduction 
was slower in those with poor outcome (Gresa-Arribas et al., 2014). Similarly, 
serum titres remained elevated in patients with poor outcome or death in 
another study (Irani et al., 2010b). It is noteworthy that both serum and CSF 
antibodies remain detectable in a proportion of patients after recovery from 
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NMDAR-Ab encephalitis (Irani et al., 2010b; Finke et al., 2012; Gresa-Arribas et 
al., 2014), posing questions about the significance of continued antibody 
production. Few studies have systematically studied the effect of 
immunotherapy on antibody levels. Case reports occasionally describe 
reduction (Kurian et al.; Turkdogan et al.; Seki et al., 2008; Irani et al., 2010b) or 
eradication (Batra et al.; Ishiura et al., 2008) of NMDAR-abs in serum following 
1st-line immunotherapy in patients with good outcome, with concomitant 
decrease in CSF titres (Kurian et al.; Turkdogan et al.; Ishiura et al., 2008; Seki 
et al., 2008). Reductions in CSF titres with 2nd-line treatments have also been 
demonstrated (Frechette et al., 2011; Hachiya et al.; Thomas et al., 2013), but 
for obvious practical reasons are less commonly reported. 
Two long-term follow-up case reports may shed some light on the relative 
importance of CSF and serum Abs. Indeed, both case reports describe patients 
with very prolonged clinical courses. Frechette et al. (2011) describe an 18-
year-old man with a severe clinical course. He was comatose with dyskinetic 
facial and limb movements for nearly one year. No tumour was found on 
repeated searches. He was treated with a combination of ivIG, 
cyclophosphamide and rituximab and had monthly serum and CSF Ab titre 
measurements. His serum antibodies remained low (within the control range for 
the ELISA used) throughout the course of his illness whereas CSF titres were 
initially elevated. CSF titres fell gradually over the course of the hospitalisation 
with concomitant improvement in clinical state. It is worth noting that antibody 
titres in serum and CSF were measured using an ELISA, which is no longer in 
routine use as it is less sensitive than cell-based assays (Dalmau et al., 2008; 
Irani et al., 2010b) and this might explain the apparent negativity of the serum 
samples. 
Alexopoulos et al. (2011) describe a 42-year-old woman with a very severe 
syndrome in whom a mature ovarian teratoma was only found one year after 
admission to hospital, after repeated tumour searches. Her CSF Ab titre had 
initially been higher than the serum titre. She had been treated with monthly 
intravenous immunoglobulin up until oophorectomy with no improvement in 
clinical state. She started to improve after oophorectomy but serum NMDAR-Ab 
persisted. CSF Abs were not rechecked. Her recovery was very slow and at 
four years post-admission she still had significant cognitive difficulties, at which 
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point serum Abs were still present. Unfortunately, the antibody titres are not 
available. As described above, the relationship between serum and CSF 
antibodies is unclear and the titre of one is not predictive of the other. It is 
difficult therefore to determine whether the persistent and slowly improving 
cognitive difficulties are related to the persistent serum Abs, the potential 
presence of CSF Abs as in the previous care report (Frechette et al., 2011), or 
to cortical damage in the early stages of her prolonged admission. It should be 
noted that the comparisons in Alexopoulos et al. (2011) were made using 
different assays which adds another potential confound to their conclusions. 
Post-mortem studies and biopsy findings have been quite variable with some 
studies finding areas of intense immunoglobulin deposition and extensive 
microgliosis (Dalmau et al., 2008; Tuzun et al., 2009), whilst others found very 
little in the way of parenchymal lymphocytic infiltration or gliosis 
(Camdessanché et al., 2011; Martinez-Hernandez et al., 2011). Reduced NR1 
staining intensity was measured in the hippocampus of patients with NMDAR-
Ab encephalitis at autopsy compared to controls, suggesting a specific effect of 
the antibodies (Hughes et al., 2010). All studies were remarkable for the lack of 
neuronal damage and loss reported and no complement deposition was found 
despite NMDAR-abs being of the IgG1 complement-activating subtype 
(Martinez-Hernandez et al., 2011). The most common feature was perivascular 
lymphocytic cuffing with infiltrates including antibody-secreting plasma cells 
(Dalmau et al., 2008; Tuzun et al., 2009; Camdessanché et al., 2011; Martinez-
Hernandez et al., 2011), the likely source of intrathecally-produced antibodies. 
Pathological studies have however generally been conducted late in the 
disease and after some immunotherapy (Tuzun et al., 2009; Martinez-
Hernandez et al., 2011), and therefore cannot exclude complement or cell-
mediated toxicity as important pathogenic mechanisms in the early stages of 
disease. 
A recent paper (Kreye et al., 2016) has demonstrated the presence of IgG 
directed against a multiplicity of non-NR1 targets in the CSF of patients with 
NMDAR-Ab encephalitis, both patients with active disease and those in 
remission. Having observed binding to astrocytic and neuronal antigens outside 
of NMDAR-rich areas in 6 of 8 CSFs tested, the authors isolated the antibody-
secreting cells and memory B-cells from the CSF of these patients and 
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investigated their monoclonal antibody repertoire by cloning their 
immunoglobulin genes. In total, they found 170 monoclonal antibodies across 
the 8 patients’ CSF samples, and only 9 of these (from three patients) were 
directed against the NR1 subunit of NMDARs. The NR1 monoclonal antibodies 
behaved as expected from previous studies using CSF from patients with 
NMDAR-Ab encephalitis (Dalmau et al., 2011) – causing reduction in synaptic 
NMDAR density and reduced NMDAR currents in neuronal cultures – 
confirming that these effects were solely related to the NR1 antibodies and that 
these are sufficient to cause the changes (Kreye et al., 2016). 
The specific antigenic targets of the remaining 161 monoclonal antibodies await 
investigation, but the truly surprising findings of this study are the breadth of the 
antibody repertoire in these patients and the low frequency of NMDAR-Ab-
producing cells. If Kreye et al. (2016) succeeded in isolating all the antibody-
producing cells from the CSF samples provided, and if the sampled cells 
represented a true reflection of the intracerebral/intrathecal antibody-secreting 
cells in vivo in the patients, then the results of this study would suggest that the 
CSF NMDAR-Abs in most patients have originated in the periphery. This is in 
contrast with findings of intrathecal antibody production in most patients 
(Dalmau et al., 2008; Irani et al., 2010b). Furthermore, and as pointed out in a 
vehement letter to the editor of Brain (Dalmau, 2017), previously reported 
immunohistochemical findings with patient CSF are not in keeping with the 
presence of non-NR1 directed antibodies, and some studies have specifically 
ruled this out by performing NR1-Ab pre-absorption studies (Pettingill, 2013), 
showing abrogation of brain reactivity with removal of NMDAR-Abs. 
The presence and extent of a significant non-NMDAR-directed antibody 
response in NMDAR-Ab encephalitis therefore remains controversial at present. 
1.3.7 The origin of the immune response in NMDAR-Ab encephalitis 
In patients with paraneoplastic NMDAR-Ab encephalitis, the teratomas contain 
nervous tissue strongly expressing NMDARs (Dalmau et al., 2007; Dalmau et 
al., 2008; Seki et al., 2008; Hara et al., 2011). This may well be responsible for 
the breakdown of immune tolerance to NR1 subunits and the initiating step in 
NMDAR-Ab encephalitis. This would account for the peripheral production of 
NMDAR-Abs. It is still unclear how these antibodies subsequently gain access 
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to the CNS in sufficient quantity to cause disease. The CSF:serum IgG ratio 
under normal circumstances is around 1:400 to 1:500 (Reiber, 1998), but 
diffusion of antibodies would increase through areas of blood-brain-barrier 
(BBB) disrupted by the systemic inflammation accompanying the neoplastic 
process or by preceding or prodromal infections. Additionally antibody-secreting 
B-cells also enter the CNS, as intrathecal NMDAR-Ab synthesis has been 
demonstrated (Dalmau et al., 2008; Irani et al., 2010b). Dalmau et al. (2008); 
(2011) state that the BBB is intact in most patients at the time that paired serum 
and CSF samples were studied. However, both the increased protein 
concentration in the CSF and contrast enhancement on brain MRI of patients 
with NMDAR-Ab encephalitis suggest that the BBB is disrupted. 
In non-paraneoplastic cases it is not clear how the immune response is initiated. 
Irani et al (2010b) suggest that the much higher serum than CSF antibody titres 
signify that the antigenic stimulus is to be found peripherally rather than in the 
CNS. Some, usually monophasic, autoimmune disorders such as Guillain-Barre 
syndrome or Sydenham’s chorea are caused by antibodies formed in response 
to bacterial agents cross-reacting with nervous system epitopes. A significant 
proportion of patients with NMDAR-Ab encephalitis describe a prodromal viral-
like illness with headache, fever and occasionally vomiting or diarrhoea (75% in 
Dalmau et al. (2007), 72% in Dalmau et al. (2008), but only 25% in Irani et al. 
(2010b)) and in very few of these has an IgM response been demonstrated 
(indicating a true infectious event rather than an inflammatory event). When the 
temporal association with the onset of the neurological syndrome has been 
examined in detail (Irani et al., 2010b), only two of eleven patients suffered their 
infectious prodrome sufficiently early for the development of cross-reactive 
antibodies to occur, and extensive immunological studies of CSF and serum 
argue against cross-reactivity with bacterial epitopes (Dalmau et al., 2008). It is 
of note that both patients with or without tumours suffer infectious-like 
prodromes (fever and headache), suggesting these may be inflammatory in 
nature rather than infectious. This systemic inflammation may disrupt the blood-
brain-barrier resulting in passive diffusion of antibodies into the CNS. However, 
intrathecal production of antibodies needs to be explained and its contribution 
evaluated. In fact, Irani et al (2010b) suggested that intrathecal antibody 
production might occur later in the disease process and be responsible for the 
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appearance of oligoclonal bands in the CSF and the more global encephalitic 
process with basal ganglia and brainstem features. 
Intrathecal antibody production has significant implications for treatment, as 
most first line immunotherapies reduce serum antibody concentration whilst the 
effects on CSF antibodies are not clear. It remains to be shown whether agents 
such as rituximab or cyclophosphamide, which appear efficacious in the 
treatment of NMDAR-Ab encephalitis, can affect intrathecal antibody 
production. 
1.3.8 Are NMDAR-Abs pathogenic? 
Evidence for a pathogenic role of NMDAR-Abs is accumulating but has not yet 
been proven beyond doubt. The extracellular nature of the epitope recognised 
by NMDAR-Abs, the correlation between disease course and CSF and serum 
NMDAR-Ab titres, and the effectiveness of treatments that reduce serum 
antibody concentrations are appealing arguments in favour of the pathogenicity 
of the antibodies. Below, in vitro and in vivo work pointing to an effect of 
NMDAR-Abs on NMDAR function will be reviewed. 
In vitro effects of NMDAR antibodies 
There is good evidence that CSF and purified serum IgG from patients with 
NMDAR-Ab encephalitis alter synaptic NMDAR content and function in cultured 
hippocampal neurons. Dalmau et al (2008) showed that numbers of NMDAR 
clusters on postsynaptic dendrites were reduced after 3 and 7 days of 
incubation with CSF from patients with NMDAR-Abs compared to control patient 
CSF. This reduction was reversible, as substituting patient CSF with control 
CSF after 3 days’ incubation led to normalisation of NMDAR cluster numbers at 
day 7. The same effect was seen with purified IgG. These effects appeared to 
be NMDAR-specific, as the number of clusters of PSD95, another post-synaptic 
protein, was unaltered by patient CSF application. 
More detailed in vitro studies showed that incubating cultured HPC neurons with 
patient CSF or purified IgG decreased the total amount of NR1 protein as well 
as the cell-surface expressed fraction of NR1 protein (Hughes et al., 2010). 
Purified patient IgG reversibly and selectively reduced synaptically located 
NMDAR without affecting the number of excitatory synapses. AMPA receptors 
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and GABA receptors were not affected and dendritic branching and complexity 
remained unaltered. Also, cell density and the number of cells expressing 
markers of apoptosis were similar in cultures exposed to patient or control CSF. 
Thus NMDAR-Abs appear non-toxic to cultured neurons. Later, the reduction in 
surface NMDAR clusters was shown to be significant only after twelve hours of 
exposure to patient CSF (Moscato et al., 2014). 
Experiments using the isolated Fab fragments of the NMDAR Ab showed no 
effect on NMDAR cluster density (see Figure 1.2) (Hughes et al., 2010). Using 
anti-Fab antibodies to cross-link the individual Fab fragments restored the 
effect, suggesting that antibody capping and cross-linking of the antigen 
followed by internalisation and degradation underlie the change in density and 
localization of NMDARs described above (Hughes et al., 2010). Finally, the 
decrease in surface and synaptic NMDAR was accompanied by reduced 
NMDAR-mediated currents, whilst AMPAR-mediated currents remained intact, 
in whole cell patch-clamp recordings of cells exposed to NMDAR-Ab positive 
CSF (Hughes et al., 2010). The reduction in NMDAR-mediated currents was 
shown to be related to receptor internalisation rather than an acute antagonistic 
effect on NMDAR by demonstrating the lack of effect of acute application of 
patient CSF (30 minutes, at which time surface NMDAR density in essentially 
unchanged) and the chronic (24 hours) application of patient Fab (Moscato et 
al., 2014). 
On the other hand, three small electrophysiological studies have proposed that 
NMDAR-Abs can have an acute antagonistic effect on NMDAR function. In 
cultures of cerebellar neurons exposed to the CSF of a single patient with 
NMDAR-Ab encephalitis, calcium influx after addition of NMDA to the medium 
was prevented (Rubio-Agustí et al., 2011). However, it is worth noting that the 
clinical history of the patient was atypical for NMDAR-Ab encephalitis and that 
little detail of the diagnostic technique, which had been carried out in-house 
rather than at an experienced diagnostic laboratory, was given. 
Spike rate and burst rate recorded by multi-electrode array in spontaneously 
bursting in vitro neuronal networks obtained from dissociated rat cortical 
cultures were reduced 15 minutes after application of patient CSF and 
recovered after removal of patient CSF (Jantzen et al., 2013). The synchrony of 
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the remaining activity was unaffected however. Unfortunately, it is not possible 
to directly attribute the reduction in global network activity to the effects of 
NMDAR-Abs or even to changes in NMDAR function in this study, and the 
effect of other factors, such as the anticonvulsant and neuroleptic drugs given 
to the patient whose CSF was used were not controlled for. 
Another paper demonstrated altered synaptic plasticity in mouse hippocampal 
slices briefly exposed to NMDAR-Ab positive CSF (Q. Zhang et al., 2012). The 
authors examined the effect of the CSF of four patients with NMDAR-Ab 
encephalitis on long-term potentiation (LTP) in the Cornu Ammonis 1 (CA1) 
area of the hippocampus. LTP occurred in slices exposed to artificial CSF and 
CSF from patients with viral encephalitis or other neurological conditions. 
However, 5-minute exposure to NMDAR-Ab positive CSF prevented LTP from 
taking place. LTP was not prevented if NMDAR-Abs had been pre-absorbed 
from CSF prior to application to slices, confirming that the effect was NMDAR-
Ab-mediated. 
As mentioned above, there is evidence to suggest that NMDAR-Abs may 
prolong the open time of NMDARs (Gleichman et al., 2012). One might 
hypothesise that this could increase the rate of desensitisation of NMDARs and 
thus depress NMDAR-mediated transmission. However, NMDARs have long 
open times, a low open probability and presynaptic stimuli cause opening of 
only about 50% of the NMDAR channels that bind glutamate, suggesting that 
NMDAR-mediated neurotransmission has significant “functional reserve” 
(Rosenmund et al., 1995). Although stimuli that induce LTP probably recruit 
significantly more NMDAR than the stimulation protocol in the latter study, thus 
increasing the likelihood of receptor desensitisation by prolonged opening, it still 
seems difficult to reconcile a potential prolonged opening time with the 
depressing effect on LTP seen in Zhang et al’s study (2012). Overall, a different 
mechanism of action seems likely to have been invoked here. 
Finally, the time frame within which significant NMDAR internalisation, or at 
least sequestering by the antibodies, takes place has been challenged by 
Mikasova et al. (2012). Like Hughes et al. (2010) and Moscato et al. (2014), 
they found significant reductions in surface NMDARs in cultured hippocampal 
neurons after 20-hour incubation with patient CSF. By contrast, the reduction 
 25
was already significant at two hours’ incubation for extrasynaptic NMDARs 
(NR2B-containing NMDARs). Unfortunately, they did not examine if this was the 
case for synaptic NMDARs as well. Furthermore, by using quantum dot imaging 
to label and follow individual NMDARs, they were able to show that patient 
antibodies removed synaptic NR2A-containing NMDARs from synapses and 
caused the internalisation of extrasynaptic NR2B-containing NMDAR after two 
hours’ incubation with patient CSF. No effect was seen in the first 10 minutes or 
so of incubation, indicating that these effects took 20-120 minutes to occur 
(Mikasova et al., 2012). This time frame is still not compatible with that seen in 
the study by Q. Zhang et al. (2012), but a significant loss of NMDARs from 
synapses within a short time frame is of great interest as it could foreseeably 
acutely depress NMDAR-mediated transmission. 
In conclusion, bar one well-controlled study demonstrating an acute 
electrophysiological effect of NMDAR-Abs in patient CSF (Q. Zhang et al., 
2012) suggestive of a direct antagonistic or blocking effect on NMDARs, most of 
the evidence would suggest that NMDAR-Abs exert their effect by causing 
NMDAR internalisation, both at the synapse and extrasynaptically, without 
causing toxicity to cultured neurons (Dalmau et al., 2008; Hughes et al., 2010; 
Moscato et al., 2014). The time-frame within which the internalisation occurs is 
not yet clear, with evidence both for a relatively rapid effect within two hours of 
exposure (Mikasova et al., 2012), and for a slow process requiring at least 12 
hours of exposure (Moscato et al., 2014). 
In vivo effect of NMDAR-antibodies 
Evidence for an in vivo effect of NMDAR-Abs is much sparser. Currently, there 
are five studies reporting such effects. Dalmau’s group (Hughes et al., 2010) 
showed that infusing NMDAR-Ab-positive patient CSF into rat hippocampus in 
vivo for two weeks resulted in selectively decreased NMDAR cluster density 
and NR1 immunostaining in the hippocampus. In accordance with this, autopsy 
studies of patients with NMDAR-Ab encephalitis showed diminished NMDAR 
immunolabeling in hippocampus compared to control brains. 
Manto et al. (2011) studied the effect of patient CSF and purified IgG on 
corticomotor responses in anaesthetised rats. They infused 5L of patient CSF 
(at 1L/min) into the prefrontal area, which is known to modulate the excitability 
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of the motor cortex. Motor evoked potential (MEP) amplitudes before and after 
afferent facilitation were not affected. However, after trains of high-frequency 
stimulation (HFS) to the premotor cortex, which are known to enhance afferent 
facilitation in motor cortex, both unconditioned (no afferent facilitation) MEP 
amplitudes, and post-afferent facilitation MEP amplitudes were significantly 
greater in rats treated with NMDAR-Ab positive CSF than in those of control rats 
and rats treated with control CSF. So, although the antibodies did not increase 
cortical excitability by themselves, they appeared to enhance the LTP-like effect 
of HFS. The effect on afferent facilitation was much greater in forelimb MEPs 
compared to hindlimb MEPs. The effect was restricted to the area into which the 
CSF had been infused as spinal cord excitability was unchanged. The reason 
for the marked asymmetry of effect on forelimbs and hindlimbs is unclear. 
Overall, the authors conclude that NMDAR-Abs markedly enhance motor cortex 
excitability and postulate that this hyperexcitability could result from loss of 
inhibitory tone from GABAergic interneurons due to NMDAR-Ab-related 
inhibition of NMDAR on these interneurons. 
In another study by the same group (Manto et al., 2010), CSF and purified 
serum IgG from patients with NMDAR-Ab encephalitis and control patients were 
infused into the hippocampus of anaesthetised rats (5L at 1L/min). Levels of 
extracellular glutamate were then measured by microdialysis over a period of at 
least one hour. Patient CSF caused a significant increase in the extracellular 
glutamate concentration. The increased extracellular glutamate concentration is 
likely to be related to impaired glutamatergic auto-regulation and reduced 
inhibitory drive from interneurons. 
The results of these two studies would be consistent with NMDAR-Abs having 
an acute effect on NMDAR-mediated transmission. That would be in contrast to 
the most recent in vivo study, in which mice were administered NMDAR-Ab-
positive CSF or control CSF intracerebroventricularly over 14 days (Planagumà 
et al., 2014). Recapitulation of disease features in experimental animals with 
transfer of antibodies is required for definitive proof of the pathogenicity of 
autoantibodies. In this study, the authors found that the mice that received 
NMDAR-Abs developed progressively worsening memory deficits on the novel 
object recognition test during the infusion period and up to four days after the 
end of the infusion, as well as some anhedonic behaviours. The impairments 
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recovered in the following week. Increases in the intensity of staining for human 
IgG deposited in the hippocampus and decreases in density of NMDAR clusters 
and total NMDAR protein mirrored the memory deficits observed in the mice 
during the infusion period, and normalised after the cessation of the infusion. 
Although only a limited phenotype was obtained (no seizures, movement 
disorder or reduction in conscious level), this finding is still an important 
demonstration that the effects of the patient antibodies in vitro do translate to 
relevant behavioural changes, and does substantiate the removal of antibodies 
with immunomodulatory treatments. 
Finally, another study (Wright et al., 2015b)was able to demonstrate increased 
seizure susceptibility 48 hours after mice were given a single bolus of purified 
NMDAR-Ab IgG intracerebroventricularly, with pentylenetetrazole (PTZ) as a 
pro-convulsant. Surprisingly, there was no apparent loss of NMDARs in this 
acute model and thus the mechanisms by which seizure threshold was reduced 
are not known. 
In summary, there is good evidence for a pathogenic role for NMDAR Abs in 
NMDAR-Ab encephalitis. The published findings so far provide potential partial 
mechanisms of action for the Abs at a cellular and synaptic level 
(internalisation, although which cell types are predominantly affected is not 
clear) but no mechanistic link to the devastating deficits in memory and 
behaviour seen in this condition has yet been established. These deficits are 
likely to be caused by changes in neuronal network function in the medial 
temporal lobe and this is what this thesis proposes to investigate further. 
1.4 NMDAR in memory and learning and behaviour 
The slow kinetics and double-gating of NMDARs underlie their ability to 
integrate pre- and postsynaptic activity and thereby change synaptic efficiency. 
The latter was long thought to underlie learning and memory (Hebb, 1949) and 
the role of NMDARs in this process was confirmed when NMDAR antagonists 
were shown to block the induction of long-term potentiation (LTP), one of the 
most prevalent forms of activity-dependent synaptic plasticity (Bliss and 
Collingridge, 1993). A number of pharmacological and NMDAR knockout 
studies have demonstrated the importance of NMDAR-dependent LTP in 
certain forms of memory. Impaired spatial memory, but not non-spatial learning, 
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together with loss of CA1 LTP were demonstrated in mice lacking NR1 (and 
therefore NMDARs) in CA1 of the hippocampus by Tsien et al. (1996). CA3 
NR1 knock-out mice were found to have impaired acquisition of spatial memory 
during one-time experiences, but normal spatial memory acquisition and 
retrieval for repeated experiences (Nakazawa et al., 2003). Similarly, dentate 
gyrus granule cell NR1 knockout mice with deficient LTP in the dentate gyrus 
inputs, were shown to have spatial working memory but not reference memory 
impairments (Niewoehner et al., 2007). NMDARs also appear important for the 
consolidation of long-term contextual memories stored in the frontal cortex 
rather than hippocampus (Wiltgen et al., 2004). Selective ablation of NR1 in 
parvalbumin-positive interneurons, a subtype of GABA-ergic interneuron that 
plays a critical role in network synchronisation (see later), also led to deficits in 
spatial working memory and spatial recognition memory (Korotkova et al., 
2010). 
In addition to their role in memory, NMDARs have been implicated in several 
neurological and psychiatric disorders (for review see Waxman and Lynch 
(2005)). The most relevant to this thesis is the NMDAR hypofunction model of 
schizophrenia. This was formulated on the basis of the similarity of symptoms 
experienced by individuals taking NMDAR antagonists and both the positive 
and negative symptoms of schizophrenia. Indeed, healthy volunteers receiving 
a single low dose of intravenous ketamine reported transient alterations in 
perception, including illusions, perceptual distortions and occasionally simple 
auditory hallucinations such as popping noises (Krystal et al., 1994; Lahti et al., 
2001). Disturbance of thought content and organisation, and experiences 
similar to dissociative states were also reported. The subjects’ performance on 
the social withdrawal subsection of the Brief Psychiatric Rating Scale as well as 
several tests of executive function and memory was also disrupted, suggesting 
that the negative symptoms of endogenous psychoses could also be elicited by 
ketamine. Furthermore, when ketamine was administered to volunteers with 
schizophrenia, they reported a brief increase in positive symptoms including 
delusions similar to those they had experienced in a previous psychotic phase, 
formed visual or auditory hallucinations and thought disorder (Lahti et al., 1995; 
Lahti et al., 2001). This led to the development of several animal models of 
NMDAR hypofunction, each exhibiting some cellular, anatomical or behavioural 
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correlate of schizophrenia in humans. For example, Mansbach and Geyer 
(1989) found that injections of the NMDAR non-competitive antagonists 
phencyclidine and MK-801 in rats caused increased startle responses and 
reduced pre-pulse inhibition indicating a deficit in sensorimotor gating, which is 
also found in patients with schizophrenia (Parwani et al., 2000). Rujescu et al. 
(2006) found changes in NR2B subunit expression and a reduction in 
parvalbumin-positive interneuron numbers in the hippocampus of rats 
administered low-dose MK-801 chronically, similar to those seen in humans 
with schizophrenia (Gao et al., 2000; Z. J. Zhang and Reynolds, 2002). Keilhoff 
et al. (2004) also found reduced density of parvalbumin-positive cells in the 
hippocampus of rats treated with low doses of ketamine. 
The first genetic model of NMDAR hypofunction was developed by Mohn et al. 
(1999). They generated mice with 5-10% of normal NR1 expression. These 
mice exhibited several behaviours similar to those seen in rodents treated with 
NMDAR antagonists and relevant to patients with schizophrenia, including 
increased locomotion and stereotypic movements during habituation to a new 
environment, and social and sexual interaction deficits. These behaviours 
improved with treatment with antipsychotic drugs. NR1 knock-down mice were 
further shown to have deficient sensorimotor gating on the pre-pulse inhibition 
test (G. E. Duncan et al., 2004), as well as reduced numbers of parvalbumin-
positive interneurons and reduced parvalbumin expression in the prefrontal and 
sensorimotor cortices (Gandal et al., 2012). Further implicating GABA-ergic 
interneurons, Belforte et al. (2010) found schizophrenia-like behaviours similar 
to those seen in the NR1 knock-down mice above in mice with selective NR1 
deletion from 40-50% of corticolimbic GABA-ergic interneurons. GAD67 and 
parvalbumin expression were reduced in the GABAergic interneurons targeted 
by the NMDAR deletion, and cortical pyramidal cells were found to have 
increased firing rates and reduced cross-correlation of firing with nearby 
neurons, suggesting less efficient inhibition and synchronisation by surrounding 
interneurons. 
In summary, there is evidence for NDMAR dysfunction in schizophrenia, and 
this is of particular interest here, in view of the prominent psychotic symptoms 
seen in NMDAR-Abs encephalitis and the demonstrable reduction in surface 
NMDAR in this condition. What mechanism link disrupted NMDAR signalling 
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and the behavioural deficits described in this section? One of the many 
potential mechanisms is hinted at by the decrease in parvalbumin-positive 
interneurons found in a number of the studies discussed above. These 
interneurons are crucial for synchronisation of brain oscillatory activity in the 
gamma-frequency range, which in turn underlies several cognitive and sensory 
processes. The evidence for this is discussed below. 
1.5 Gamma-frequency oscillations 
Since Hans Berger discovered that he could record brain electrical activity from 
electrodes placed on the scalp in 1923 it has become clear that such activity 
tends to be organized into oscillatory patterns (Buzsaki and Draguhn, 2004). 
Several frequency bands of oscillations exist, spanning 50 orders of magnitude, 
and each correlates with a particular brain state. Low frequency oscillations 
tend to involve large and widespread cortical networks, allowing for long-range 
synchronization of cortical areas, whereas high-frequency oscillations recruit 
smaller more localized neuronal assemblies. It has also become clear that 
oscillation frequency bands and their behavioural correlates are well preserved 
throughout mammalian evolution (Buzsaki and Draguhn, 2004) allowing 
reasonable conclusions to be drawn from animal data where human studies are 
difficult or unacceptable. 
Slow-wave (<1Hz) and low frequency (delta, 1-4Hz) oscillations are 
predominantly seen during deep sleep and anaesthesia (Steriade et al., 1993), 
and are important for memory consolidation (Castro-Alamancos and Connors, 
1996). Theta-frequency oscillations (4-12 Hz) are prominent in the limbic 
system during low-level brain activity such as exploration in rodents and 
probably define the active state of the hippocampus. They are thought to 
represent a computational process allowing linking of activity in different areas 
activated by sensory stimuli and also areas involved in memory retrieval, thus 
allowing the organisation of segregated cell assemblies dealing with and 
integrating new and old information. In the hippocampus, theta rhythms are 
intrinsically linked with gamma-frequency rhythms (30-80 Hz), with increased 
power of gamma-rhythms during theta-associated behaviours and modulation of 
gamma amplitude by the theta cycle (Bragin et al., 1995). Beta-frequency 
oscillations are intermediate to theta and gamma rhythms with frequencies 
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ranging from 13-30Hz. They occur prior to directed motor function following a 
sensory cue and also in response to novel stimuli, when their interplay with 
gamma-frequency oscillations appears important for encoding the information 
(Tallon-Baudry et al., 1999; Haenschel et al., 2000; Roopun et al., 2006). 
Finally, rhythms with frequencies over 80 Hz are collectively termed very fast 
oscillations (VFOs). They are implicated in memory consolidation (Chrobak and 
Buzsaki, 1996; Ego-Stengel and Wilson, 2010) but also in seizure onset and 
epileptogenesis (Traub et al., 2001; Grenier et al., 2003). 
Gamma-frequency oscillations (-oscillations, 30-80Hz) have been recorded in 
several cortical areas in humans and other animals and can be transiently 
elicited by sensory stimuli (for example (Gray and Singer, 1989; Pantev et al., 
1991; Llinas and Ribary, 1993; Haenschel et al., 2000; Howard, 2003; 
Hanslmayr et al., 2009)). Evoked -oscillations occur within the first 100 ms 
following a stimulus and are phase-locked to it. Although they do not appear to 
have a direct role in the object representation, evoked -oscillations provide a 
mechanism to process the different features of a stimulus by temporally 
synchronising the activity of spatially separate cortical areas (Gray and Singer, 
1989; Tallon-Baudry and Bertrand, 1999; Tallon-Baudry et al., 1999). 
Fractionally later (200-400ms after a stimulus), induced -oscillations appear. 
These oscillations are not phase-locked to the stimulus and play a role in 
binding observed features together into a coherent perception (“bottom-up” 
processing and object representation) (Singer and Gray, 1995; Tallon-Baudry et 
al., 1999). They also appear to play a role in the “top-down” processes that 
allow percepts to be compared with memorised internal representations (Tallon-
Baudry and Bertrand, 1999; Tallon-Baudry et al., 1999). -oscillations carry out 
these roles by acting as a precise temporal structure for neuronal firing. This 
way, the binding problem of how to establish which perceived features belong 
together in active distributed systems, where potentially large numbers of 
neurons might be responding to individual features of the percept, is bypassed 
(Singer and Gray, 1995); by synchronising action potential firing in distributed 
groups of neurons (or cell assemblies) responding to a stimulus defined in time, 
-oscillations mediate the integration of information carried by the neurons 
activated by different aspects of a perceived stimulus into a coherent perception 
(Miltner et al., 1999; Rodriguez et al., 1999). This mechanism is also efficient in 
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that it allows cells to be part of any number of assemblies through modulation of 
their output (Singer, 2001).  
In addition to this central role in perception, -oscillations are associated with 
selective attention (Tiitinen et al., 1993), and a specific role in memory formation 
has been confirmed by a number of human scalp and intracranial 
electroencephalogram studies. -oscillations have been shown to increase with 
memory load in working memory tasks (Howard, 2003) and to be increased in 
the hippocampus and left frontal cortex during successful memory formation 
(Sederberg et al., 2007) and during associative learning (Miltner et al., 1999). 
Increased rhinal-hippocampal -oscillation synchronisation occurs with 
successful memory formation (Fell et al., 2001). 
Gamma-oscillations have been found to be impaired in individuals with 
schizophrenia. Delayed -band synchronisation during steady-state auditory 
stimulation using click trains (Kwon et al., 1999), and absent stimulus-locked 
visual cortex -oscillations in response to viewing of illusory squares (Spencer 
et al., 2004), have been demonstrated in patients with schizophrenia. 
Furthermore, individuals with schizophrenia produced a much slower reaction 
time phase-locked Beta-band oscillation in response to the illusory square than 
the healthy controls, who demonstrated a -band response, suggesting that 
neural networks in the brains of individuals with schizophrenia were less able to 
support high-frequency synchronisation (Spencer et al., 2004). Deficits in 
evoked -oscillations have been demonstrated in first episode psychosis 
patients as well as patients with a chronic course and first-degree relatives of 
patients with schizophrenia (Uhlhaas et al., 2008), suggesting that these deficits 
are likely to be related to the pathophysiology of the disease rather than be a 
result of medication or other consequences of the syndrome. Reductions in 
induced -oscillations during perception tasks and decreased -power during 
executive and working memory tasks have also been demonstrated in patients 
with schizophrenia (Uhlhaas et al., 2008). 
In summary, -oscillation power and synchronisation are associated with 
perception and cognition and deficits appear linked to the pathophysiology of 
schizophrenia, where reductions in parvalbumin-positive interneuron numbers 
and NMDAR dysfunction also appear to play a role. The elucidation of the 
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mechanisms underlying -oscillations in vitro has provided a convincing link 
between these entities, and is discussed below. 
There are now several in vitro models of -oscillations. In each case the 
oscillation is an emergent property of neuronal networks involving phasic 
inhibitory post-synaptic potentials onto local principal cells at -frequency (30-
80Hz). The models vary in terms of the role attributed to principal cells. All 
forms have been extensively studied in the hippocampus and the studies 
discussed below have all been performed in the hippocampus. 
1.5.1 Interneuron Network Gamma-Frequency Oscillations (ING) 
In the earliest in vitro model of -oscillations, oscillations were seen in networks 
of interconnected interneurons isolated from ionotropic glutamatergic excitation 
(Whittington et al., 1995) in the hippocampus. Intracellular recordings were 
made from pyramidal cells in hippocampal slices where ionotropic glutamate 
receptors (AMPA, KA and NMDA) were blocked pharmacologically. Upon 
electrical stimulation, 40 Hz trains of inhibitory post-synaptic potentials (IPSPs) 
were recorded in pyramidal cells. These were blocked by a GABAA receptor 
antagonist, suggesting they were generated by networks of interconnected 
tonically activated inhibitory interneurons. Similar results were obtained using 
pressure ejection of glutamate and a metabotropic glutamate receptor agonist, 
the latter highlighting the role of tonic excitation of the interneurons. The IPSP 
trains were felt to entrain pyramidal neuronal firing at the frequency of the IPSP 
train (with firing occurring on the ascending/depolarising phase of the IPSP). 
This form of -oscillation is transient only, limited by metabotropic receptor 
desensitisation. Its frequency is controlled by the decay kinetics of inhibitory 
postsynaptic currents in interneurons, the amplitudes of which are related to the 
magnitude of tonic excitation received by interneurons. One of the shortcomings 
of this model is the non-physiological conditions in which ING is seen. 
1.5.2 Pyramidal- Interneuron Network Gamma-Frequency 
Oscillations (PING) 
The non-physiological conditions under which ING is seen experimentally led to 
the investigation of the role of principal neurons and ionotropic glutamatergic 
neurotransmission in the generation of -frequency oscillations. Computer 
modelling of networks of excitatory and inhibitory cells showed that excitatory 
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input to interneurons via ionotropic glutamate receptors also established -
frequency rhythms. These rhythms combined aspects of ING (slow excitation 
via NMDA receptor activation acting like tonic excitation in ING model) and a 
frequency-modulating role provided by AMPAR-driven fast excitation of the 
interneurons (Traub et al., 1997). It remained to be shown that such rhythms 
could occur in cortical structures. The hippocampus is known to receive strong 
cholinergic inputs and the ability of cholinergic activation to induce oscillations 
in the hippocampus was therefore investigated. Carbachol, a muscarinic 
acetylcholine receptor agonist, elicited -frequency field oscillations in vitro (A 
Fisahn et al., 1998). These were blocked by GABAA receptor antagonism, 
suggesting, as in ING, that the oscillation is dependent on rhythmic IPSPs from 
inhibitory interneurons to synchronise the activity of pyramidal neurons. The 
decay kinetics of the GABAA receptor mediated IPSPs controlled the precise 
frequency of the oscillatory activity. In contrast to ING however, it was the 
phasic excitatory synaptic ionotropic glutamate receptor activation onto 
interneurons that generated and maintained the oscillation. Indeed, blocking 
AMPA and kainate receptors using 6-nitro-7-sulphamoylbenzo(f)-quinoxaline-
2,3-dione (NBQX) abolished the oscillation. Blockade of NMDA-type ionotropic 
glutamatergic receptors and metabotropic glutamate receptors did not affect the 
oscillation, supporting a role for fast phasic glutamatergic excitation in these 
oscillatory rhythms. Thus, in this model, pyramidal cells provide sufficient 
excitatory input to inhibitory interneurons to produce IPSPs, which in turn 
rhythmically modulate principal cell output (see Figure 1.3). Support for the 
physiological relevance of this rhythm comes from two genetic knock-out 
models with neurotransmitter receptor deletions on parvalbumin-positive (PV+) 
interneurons only: mice that lack the AMPAR on PV+ interneurons had 
dramatically reduced -oscillations in keeping with the loss of fast synaptic 
excitation in these interneurons (Fuchs et al., 2007), whilst mice lacking the 
GABAA receptor on PV+ interneurons still displayed -oscillations (Wulff et al., 
2009). This is in keeping with the preserved ability of interneurons, synaptically 
activated through ionotropic glutamatergic receptors, to synchronise the activity 
of excitatory principal cells via GABAA receptors on these cells. 
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Figure 1.3 Schematic representation of the interplay of principal cells and 
interneurons during -oscillations. 
Parvalbumin-positive fast-spiking interneurons produce a rhythmic output at -
frequency (30-80Hz) (first line, blue) upon stimulation. This evokes rhythmic inhibitory 
postsynaptic potentials (IPSPs) in principal cells, which is reflected as rhythmic 
negative potentials (oscillation) in the local field potential (LFP, second line). This 
powerful peri-somatic inhibition of the principal cells (in this case hippocampal 
pyramidal cells, PC, orange triangles) allows principal cells to fire only in a brief window 
as inhibition wanes. Each principal cell involved in the -oscillation does not fire on 
every cycle, but if the population of principal cells involved is considered as a group, 
action potentials at -frequency, locked to the oscillation phase can be seen  (bottom 
line), allowing precise information processing by the network. The additional excitatory 
drive to interneurons is provided via the axonal plexus (not shown). The inset illustrates 
the fact that a single interneuron contacts several principal cells. Taken from Kann et al. 
(2014). 
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1.5.3 PING and the axonal plexus 
The PING model described above requires high principal cell spike rates with 
no phase lag with interneurons to provide interneurons with sufficiently strong 
input to produce phasic IPSP trains. Fisahn et al (A Fisahn et al., 1998), 
however, found that the pyramidal cells they recorded from in CA3 during 
carbachol-induced PING fired on only 5% of the cycles of the oscillations. The 
same has been shown in kainate-induced oscillations in cortical areas 
(Cunningham et al., 2003a; Cunningham et al., 2004). This cannot provide 
sufficient excitatory input to the interneurons to generate rhythmic firing and 
thus rhythmic IPSPs in their postsynaptic principal cells. The observation that 
high-frequency activity (>100Hz) was present in the axon-containing CA3 
stratum oriens that was of axonal origin, gap-junction transmission-dependent 
and phase-locked to the field -oscillation in the pyramidal cell layer (Traub et 
al., 2003), provided an explanation for this discrepancy: indeed, a gap-
junctionally coupled principal cell axonal plexus can propagate non-somatically 
produced action potentials very rapidly and, therefore, in addition to the somatic 
spiking of principal cells, provide the strong phasic drive required to excite the 
interneurons and produce a -oscillation. This ectopic activity is thought to result 
from GABA overspill from synapses, as GABA has been shown to have an 
excitatory action on non-somatic sites, and/or from kainate-induced axonal 
excitation (Traub et al., 2003). In some neocortical areas, including the 
entorhinal cortex, fast rhythmic bursting cells have been described, whose 
intense spiking behaviour populates the axonal plexus with ectopic action 
potentials, thereby playing an essential role in  rhythm-generation 
(Cunningham et al., 2004). 
There are two widely used models of persistent hippocampal -oscillations in 
vitro: oscillations can be generated in acute brain slices using either carbachol 
as described above, or kainic acid (KA), an agonist at the kainate receptor, one 
of the ionotropic glutamatergic receptor subtypes. Both oscillations are 
abolished by GABAAR antagonism, and AMPAR antagonism blocks carbachol-
induced hippocampal oscillations (A Fisahn et al., 1998) but not KA-induced 
oscillations (A. Fisahn et al., 2004). This highlights that, whilst they both rely on 
inhibition for their generation and maintenance, they differ in the excitatory 
mechanisms invoked. Carbachol-induced oscillations also rely on phasic 
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excitation, mediated by AChR activation of pyramidal cells and consequent 
glutamate release. In KA-induced hippocampal oscillations, the direct activation 
of KAR on interneurons is sufficient to generate the oscillation. 
1.5.4 The role of PV+ interneurons in -oscillations 
As discussed above, in vitro models of -oscillations have revealed a reliance 
on GABAAR-mediated inhibition. There are several types of inhibitory 
interneurons, classified according to their intrinsic properties, such as fast-
spiking or non-fast spiking, whether they preferentially target the soma or the 
dendrites of other cells, and further subdivided using their expression of 
intracellular proteins such as calcium-binding proteins (parvalbumin, calbindin, 
calretinin) and neuropeptides (e.g. somatostatin). Fast-spiking parvalbumin-
positive interneurons that target the perisomatic region of pyramidal cells (also 
called basket cells) have been shown to play a crucial role in the generation 
and maintenance of -oscillations in both hippocampus and cortical areas in 
vivo and in vitro (Buhl et al., 1994; Klausberger et al., 2003). Several of their 
intrinsic properties place them in an ideal position to fine-tune the activity of 
pyramidal cells. Their axons arborize extensively in the pyramidal layer of the 
hippocampus and innervate the soma and proximal dendrites of pyramidal cells, 
with around twelve synapses onto each pyramidal cell, as well as other PV+ 
interneurons (Buhl et al., 1994; Klausberger et al., 2003). The somatic location 
of the synaptic contacts controls the spiking of pyramidal cells and shortens the 
window for input integration by pyramidal cells, enforcing precise coincidence 
detection and thus reducing noise in the soma (Pouille and Scanziani, 2001). It 
has been estimated that each basket cell synapses with up to 2,500 principal 
cells (Kann et al., 2014). Together with the mutual connections, this allows 
synchronisation of activity in interneuron networks as well as large and spatially 
distributed pyramidal cell populations (Strüber et al., 2015). These cells are able 
to fire action potential trains up to 100Hz in frequency and are the most active 
interneuron subtype during -oscillations when their firing is phase-locked to the 
oscillation, with action potentials occurring rhythmically at every cycle of the 
oscillation (Hájos et al., 2004; Mann et al., 2005; Gulyás et al., 2010). In 
addition to the genetic knock-out models described in section 1.5.2 that strongly 
implicate PV+ interneurons in -rhythmogenesis, recent optogenetic 
experiments in vivo using mice with channelrhodopsin-2 expression on PV+ 
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fast-spiking cells demonstrated an increase in -band activity of the local field 
potential with activation in the -frequency range in somatosensory cortex 
(Cardin et al., 2009) and even with non-rhythmic drive in neocortex, whilst 
inhibiting PV+ cells suppressed -frequency rhythms (Sohal et al., 2009). 
Additionally, -oscillations modulated sensory stimulus response such that 
temporal precision of spike-timing was enhanced (Cardin et al., 2009) and 
improved the signal-to-noise ratio during transmission (Sohal et al., 2009). 
1.5.5 The role of NMDAR in -frequency oscillations 
In the sections above, we have seen that -oscillations are dependent upon 
GABAAR kinetics and phasic drive to interneurons through AMPA receptors. 
The putative roles of NMDA receptors as coincidence detectors and mediators 
of synaptic plasticity, and of -oscillations as a mechanism to strengthen 
synapses between co-active cells would predict that NMDAR should have a role 
in modulating -oscillations. However, several in vitro experiments have 
indicated that blocking NMDAR has no effect of hippocampal -oscillations (A 
Fisahn et al., 1998; Mann et al., 2005). Whilst some studies have demonstrated 
preferential inhibition of interneurons by NMDAR antagonists and consequent 
pyramidal cell disinhibition with increased firing rate in several cortical areas in 
vitro (Li et al., 2002) and in vivo (Homayoun and Moghaddam, 2007) - which 
would be predicted to impair -oscillations - the specific interneuron subtype 
affected by the NMDAR antagonism was not determined. On the other hand, 
the contribution of NMDAR activity to synaptic excitation of PV+ fast-spiking 
basket interneurons has been shown to be relatively weak: in the hippocampus, 
the NMDAR content of glutamatergic synapses on PV+ interneurons is 
remarkably low (NyÍri et al., 2003). NMDAR-mediated currents are present only 
in the minority of fast-spiking interneurons in the adult rat prefrontal cortex 
(Wang and Gao, 2009). Similarly, AMPAR-mediated currents are three times 
larger than their NMDAR counterparts at the thalamocortical synapses onto 
fast-spiking interneurons in the rat somatosensory cortex, and individual 
NMDARs passed less charge at fast-spiking cell synapses than at regular-
spiking interneuron synapses (Hull et al., 2009). 
Nevertheless, it is possible that this apparent lack of NMDAR contribution to 
PV+ fast-spiking cells is region-specific. Indeed, marked region-specific 
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differences in the effect of ketamine on KA-induced -oscillations have been 
described: ketamine had no effect on hippocampal, somatosensory cortex and 
insular cortex oscillations, but reduced entorhinal cortex oscillations and 
increased auditory cortex oscillations in one study (Roopun et al., 2008). 
Cunningham et al (Cunningham et al., 2006) showed that ketamine reduced the 
power of kainate-induced -oscillations in the superficial layers of the medial 
entorhinal cortex (mEC). The frequency of the oscillation also decreased (from 
45Hz to 39Hz) but this reduction was not statistically significant. Intracellular 
recordings from pyramidal cells during the field -oscillation revealed less 
frequent IPSPs and more frequent action potentials in the presence of 
ketamine, suggesting that the principal cells were disinhibited in the presence of 
ketamine, in keeping with a preferential effect of ketamine on the local layer II 
PV+ fast-spiking interneurons. Further support for a strong contribution of 
NMDAR to PV+ interneuron activity in the EC comes from the finding that 
stimulus-evoked synaptic responses of basket-like fast-spiking interneurons in 
layer II mEC are dominated by NMDAR-activity, with only a small fast 
component of the excitatory post-synaptic potential abolished by AMPAR 
blockade (Jones and Buhl, 1993). Spontaneous EPSPs also appeared 
mediated by NMDAR: they were abolished by the selective NMDAR antagonist 
D-AP5 but not by an AMPAR antagonist, indicating that NMDARs may be 
tonically activated in interneurons in the mEC 
Further to this, it was shown that ketamine reduced both the frequency (this 
time from an average of 41 Hz to 31Hz) and power of -oscillations in superficial 
mEC layers (Middleton et al., 2008). Here it was shown that basket-type 
interneurons significantly reduced their firing rate from a -frequency to about 
3Hz in the presence of ketamine, suggesting they were no longer participating 
in -rhythmogenesis. Instead, goblet-type interneurons were found to fire at the 
new field oscillation frequency, indicating that tonic NMDAR activation on 
basket-type interneurons is essential in maintaining -oscillations above 40Hz in 
the superficial mEC layers. This is likely to be of functional significance as the 
different hippocampal areas to which the mEC projects preferentially oscillate at 
different frequencies, suggesting that changes in mEC oscillations could affect 
information flow by altering synchronization ability (Middleton et al., 2008). 
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Further evidence for a modulating role of tonic NMDAR activation on gamma 
oscillations comes from a study by Mann and Mody (2010). Here, the authors 
sought to explain why in vivo hippocampal oscillations can have frequencies up 
to 200 Hz whereas in vitro oscillations seem restricted to around 40 Hz. They 
found that in vitro carbachol-induced hippocampal oscillations in mice lacking 
the delta-subunit () of the GABAAR were significantly faster than in slices from 
wild-type mice, and that the oscillation frequency was reduced by the NMDA 
receptor antagonist D-AP5 in the knock-out mice. The -GABAAR subunit 
mediates tonic inhibition in interneurons. In slices obtained from -subunit 
knock-out mice, the hippocampal interneurons were therefore less inhibited and 
this exposed an NMDAR-dependent excitatory drive to the interneurons, 
resulting in increased frequency oscillations. In further experiments, they 
showed that NMDA increased the oscillation frequency in hippocampal slices 
from juvenile -subunit knock-out mice. This was reflected in increased phasic 
inhibitory currents in pyramidal cells, mediated by an increase in the amplitude 
of IPSPs but not a change in frequency of IPSPs.  
Several important conclusions can be drawn from this work: firstly, tonic 
inhibition via extrasynaptic GABAARs controls the activation of NMDAR in 
hippocampal interneurons. This is consistent with the fact that NMDAR are 
voltage- as well as ligand-gated. Secondly, network activity frequency in the 
gamma-range is modulated by a balance between NMDAR-mediated excitation 
and GABAAR-mediated inhibition in the hippocampus. This balance is of likely 
functional importance, because network activity frequency will dictate which 
neurons are active simultaneously and therefore what connections undergo 
synaptic plasticity. Finally this work also suggests, on a more general level, that 
oscillation power and frequency respond differently to changes in neuronal 
excitability.  
By contrast, NMDAR antagonism in vivo has been shown to increase the power 
of basal -oscillations in several cortical areas and in awake as well as 
anaesthetised rodents (Hakami et al., 2009). It is important to note that it is 
difficult to tease out the mechanisms for this increase in the whole brain, but this 
generalised increase in -activity was felt to represent diffuse network noise 
rather than cognitively important activity. The development of a mouse model 
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with a selective loss of NMDAR from PV+ fast-spiking interneurons has 
provided a more useful approach to the study of the role of NMDAR in -
oscillations and supports a role for NMDAR in the generation of normal, 
behaviourally-relevant -rhythms. These mice displayed increased power in the 
-frequency band of the local field potential recorded in the hippocampus during 
awake exploration (Korotkova et al., 2010) and somatosensory cortex during 
anaesthesia (Carlen et al., 2011). Theta-modulation of the hippocampal -
rhythms was impaired and positional firing of pyramidal cells was less precise in 
the knock-out mice (Korotkova et al., 2010), supporting the idea of reduced 
signal-to-noise ratio. When the PV+ interneurons were selectively 
optogenetically stimulated at either -frequency or non-rhythmically (Carlen et 
al., 2011), there was no further increase in -activity in the knock-out mice, 
suggesting an inability to produce stimulus relevant -oscillations. This deficit in 
-induction was related to less well-synchronised firing of PV+ interneurons in 
the knock-out mice. Furthermore, the knock-out mice performed poorly on 
spatial working memory, short and long-term recognition memory (Korotkova et 
al., 2010), habituation and associative learning tasks (Carlen et al., 2011). 
The evidence discussed above supports a role for NMDAR on PV+ 
interneurons in the modulations of normal -oscillations and suggests that the 
mEC, with its exquisitely NMDAR-sensitive basket interneurons, might provide 
an ideal region to study the effects of NMDAR antagonism on -oscillations. 
1.6 The medial entorhinal cortex (mEC) 
In rats, the HPC and the EC-containing parahippocampal region lie in the 
caudal part of the brain. The hippocampus consists of three subregions: the 
dentate gyrus (DG), the Cornu Ammonis areas 1-3 (CA1, 2 and 3) and the 
subiculum. The PHR borders the subiculum and consists of the presubiculum, 
the parasubiculum, the entorhinal cortex, the perirhinal cortex and the postrhinal 
cortex (see Figure 1.4). 
The hippocampus is a three-layered cortex, therefore classified as “allocortex”. 
From superficial to deep, the layers consist of the molecular layer, the cell layer 
and finally a layer consisting of axons and interneurons, whose name varies by 
subregion. The molecular layer is referred to as the stratum moleculare in the 
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DG and subiculum. In the CA areas, it is further subdivided into stratum 
lucidum, radiatum (containing apical dendrites of neurons in the cell layer), and 
lacunosum-moleculare (containing the apical tufts of the apical dendrites), 
although stratum lucidum is not present in CA1. The cell layer is composed of 
principal cells and interneurons and is called stratum pyramidale in CA areas 
and subiculum, and granule layer in the DG. The deepest layer is named hilus 
in the DG and stratum oriens in the CA areas (van Strien et al., 2009). 
The EC is classed as a transitory zone, in that its laminar structure can be 
viewed as a transition from three-layered allocortex to six-layered neocortex. 
Indeed, the EC has six distinct layers, although no cell bodies are visible in 
layer IV (lamina dissecans). 
Up until recently it was felt that the EC functioned mainly as an input-output 
station for the HPC. Research into memory formation had resulted in the 
development of a standard model for the circuitry of the PHR and HPC, which is 
depicted in Figure 1.5. In this model, information flows from unimodal or 
polymodal neocortical association areas to the postrhinal (POR) and perirhinal 
(PER) cortices in functionally distinct pathways, with the POR cortex receiving 
input from visual association areas whereas input to the PER cortex originates 
from all other association areas. The peri-and postrhinal cortices project to the 
lateral and medial EC respectively, keeping the two streams segregated. The 
EC then relays the input to the HPC, projecting to all its subregions through the 
perforant pathway. Layer II of the EC projects to the DG and CA3, and layer III 
of the EC to CA1 and the subiculum. In the HPC, a polysynaptic pathway 
connects all the HPC subregions sequentially. The mossy fibres project from 
the DG to CA3, which in turn targets CA1 through the Schaffer collaterals. CA1 
is connected to the subiculum, and both project to the deep layers of the EC. 
The EC then projects back out to neocortical areas via the rest of the PHR 
(Kandel et al., 2000).  
It has since then become clear that the connectivity between the PHR and HPC, 
as well as within each area, is far more complex and intricate (van Strien et al., 
2009). A lengthy discussion of these connections is outwith the scope of this 
review. Suffice it to say that significant overlap in POR and PER projections to 
the EC as well as reciprocal connections between the mEC and lEC suggest 
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that visuospatial and non-visuospatial information may be integrated at the level 
of the EC, a role classically left to the HPC. 
A role for the medial temporal lobe (MTL) structures in memory was first 
suggested in the 1940s by Penfield. He had found that, by stimulating the MTL 
electrically in awake surgical patients, he could occasionally elicit memories 
(Penfield, 1947). In the 1950s, his findings were confirmed when the now 
famous patient H.M. was studied (Squire, 2009). H.M. had had both MTLs 
excised for intractable epilepsy. After the surgical procedure he was found to 
have severe anterograde amnesia, although his memory of past events was 
unaffected. This suggested that the HPC and PHR were necessary to form new 
declarative memories, but that storage of memories took place elsewhere, 
namely in association cortices. Further animal and human lesion studies 
established that lesions to PHR and in particular the EC caused more severe 
memory deficits than lesions to HPC (Kandel et al., 2000). The mEC has been 
shown to play an important role in spatial navigations and contains grid cells 
that are spatially modulated and accurately predict animal location in a two-
dimensional test environment (Fyhn et al., 2004; Hafting et al., 2005). 
Interactions between mEC and lateral EC appear important to link encoding of 
stimuli and their context, with lesions of lEC leading to impairment of item 
recognition in animals whilst lesion of the mEC were associated with loss of 
object-location recognition (Eichenbaum et al., 2007). Studies of the function of 
the entorhinal cortex in humans are still in their infancy, and it is not clear if the 
human entorhinal cortex can be divided into medial and lateral areas as in 
rodents, but activation of the parahippocampal region (containing the medial 
aspect of the entorhinal cortex) and the perirhinal cortex (containing the lateral 
aspect) have been demonstrated during tasks involving examination of spatial 
scenes and object processing respectively (reviewed in (Eichenbaum et al., 
2007)). Reductions in entorhinal cortex volume have also been demonstrated in 
very early Alzheimer’s disease and mild cognitive impairment, with conversion 
to Alzheimer’s disease predicted by loss of entorhinal volume (de Toledo-
Morrell et al., 2000). In keeping with the presumed role of the entorhinal cortex 
in memory, a more recent study has shown that -frequency oscillations in EC 
and HPC are more strongly synchronised during successful memory formation, 
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suggesting that rhinal-hippocampal cooperation is required for declarative 
memory formation (Fell et al., 2001). 
Furthermore, temporal lobe epilepsy in humans is associated with changes in 
the histology of the entorhinal cortex, with marked loss of pyramidal cells in 
layer III (Du et al., 1993). Many lines of evidence suggest the EC might be an 
important site of seizure generation, and its connectivity might play a role in 
seizure propagation (reviewed in Vismer et al. (2015)). 
In summary, its position at the interface between neocortical areas and 
hippocampus suggest a computational and integrational role for the entorhinal 
cortex in spatial and memory domains that are beginning to find support in 
animal and human studies. -oscillations can be induced pharmacologically in 
the mEC in rodent brain slices and these have a number of attributes, different 
from hippocampal oscillations, that make them useful to study the effects of 
NMDAR antagonism on this cognitively-relevant rhythm. 
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Figure 1.4 The anatomy of the Hippocampus and parahippocampal region. 
A Nissl-stained horizontal cross-section of the hippocampus and parahippocampus 
with superimposed colour codes indicating the location of the different subregions.  
Postrhinal cortex: pink and purple; lateral entorhinal area of EC: dark green; medial 
entorhinal area of EC: light green; parasubiculum: dark blue; presubiculum: light blue; 
subiculum: yellow; CA1: orange; light brown: CA3; dentate gyrus: dark brown. The 
roman numerals indicate cortical layers.  
Encl, enclosed blade of the DG; exp, exposed blade of the DG; gl, granule cell layer; 
luc, stratum lucidum; ml, molecular layer; or, stratum oriens; pyr, pyramidal layer cell 
layer; rad, stratum radiatum; slmstratum lacunosum-moleculare. Taken from van Strien 
et al 2009 (van Strien et al., 2009). 
 
 
Figure 1.5 Standard view of PHR-HPC circuitry. 
Adapted from (Kandel et al., 2000) 
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1.7 Aims and hypotheses 
NMDAR-Ab encephalitis is a recently described autoimmune encephalitis 
presenting with psychiatric symptoms, amnesia, seizures, central 
hypoventilation, dyskinesia and autonomic features (Dalmau et al., 2008; Irani 
et al., 2010b). There is now good evidence that the NMDAR-Abs found in the 
blood and CSF of patients can have an effect on NMDAR density and function 
(Dalmau et al., 2007; Dalmau et al., 2008; Hughes et al., 2010), and a recent 
study found that passive transfer of NMDAR-Abs to mice induced memory 
deficits (Planagumà et al., 2014), supporting the pathogenicity of the antibodies. 
However, most of the studies investigating the mechanism of action of NMDAR-
Abs were conducted in neuronal cell cultures, which lack the connectivity seen 
in vivo or in the in vitro slice preparation. The in vivo studies performed so far 
were either short (Manto et al., 2010; Manto et al., 2011) or did not record 
electrophysiological data (Hughes et al., 2010; Planagumà et al., 2014). It is 
therefore not clear if these antibodies alter or disrupt neuronal network activity, 
which forms the basis of perception and cognition.  
The hypothesis in this thesis is that NMDAR-Abs are able to disrupt cortical 
network activity in the form of -oscillation in the medial entorhinal cortex 
through effects on parvalbumin-positive interneurons. -oscillation deficits in this 
region are likely to translate to memory and cognitive deficits as seen in 
NMDAR-Ab encephalitis. 
Firstly, a comparison of the available diagnostic assays for NMDAR-Abs will be 
carried out to determine the most sensitive and specific method of NMDAR-Ab 
detection. Currently, different diagnostic laboratories use different assay 
methods and these have not been fully compared. 
The aim of this project is then to contribute to the demonstration of the 
pathogenic nature of the antibodies by providing a network-level mechanism for 
the observed cognitive deficits seen in the presence of reduced NMDAR 
density. To achieve this, three different approaches will be used: 
 Investigate if NMDAR-Abs acutely alter organised cortical rhythms when 
applied to live rodent brain slices in vitro and explore the mechanisms by 
which this occurs. 
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 As acute exposure to NMDAR-Abs may be insufficient to cause changes 
in network activity, the effect of sub-acute exposure to NMDAR-Abs by 
passive transfer will also be examined. 
 Determine the effect of exposure to NMDAR-Abs on other measures of 
inhibition in the entorhinal cortex using immunostaining techniques 
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2.1 Purified Immunoglobulin G preparation 
Purified IgG was prepared from the serum or plasma of patients with NMDAR-
Ab encephalitis (3), VGKC-Ab encephalitis (1), and healthy controls (2). Other 
than 1 patient sample (Patient 3), all purified IgG and the purified Fab samples 
were gifts of Professor Angela Vincent and the Neuroimmunology laboratory at 
the Nuffield Department of Clinical Neurosciences, Oxford University. Patient 3 
IgG was purified from the plasma obtained following plasmapheresis as 
treatment for NMDAR-Ab encephalitis using the same protocol used for the 
other patient and control samples as follows: 20mLs of patient plasma were 
incubated overnight with 5mls of washed protein G Sepharose beads (Sigma, 
UK) and 20mLs of Hartman’s solution at 4C on a shaker, to allow IgG of all 
subclasses to bind to the protein G beads. The solution was then loaded into a 
chromatography column and allowed pass through the column until only the 
beads remained. The column was washed with 50mLs Phosphate-buffered 
saline (PBS 0.1M, ThermoFisher-Oxoid, UK) to remove non-specifically bound 
proteins. To separate the IgG from the protein G beads, 1 mL of eluting solution 
(0.1M Glycine at pH 2.3) was then allowed to quickly drip through the bead 
pellet and collected in Eppendorf tubes containing 200L 1M Tris-buffer at pH 
8.0 to neutralise the solution and avoid denaturation of the molecules. Protein 
concentration was measured using a spectrophotometer (OD 280nm measured 
by NanoDrop 2000, Thermo Scientific, UK). The four elution fractions with the 
highest protein concentration were pooled and sealed in snakeskin dialysis 
tubing (10, 000 kDA cut-off, ThermoScientific, UK), and dialysed overnight in 2 
L of Hartman’s solution. The purified IgG remaining within the snakeskin was 
then filter-sterilised, and protein concentration determined as above. Purified 
IgG was stored at 4C until use. 
2.2 Animal provision 
For acute slice experiments, male Wistar rats aged 40-60 days were obtained 
from Charles River UK and housed in a pathogen-free environment in the 
Comparative Biology Centre at Newcastle University for at least one day prior to 
use to allow acclimatisation. They were housed in standard non-ventilated 
cages enhanced with environmental enrichment, provided with food and water 
ad libitum, and subjected to a 12-hour light/dark cycle. 
 52
For experiments on slices from animals injected with purified IgG, male Wistar 
rats weighing 230-250 g were obtained from Charles River UK and housed as 
described above in cages of four or five animals for at least a week prior to 
surgery to allow acclimatisation. 
2.3 Animal procedures 
All procedures were performed in accordance to the UK Animals (Scientific 
Procedures) Act 1986 and were covered by the following personal and project 
licenses granted by the UK Home Office: 
 Anaïs Thouin 60/12991 (personal license) 
 Mark Cunningham: PPL 60/4455 (project license) 
2.3.1 Intracerebral injections 
For the experiments investigating the effect of sub-acute exposure to NMDAR-
Abs, male Wistar rats weighing 260-280g received a single intra-entorhinal 
injection of 5L of purified human IgG (10-12.5 mg/ml). The tails of animals 
were marked for identification using a marker pen. The animals were 
anaesthetised using 4% isofluorane in O2 at a flow rate of 4 L/min in a specially 
built anaesthetic chamber. Once breathing rate had slowed to about 1 
breath/second and righting reflex was abolished, the scalp was shaved and the 
animal transferred to a heating blanket placed on the stereotactic frame. 
Anaesthesia was maintained using 3% isofluorane at an oxygen flow rate of 
2L/min. The animal was positioned in the stereotactic frame (Digital New 
Standard Stereotaxic Frame, Stoelting Europe, Dublin, Ireland) using the tooth 
bar and non-traumatic ear bars. The rat was covered with bubble wrap to 
maintain body temperature, paraffin eye cream was applied to the eyes for 
protection during the procedure, body temperature was monitored using a rectal 
probe (Harvard Apparatus, UK), blood O2 saturation and pulse rate were 
monitored using a rodent digital oxymetry meter (DRE veterinary, USA), and 
analgesia and further sedation were given by intraperitoneal injection 
(Buprenorphine 0.05 mg/kg, and meloxicam 1mg/kg, diluted 1 in 10 in 0.9% 
Saline). The scalp was then cleaned with chlorhexidine. The rest of the 
procedure was performed under aseptic conditions with the help of an assistant. 
The scalp was infiltrated with ca. 1 mL 0.25% Bupivacaine along the line of the 
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incision and a central incision was made from ear level to the caudal aspect of 
the skull. The skull was exposed by dividing any subcutaneous tissue and 
allowed to dry for 1-2 minutes. Isofluorane concentration was then reduced to 
1.5% (O2 at 2 L/min) to avoid respiratory depression. Bregma was identified and 
set as point 0 on the digital stereotactic frame. The stereotaxic coordinates used 
for the injection were -8.4 mm in the anteroposterior direction, +4.8 mm laterally 
to left and -3.4 to -3.9 below the brain surface. A small hole was drilled into the 
skull at the injection site using a dental drill (Stoelting Europe, Ireland) and 
cleared of debris using sterile cotton wool. IgG was drawn up into a 25L 
Hamilton syringe (700 Series, removable needle, Sigma-Aldrich, UK) as follows: 
A 33 gauge custom length of 35mm needle was attached to the Hamilton 
syringe and cleaned three time in pure ethanol. 5L Ethanol were drawn up 
followed by 5L air then 6L IgG and a minute amount of fluorescent beads (so 
just visible above in the syringe, <1 L). The needle was lowered into the 
craniotomy and IgG was injected in a staged fashion using a microdriver 
(Harvard Apparatus, UK): 2.5 L were injected at 0.5L/min at -3.9 mm below 
brain surface. The needle was then left in this position for 1 minute before being 
retracted to -3.4 mm below the brain surface. A further two minutes were 
allowed to elapse before the remaining 2.5L were injected at 0.5L/min. The 
needle was again left in place for 1 minute, then retracted by a further 1mm and 
another pause of three minutes was made before withdrawing the needle 
completely. This was to avoid the injected IgG tracking up along the path of the 
needle. The scalp was closed using subcuticular uninterrupted sutures and the 
knot buried before applying a small amount of superglue (Vetbond, WPI, UK) to 
the caudal aspect of the wound. The isofluorane was stopped and rats were 
observed until awakening. They were then placed in a single cage in a heated 
cabinet (25C) and given a soaked diet and water ad libitum. The following day, 
they were returned to their home-cage together with their similarly injected 
cage-mates. The syringe was washed with 100% ethanol and sterile PBS. The 
rats were observed and examined daily post-operatively and welfare score 
sheets (see Appendix) were completed daily until used for experiments. 
2.3.2 Preparation of brain slices 
Rats were killed by terminal anaesthesia followed by intracardiac perfusion 
before decapitation. Rats were anaesthetised by inhalation of isofluorane (1-
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2ml, Abbott Laboratories Ltd., Kent, UK). When the righting reflex was 
abolished, an intramuscular injection of 0.3mls 2% xylazine (10mg/kg, 
Millpledge Veterinary, Retford, UK) and 0.3 mls ketamine (100 mg/kg, Fort 
Dodge Animal Health Ltd., Southampton, UK) was given. When the pedal 
withdrawal response and the corneal reflex were abolished, the heart was 
surgically exposed and an intracardiac perfusion of 50ml chilled (4°C) 
oxygenated sucrose-containing artificial CSF (composition: 25mM sucrose, 
3mM KCl, 1.25mM NaH2PO4, 24mM NaHCO3, 2mM MgSO4, 2mM CaCl2 and 
10mM glucose) at a rate of 25ml/min using a perfusion pump (Harvard 
Apparatus, UK) was performed. Pressure damage to organs was avoided by 
incising the right atrium. The animal was decapitated and the brain dissected. 
Horizontal slices 450 micrometres thick were cut using a Leica VT1000 
microtome (Leica Microsystems, Germany) and trimmed to contain only HPC 
and entorhinal, as well as auditory, cortex, in sucrose-modified aCSF. The use 
of sucrose-modified aCSF for perfusion and slicing is known to protect 
interneurons and GABA-ergic transmission in slices by preventing excessive 
action potential firing (sucrose aCSF does not contain Na+). 
Slices were transferred to a holding chamber, and maintained on a nylon mesh 
at the interface between artificial CSF (aCSF; composition: 126mM NaCl, 3mM 
KCl, 1.25mM NaH2PO4, 24mM NaHCO3, 1mM MgSO4, 1.2mM CaCl2 and 
10mM glucose) and humidified 95% O2/5% CO2 for one hour at room 
temperature to allow death-related processes at the cut surfaces to occur. 
Slices were then transferred to a recording chamber, where they were placed 
on lens paper (Whatman, UK) soaked in oxygenated aCSF. The lower Mg2+ 
concentration in this aCSF was used to potentiate NMDAR-transmission. The 
slices were maintained at the interface between humidified 95% O2/5% CO2 
and aCSF at 32°C constantly circulated using a peristaltic pump (Watson-
Marlow, UK) at a rate of 1.3 ml/min. The slices were left to equilibrate for at 
least thirty minutes prior to the addition of any drug or IgG. Slices were exposed 
to drugs and IgG by dissolving these in the circulating aCSF. Additional slices 
were maintained in the holding chamber at room temperature until use and 
were found to be viable for up to 8 hours. 
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2.4 Recording techniques 
2.4.1 Extracellular field recordings 
Extracellular field recordings were obtained using micropipettes of borosilicate 
glass (Harvard Apparatus GC120TF 1.2mm outer diameter x 0.94mm inner 
diameter) filled with aCSF. Micropipette resistance ranged between 2 and 5 
megaOhms. The field potential was recorded in current-clamp mode, amplified 
using AXOprobe-1A amplifiers (Axon instruments Inc, USA), and filtered at 0.1-
300Hz. Mains noise was filtered from the signal using Humbugs (Quest 
Scientific Instruments Inc., Canada). The signal was then digitized at 5-10 kHz. 
Data were recorded and analysed using Axograph 4.6 software (AxoGraph 
Scientific Software, Axon Instruments, Sydney, Australia). 
2.4.2 Intracellular recordings 
Intracellular recordings were made using borosilicate glass micropipettes 
containing an inner filament (Harvard Apparatus, UK; GC120F 1.2mm O.D. x 
0.69mm I.D.) with very sharp tips capable of impaling single cells. The 
micropipettes were pulled using a P-97 Flaming-Brown horizontal puller and 
filled with 2M potassium acetate at pH 6.8-7, with resistances between 70 and 
170 MΩ. The signal was filtered between DC and 1 KHz and the remaining data 
acquisition process was as for extracellular field potential recordings. Biocytin-
HCl (Sigma-Aldrich, UK) was diluted in the potassium acetate to a 2% solution 
to slowly fill the recorded cells during recording for post-hoc visualisation by 
immunohistochemistry. Only cells with a resting membrane potential of less 
than -50mV and action potentials overshooting 0mV were used in these 
experiments. Cell type was determined electrophysiologically using their 
membrane and action potential characteristics (see later chapters). 
Hyperpolarising cells to a membrane potential of -70mV using DC current 
revealed invading excitatory post-synaptic potentials (EPSPs). Evoked EPSPs 
were recorded by placing a bipolar stimulating electrode made of silver wire and 
connected to a stimulating box capable of delivering stimuli ranging from 0.1-
100V (Constant Voltage Isolated Stimulator, Digitimer Ltd., UK) in the most 
medial portion of layer II/III of entorhinal cortex whilst recording from a cell more 
laterally in the same layer. Stimuli of up to 20V and of 25s duration were given 
singly or at 1Hz frequency for 10 seconds. 
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2.5 Experimental protocol 
Slices were allowed to equilibrate to the rig temperature (32°C) for 30 minutes 
prior to the start of experiments. Extracellular or intracellular recording 
electrodes were then placed in layers II or III of the medial entorhinal cortex or 
stratum radiatum of CA3 (Figure 2.1 B). It is not possible to visually determine 
whether the recording electrode is in layer II or III of the mEC, and the 
recordings are therefore describes as being from layers II/III. Baseline activity 
was observed and recorded as control recordings to ensure that there was no 
spontaneous oscillatory or epileptiform activity (Figure 2.1 Ai). Slices displaying 
spontaneous epileptiform activity were not used for experiments. Gamma-
frequency oscillations were generated by adding kainic acid (KA) to the 
perfusing aCSF to a concentration of 400nM KA (Figure 2.1 Aii) for the mEC 
and 50nM for the HPC. Oscillations developed in power and frequency over 45 
minutes to 1 hour (Figure 2.1 Di). Oscillation parameters (peak power, 
frequency at peak power and area power (the overall power within the 20-80Hz 
range)) were determined by applying a fast-Fourier transform (FFT) to a 60-
second epoch of activity (see below 2.5.2 for discussion and Figure 2.1 Ci). The 
power and frequency of oscillations were assessed 1 hour after addition of KA, 
and if found to be outside the gamma-frequency range (i.e. below 30Hz) or to 
be too small or to large in amplitude (corresponding to a peak power less than 5 
V2/Hz or greater than 100 V2/Hz), the electrode was moved to a new location 
within layer II/III of mEC. These power values were chosen as oscillations with 
peak powers outside these limits were rare and tended to collapse over 1-2 
hours. Much larger power values were accepted for hippocampal -oscillations 
as these are known to be much stronger due to the simple laminar organisation 
of the hippocampus (Bartos et al., 2007). Oscillations were then observed every 
ten minutes until the values obtained for peak power, frequency at peak power, 
and area power were within 20% of each other for four consecutive readings 
(30 minutes of stability, Figure 2.1 Di and ii). The drug or IgG under 
investigation was then dissolved into the circulating KA-containing aCSF and 
allowed to perfuse the slices for 1 hour before being washed out with KA-
containing aCSF for at least 30 minutes (Figure 2.1 Dii). Drug and IgG 
concentrations are given in the relevant chapter. Drug concentrations were as 
used in relevant literature. 
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2.5.1 Blinding of experiments 
In order to reduce bias, experiments were carried out blind to the IgG 
preparation applied. Blinding was achieved by preparing aliquots containing the 
volume of purified IgG required for dilution into 25ml of aCSF as well as aliquots 
with similar volumes of aCSF only. A colleague was then asked to label the 
aliquots randomly using numbers or letters, and kept a record of the labels for 
future identification of the samples. Experiments to include in the analysis were 
chosen whilst still blind to the IgG preparation used. Experiments were 
accepted for analysis based on the stability of the γ-frequency oscillation before 
IgG perfusion, and also the quality of the recording during the experiment: if 
strong mains noise was present or if sudden wide variations in oscillation power 
occurred or the electrode was found to have exited the slice, as can happen 
when a drop of condensation runs down the electrode and falls onto the slice, 
the experiment was excluded. 
Blinding was applied in a similar fashion for the intra-entorhinal injections in the 
subacute exposure experiments, except the aliquots were kept in batches, such 
that all rats injected in one week received the same IgG preparation. Here, all 
experiments were included in the first analysis focussing on baseline γ-power 
and frequency, unless epileptic activity or mains noise were present. Analysis 
was performed by grouping recordings by week, i.e. IgG preparation, and 
calculating all relevant information before removing the blinding. 
2.5.2 Fast Fourier Transforms and the meaning of their results 
A fast Fourier transform (FFT) is a mathematical method transforming a function 
of time into the frequency domain. Complex signals, such as LFP recordings, 
are composed of simple waves of different amplitude, frequency and phase, 
and these can be extracted from the signal using the Fourier analysis. Fourier 
Transforms use the Fourier analysis to express this same signal in terms of the 
frequencies of each component wave, by giving a measure of “how much” of 
each frequency component is required to make up the original signal. In other 
words, an FFT plots the power of each component frequency. 
The FFT provides three important parameters to describe the recorded field 
potential oscillation: the area power, peak power and the frequency at peak 
power (see Figure 2.1). The area power, sometimes called total power, is a 
 58
measure of the size of the population of neurons within the area recorded by 
the electrode, whose membrane potential is oscillating in the γ-range (30-80Hz). 
The peak power and frequency at peak power must be looked at together as 
they define each other. The peak power is a measure of the strongest 
frequency within the γ-range; that is the size of the population of neurons whose 
membrane potential is oscillating at the strongest frequency.  
In a persistent γ-oscillation generated pharmacologically in a slice preparation, 
area power reflects the level of activation in the slice, but also the health of the 
slice, as a slice with a large proportion of dead or damaged cells has less cells 
overall to participate in any oscillation. Changes in peak power, on the other 
hand, also give a measure of changes in the synchronicity of oscillations within 
the area recorded by the electrode. Indeed, a new lower peak power with little 
change to area power in response to a pharmacological intervention, would 
suggest that the strongest synchronous oscillation in the slice has lost a 
proportion of the population previously engaged in it in favour of the pool of on-
going frequencies. On the other hand, an increase in peak power at the 
expense of area power would suggest an increased synchronicity as more cell 
assemblies in the slice would be oscillating at the same frequency. A change in 
peak power frequency suggests either a change in the output of γ-generating 
interneurons or a change in the subtype of interneuron responsible for the 
strongest oscillation recorded (Middleton et al., 2008).
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Figure 2.1 Generating and quantifying gamma-frequency oscillations in mEC. 
The glass recording electrode is placed in layer II/III of mEC (B) and baseline activity in 
aCSF in the local field potential (LFP) is recorded (Ai). Kainate is then added to 
generate -oscillations (Aii). A fast Fourier tansform is applied to 1-minute epochs of 
recording to obtain a power spectrum, which allows determination of the peak power, 
frequency at peak power and area power of the activity (Ci). IF these values vary by 
<20% over 40 minutes, oscillations are deemed stable (e.g. from 2.5 hours in Di). Once 
stable, drugs can be applied to the circulating aCSF and KA (Dii). A washout period is 
used to ensure the effect is specific to the drug and not simply due to deterioration of 
the slice.
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2.6 Data Analysis 
For each experiment, data from at least five to six slices were used. Data were 
analysed off-line using Microsoft Excel (Microsoft Inc., USA) and Prism 6.0 
(GraphPad Software, San Diego, California). For -oscillations, either the raw 
values (slices from injected animals) or the normalised values (acute exposure 
experiments) for power and frequency at baseline (average of last three 
recordings in stable period), after 60 minutes of drug/IgG application, and at 30 
minutes of washout were used for analysis. For normalisation, the average of 
the last three values during the stable baseline was defined as 100% for each 
individual slice. The power and frequency values for subsequent measurements 
were then converted to percentages of the baseline value. This allowed more 
accurate comparisons of the change in power or frequency by reducing the 
variability introduced by the highly variable baseline power. The normality of the 
results was determined by performing D’Agostino & Pearson’s omnibus 
normality test. This suggested that raw values for peak power, area power and 
frequency were mostly normally distributed in the larger groups of slices. When 
a sample size in an experiment was too small for the normality test to be valid, it 
was assumed that the data were likewise parametrically distributed. Results 
were therefore expressed as mean plus and minus standard deviation of the 
values at baseline, 60 minutes after addition of drug/IgG, and 30 minutes after 
the beginning of washout. In small experiments, this sometimes resulted in a 
standard deviation larger than the mean, because one oscillation had a much 
larger power than others and skewed the distribution within that group. 
However, to maintain consistency, it was assumed that the sample was part of 
a normally distributed population as in the larger groups. Means were compared 
using repeated measure ANOVAs. If data failed the normality test, they were 
expressed as median and interquartile range and compared with a Friedman 
test. The percentage change in power and frequency between groups (patient 
IgG, control IgG, vehicle, etc.…) were also compared using ordinary one-way 
ANOVAs or Kruskal-Wallis tests depending on normality. A p value of <0.05 
was considered significant. For data from the injected slices, two-way ANOVAs 
were used with IgG type (control or patient) and drug as factors. Correction for 
multiple comparisons was applied in most cases, unless it was clear that each 
comparison was independent of the other comparisons. 
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The choice of statistical test was not always straightforward. Non-parametric 
tests such as the Friedman or Kruskal-Wallis test have lower power to detect 
differences in groups that are actually present. This is because they compare 
ranks rather than means. There are therefore arguments to use parametric tests 
to compare results among the IgG preparations used. Firstly, peak and area 
power measurements were sometimes found to be normally distributed and 
other times not, suggesting that the result of the normality test was more likely 
related to the small sample sizes in this thesis than the real distribution of the 
measurements. Indeed, normality tests do not have much power in small 
sample sizes. Also, parametric tests such as t-tests and ANOVAs are relatively 
robust to violations of the parametric distribution of the groups compared. 
However, this only holds true for large sample sizes. The sample sizes 
compared here are relatively small, comprising n=5 to n=13. Additionally, many 
observations in the natural world are not normally distributed and it may be that 
oscillation power and frequency in slices similarly are not. A compromise 
position was therefore chosen of using non-parametric tests were when 
normality tests failed to demonstrate parametric distribution of the groups 
compared, in order to avoid type I error. 
2.7 Histological reconstruction of cells and 
immunohistochemical techniques 
Following the end of intracellular recording experiments, cells were filled with 
2% biocytin according to a standard protocol, giving 200ms hyperpolarising 
current pulses (-0.2 nA) every 100 ms for 15-20 minutes. The intracellular 
electrode was then carefully withdrawn, the slices was washed in aCSF for 10-
20 minutes and then placed in 4% paraformaldehyde in PBS and stored at 4°C 
until used for IHC.  
For cell reconstruction, no re-sectioning was carried out. The slices were 
washed in PBS, then incubated in 1% H2O2 in 10% methanol for 15 minutes. 
Following further PBS washes, the sections were permeabilised in 2% Triton X-
100 in PBS for 1 hour at room temperature. The slices were then incubated 
overnight in 1:200 Avidin-Biotin Complex (ABC Elite kit, Vector Labs, UK) in 1% 
Triton X-100 in PBS. The following day, slices were washed extensively in PBS 
and the chromogenic reaction was performed by incubating the slices in 3,3’-Di-
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aminobenzidine tetrahydrochloride (DAB, SigmaAldrich, UK) prepared in PBS 
for 5-10 minutes. Once the cells were visible under a microscope, the reaction 
was stopped by washing in PBS. The slices were mounted onto poly-lysine 
coated glass slides (VWR, UK) and allowed to air-dry before dehydration and 
coverslipping (see below). 
For immunohistochemistry for interneuron markers, slices were placed in 4% 
PFA in PBS at the end of electrophysiological recordings and stored at 4°C. On 
the day of use they were cryoprotected in 40% sucrose in TBS until sunk and 
resectioned to 40 m on a freezing stage microtome. Any remaining PFA and 
sucrose were washed off in TBS. Antigen retrieval was performed by two 5-
minute incubations in just-boiled 50mM Na+ citrate at pH 6.00, followed by TBS 
washes. Endogenous peroxidase activity was quenched with a 30-minute 
incubation in 70% methanol and 3% hydrogen peroxide (H2O2) at room 
temperature. This was followed by TBS washes and non-specific binding block 
by 1 hour incubation with 10% normal goat, horse or rabbit serum (Vector Labs, 
UK) depending on the secondary antibody being used. The primary antibody 
was diluted in TBS with 3% normal serum and 0.05% Tween as below: 
 Parvalbumin: 1:1500 
 Calretinin: 1:1000 
 Calbindin 1:10000 
 Somatostatin 1: 500 
 GAD67 1:1000 
 GABA 1:1000 
Slices were incubated in primary antibody overnight at 4°C then washed in 
TBS. Secondary antibodies were diluted to 1:200 in TBS with 0.05% Tween. 
Secondary antibodies used were: 
 Biotynilated horse anti-mouse 
 Biotynilated rabbit anti-goat 
 Biotynilated goat anti-rabbit 
Slices were exposed to the secondary antibody for 2 hours at room temperature 
on a rocker then washed in TBS and incubated in horseradish peroxidase 
(Ready-to-Use Streptavidin Horseradish Peroxidase, VectorLabs, UK) for 1 
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hour at room temperature followed by three TBS washes. The chromogenic 
reaction was then developed using DAB (Sigma-Aldrich, UK) for 5 minutes. 
Slices were then washed and mounted onto poly-lysine coated glass slides 
(VWR, UK). After air-drying overnight, sections were briefly re-hydrated in 
distilled water, followed by dehydration in increasing ethanol concentrations. 
Slides were bathed in 70%, 90%, 100% and a further 100% ethanol for 5 
minutes each. They were then bathed in Histoclear I and Histoclear II for 5 
minutes each before being coverlipped using Histomount. 
For slices undergoing double-labelling with anti-human IgG, antigen retrieval 
was performed as above. A 1-hour blocking step in 10% normal goat serum 
was performed and the sections were then incubated overnight with the primary 
antibody as above. The next day, the sections were incubated with 1:200 
fluorescently-labelled secondary antibodies (Goat anti-human IgG H+L antibody 
AlexaFluor 488, goat anti-mouse IgG AlexaFluor 568 and goat anti-rabbit 
AlexaFLuor 568, all Invitrogen, UK) for 2-3 hours at room temperature. The 
sections were then washed and mounted using DAKO fluorescent mounting 
medium containing DAPI. 
2.8 Cell-based assay 
The cell culture techniques described below were performed in a class II tissue 
culture hood under sterile conditions in the Neuroimmunology laboratory at the 
Nuffield Department of Clinical Neurosciences in Oxford. 
Human embryonic kidney 293 (HEK293) cells were grown in Corning T175cm2 
tissue culture flasks (APPW) in Dulbecco’s Modified Eagle Medium (DMEM, 
Sigma, UK) supplemented with 10% fetal calf serum (FCS, Sigma, UK) and 1% 
penicillin + streptomycin + amphotericin (PSA, Invitrogen, UK), maintained at 
37°C in a humidified atmosphere with 5% CO2 in an incubator. Cells were split 
at day 3-4, when 80-95% confluent, by aspirating the medium, and adding 2mls 
of 1% trypsin in PBS to the flasks. This separated the cells from the flask 
surface. Cells were then resuspended in DMEM-FCS-PSA, counted, and 
centrifuged at 1000RPM for 5 minutes. The supernatant was aspirated and the 
cells were partly re-seeded into new culture flasks or resuspended in DMEM-
FCS-PSA and seeded onto poly-L-lysine (PLL, Sigma, UK) coated 13mm glass 
coverslips (VWR, UK; briefly, this was done by placing four 13mm glass 
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coverlips in each well of a 6-well plate, adding 2 mls of PLL solution (0.01% in 
PBS) for 15-20 minutes, then aspirating the PLL solution and allowing the 
coverlips to air-dry inside the tissue culture hood) at a concentration of 4.6 x 105 
cells/well in 2mls of medium in 6-well plates. The plates were then incubated 
overnight. Transfection occurred the following day and was different for live and 
fixed cell assays. 
2.8.1 Live cell-based assay 
The cells in each well were transfected by adding a transfection mixture 
containing 2.1 g of NR1 cDNA, 0.7g of NR2B cDNA (i.e. 3:1 NR1: NR2B), 
0.2g of EGFP cDNA, 1.25L of 20% glucose and 1.5L of polyethylenimine 
(PEI) to 2mls of fresh DMEM-FCS-PSA. At 16 hours, the transfection medium 
was aspirated and replaced with fresh DMEM-FCS-PSA containing 500M 
ketamine to avoid glutamate-mediated cytotoxicity. The cell-based assay was 
performed the next day. First, the patient sera and CSF samples were diluted in 
DMEM containing 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buffer 
(HEPES, Sigma, UK) and 1% bovine serum albumin (BSA, Sigma, UK) for 
blocking. Serum was diluted 1:40 and CSF 1:10 to a total volume of 250L per 
sample. Further dilutions were done in steps of 3 (i.e. for serum 1:40, 1:120, 
1:360 etc.). Samples were transferred into 24-well plates and one transfected 
coverslip was added cell-side up to each well and incubated for 1 hour at room 
temperature. The supernatant was aspirated and the coverslip washed three 
times in DMEM-HEPES. The cells were then fixed in 4% formaldehyde in PBS 
for 10 minutes at room temperature, and the coverlips then washed again in 
DMEM-HEPES three times. The coverlips were then incubated in 250L/well of 
secondary antibody (goat anti-human IgG H+L, AlexaFluor 568, Invitrogen, UK) 
diluted 1:750 in DMEM-HEPES-1% BSA for 45 minutes at room temperature in 
the dark. Following aspiration of the secondary antibody, the coverslips were 
washed three times in DMEM-HEPES and 3 times in PBS prior to being 
mounted onto glass microscope slides (VWR, UK) using DAKO fluorescent 
mounting medium containing DAPI (Invitrogen, UK). Slides were allowed to dry 
for at least 30 minutes before being examined under a fluorescent microscope. 
Positive and negative controls were included in each assay. 
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Binding was assessed semi-quantitatively using the CBA scoring system 
developed by the Oxford group (Irani et al., 2010b). It is important to note that 
co-localisation of IgG surface binding with EGFP expression in the live cell 
assay was not frequent and that EGFP expression was mainly used as a 
marker to determine the success of the transfection. When no cell surface IgG-
binding was detected, a score of 0 was given. A score of 0.5 was given if a 
small number of cells were faintly bound. Scores of 1-4 denoted increasing 
number and intensity of fluorescence of IgG surface-binding. 
2.8.2 Fixed cell CBA 
There were a few notable differences in the preparation of the fixed CBA. The 
process of establishing the assay is discussed in Chapter 3, and the differences 
between the final form of the fixed CBA and the live CBA are described here. 
HEK293 cells were cultured and seeded as above. They were transfected using 
1.5L of NR1 DNA and 1.5L of NR2B DNA with glucose and PEI as above. No 
EGFP was used. On the day of the assay, the cells were fixed using 4% PFA in 
PBS for 5 minutes at room temperature and then washed 6 times in PBS. The 
coverslips were then incubated with PBS containing 10% BSA and 0.1% Triton-
X100 for permeabilisation and block for 1 hour at 37°C. The serum and CSF 
samples were diluted (1:40 and 1:10 respectively) in PBS with 1% BSA and 
coverlips incubated for 2 hours at room temperature. The coverslips were 
washed 3 times in PBS before incubating for 1 hour at room temperature with a 
commercial antibody against NR1 (IgG2a mouse monoclonal antibody against 
NR1 extracellular loop at amino acids 660-811, BD pharmingen) diluted 1:1000 
in PBS-1% BSA This is the same antibody used by Gresa-Arribas et al. (2014). 
This was followed by a further three washes in PBS and a 90-minute incubation 
with the secondary antibodies diluted in PBS-1% BSA at room temperature in 
the dark (AlexaFluor 568 goat anti-human IgG H+L antibody and AlexaFluor 
488 goat anti-mouse IgG2a antibody, Invitrogen). The coverlips were washed 
again in PBS and mounted, examined and scored as for live CBA. 
2.8.3 Euroimmun cell-based assay 
Euroimmun slides (Euroimmun, Lübeck, Germany) were used as per 
instructions, using the reagents provided in the diagnostic kit. Serum and CSF 
were diluted 1:10 (instructions suggest using undiluted CSF) using the PBS-
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tween supplied in the pack. 30L diluted sample was applied to each reaction 
field on the reagent tray and the biochip slides placed on the reagent tray. Once 
the biochips had been incubated with the samples for 30 minutes they were 
washed in PBS-tween and incubated with 25L of the ready to use fluorescein-
labelled anti human globulin provided for 30 minutes. Following a final wash in 
PBS tween they were cover-slipped in fluorescent mounting medium containing 
DAPI to visualise nuclei and examined under a fluorescent microscope. Results 
are normally reported as positive or negative, but here, a visual scoring system 
similar to the one for live CBA was used in order to correlate Euroimmun results 
with live CBA and fixed CBA results. Some samples were diluted further to 
determine endpoint titration. The procedure for Euroimmun 
immunohistochemistry was exactly the same. 
2.9  Immunohistochemistry for NMDAR-Ab 
IHC was performed as described in the most recent publications from Dalmau’s 
group (Gresa-Arribas et al., 2014; Planagumà et al., 2014). Female Wistar rats 
were anaesthetised in isofluorane and killed by CO2 inhalation. The brain was 
removed without perfusion, sagitally bisected and immersed in 4% PFA at 4C 
for one hour. The brain halves were then cryoprotected by immersion in 40% 
sucrose until sinking followed by embedding in freezing medium and snap-
freezing in isopentane chilled in dry ice. Attempts at cutting 7m thick section 
were abandoned in favour of slightly thicker slices (10-12µm), as the cryostat 
slicing was technically very difficult. Sections were air-dried overnight and then 
stored at -20C until use. When ready to use, slides were thawed for 30 minutes 
at room temperature and washed once in PBS. They were then serially 
incubated in 0.25% hydrogen peroxide at 4C for 10 minutes, 10% normal goat 
serum (NGS) for 1 hour at room temperature, and patient serum (1:120 in PBS 
with 3% NGS) or CSF (1:10 in PBS with 3% NGS) overnight at 4C. The next 
day, slides were washed and incubated with 1:2000 biotinylated goat anti-
human IgG antibody in PBS for 1 hour at room temperature. Reactivity 
amplification was performed by incubation with avidin-biotin complex for 1 hour 
at room temperature as per the “Vector lab” instruction manual and colour 
developed with diaminobenzidine for 5 minutes. Staining was scored visually 
from 0 to 4 as for live CBA at 1:120 for serum and 1:10 for CSF. Some samples 
were diluted further to determine endpoint titration. 
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3.1 Introduction 
When “anti-NMDAR encephalitis” was first described, it appeared to be a 
striking clinical syndrome of rapidly progressive neuropsychiatric symptoms 
followed by encephalopathy, autonomic instability and characteristic movement 
disorders, occurring almost exclusively in young women, most of whom had 
ovarian teratomas (Dalmau et al., 2007; Dalmau et al., 2008). Rapidly, the 
phenotype widened: the proportion of female patients decreased, as did the 
proportion of paraneoplastic cases, and the disorder was increasingly 
diagnosed in children of both sexes (Florance et al., 2009; Irani et al., 2010b; 
Titulaer et al., 2013). Partial phenotypes were reported. For example, Irani et al. 
(2010b) reported a cohort of 44 NMDAR-Ab positive patients, of whom 4 had 
seizures as the only symptom. Then, NMDAR-Abs were detected in the serum 
of 3 out of 47 patients presenting to an early intervention in psychosis service 
with psychiatric symptoms and without encephalopathy throughout the follow-up 
period (Michael S. Zandi et al., 2011), and also in two patients with 
subsequently pathologically confirmed sporadic Creutzfeldt-Jakob disease 
(Mackay et al., 2012). Although both patients had a clinical course typical for 
sCJD, negative CSF NMDAR-Abs and low serum titres, the results were 
surprising: no NMDAR-Abs had been reported in the serum of 32 healthy 
controls or 138 disease controls (including patients with autoimmune 
encephalopathy, chronic psychosis, multiple sclerosis, systemic lupus 
erythematosus, opsoclonus-myoclonus, herpes simplex encephalitis and 
epilepsy) using the same diagnostic assay (Irani et al., 2010b).  
These cases raised questions about the clinical specificity of the NMDAR-Abs, 
and the positive predictive value of the diagnostic assay used. For the purposes 
of this thesis and the work that follows in Chapters 4 to 6, it was important to 
better understand the nature of the assays performed, and their relationship 
with the well-defined clinical syndrome of “anti-NMDAR encephalitis” or 
NMDAR-Ab encephalitis as it will be called here. 
3.1.1 NMDAR-Ab assays currently in use 
Dalmau and co-workers originally detected NMDAR antibodies by 
immunohistochemistry on fixed rat brain sections (Vitaliani et al., 2005; Bataller 
et al., 2007; Dalmau et al., 2007), as used previously by the same group for 
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detecting paraneoplastic antibodies. What was striking in this case was the 
predominance of hippocampal neuropil staining. They then established a 
diagnostic approach based initially on CSF (and serum) binding to rodent brain 
sections in this pattern, together with binding of antibodies to fixed and 
permeabilised human embryonic kidney cells (HEK293 cells) transfected with 
equimolar NR1 and NR2B cDNA (f-CBA). To confirm that the antibodies were 
against cell surface epitopes of the NMDAR, they also used binding to live non-
permeabilised hippocampal neurons cultured from E18 rat foetuses, and 
modified the immunohistochemistry (IHC) technique to optimise the detection of 
cell-surface antigens (Dalmau et al., 2008; Gresa-Arribas et al., 2014).  
More recently they have reported that the live neurons are unnecessary as they 
cannot distinguish between different surface antigens, and that IHC and the f-
CBA are sufficient (Gresa-Arribas et al., 2014). In their experience, all patients 
who have NMDAR-Abs in either serum or CSF detected by these methods 
suffer from the characteristic NMDAR encephalitis syndrome they initially 
described (Dalmau et al., 2007; Dalmau et al., 2008; Gresa-Arribas et al., 
2014). Conversely, antibodies were not detected in a 250-strong control group 
consisting of healthy blood donors and disease controls (limbic encephalitis, 
Morvan’s syndrome, paraneoplastic disorders, Rasmussen’s encephalitis, 
epilepsy, viral encephalitis, and cancer with no neurological symptoms (Dalmau 
et al. (2008)). However, they found that serum testing in their hands missed 7% 
of positive results (f-CBA and IHC combined) in serum-CSF pairs, and claimed 
that CSF should always be tested (Gresa-Arribas et al., 2014).  
Although all NMDAR-Ab assays used elsewhere follow on from these initial 
studies, there are two alternative approaches. A commercially available 
Biochips mosaic test has been developed by Euroimmun (Lübeck, Germany) 
and is widely used throughout the world.  This contains 1mm2 chips of fixed 
cells expressing the NR1 and NR2 subunits or untransfected cells (Euf-CBA), 
with or without additional chips containing 4m thick sections of rat 
hippocampus and cerebellum (Eu-IHC). The advantage of the Euroimmun chip 
assay is its convenience and ease of use without the need for a laboratory with 
in-house molecular biology proficiency and maintenance of cell-cultures. 
However, interpretation of results is not straightforward (discussed later) and 
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requires expertise. Results are reported as positive or negative but semi-
quantitative reporting is possible by dilutions of samples. 
By contrast with the two techniques above, the Oxford laboratory uses a cell-
based assay consisting of live HEK293 (l-CBA) transfected with NR1 and NR2B 
cDNA at a 3:1 ratio, with addition of cDNA for enhanced green fluorescent 
protein (eGFP) expression to confirm transfection efficiency and visualise the 
cells expressing the NMDAR subunits. A visual scoring system has been 
developed to report the results, with scores of 0 to 1 reported as negative, 1.5 
as low positive and 2-4 as positive (Irani et al., 2010b; M. S. Zandi et al., 2015). 
The advantage of using live cells is that the assay should only detect the 
pathologically relevant antibodies directed against the extracellular NR1 epitope 
(although antibodies to NR2, if present, could be detected). In the experience of 
the Oxford service, testing for antibodies in serum is sufficient as CSF is 
sometimes negative for NMDAR-Abs in paired serum and CSF samples 
(Vincent and Bien, 2008; Irani et al., 2010b; M. S. Zandi et al., 2015) whereas 
the reverse has never been identified. 
3.1.2 Comparisons of current assays 
Limited comparisons of some of these diagnostic assays have been published. 
After finding that f-CBA was negative in 13.2% of sera with a paired positive 
CSF sample (about half of these serum samples were positive by IHC) and that 
IHC was negative in 8.4% of sera with a paired positive CSF sample (1.2% 
positive on f-CBA), Gresa-Arribas et al. (2014) investigated whether l-CBA 
could improve detection of NMDAR-Abs in serum. Instead, they found that l-
CBA was less “sensitive” than f-CBA. It is worth noting that they introduced a 
permeabilisation step in the l-CBA, which is not present in the Oxford L-CBA, 
such that their results may not reflect the findings using the Oxford L-CBA. The 
general conclusion was that CSF was more sensitive and easier to use because 
of reduced background/non-specific binding, and sufficient in all cases. 
However, in that study, NMDAR encephalitis was defined as the “new onset of 
neuropsychiatric symptoms with positive serum or CSF antibodies” by the 
Barcelona methods. The samples, and therefore patients, used in the study 
were chosen from a larger cohort of positive serum-CSF sample pairs known to 
belong to patients with NMDAR encephalitis. The diagnosis was not 
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independent of the antibody result, and unsurprisingly therefore, they found that 
one of their methods (CSF f-CBA and/or IHC) was 100% sensitive (Gresa-
Arribas et al., 2014), and negative results were obtained in the 100 control 
patients. There is no gold standard for the diagnosis of NMDAR-Ab encephalitis 
at present. This makes it difficult to assess the sensitivity and specificity of any 
of the established tests, or the relevance of the presence of positive results in 
potentially related conditions, such as isolated psychosis or isolated focal 
epilepsy. 
The sensitivity of a test refers to the proportion of positive results in those who 
have the disease, and therefore requires an antibody-independent definition of 
the disease and acknowledgement of the false-negative rate of the test. This 
has not been reported for any of the tests. Additionally, the Barcelona group 
exemplify the high specificity of their method by pointing out that no NMDAR-
Abs were found in the serum of 80 patients with schizophrenia during their first 
psychosis episode (Masdeu et al., 2012) (cf. Michael S. Zandi et al. (2011) 
above). However, CSF studies, which they consider more sensitive, were not 
undertaken in that study. It would be more correct to say that the positive 
predictive value (PPV) rather than the sensitivity of CSF f-CBA and IHC was 
100% in Gresa-Arribas et al. (2014), whilst serum f-CBA and IHC had PPVs of 
86.8% and 91.6% respectively. 
Another notable difference between using l-CBA and f-CBA combined with IHC 
is the results of paired CSF and serum samples: negative CSF in the presence 
of positive serum has reportedly never been found in the Barcelona laboratory 
(Gresa-Arribas et al., 2014), whilst this is sometimes the case with l-CBA (Irani 
et al., 2010b; M. S. Zandi et al., 2015). The reason for this difference is not 
clear: it could be caused by non-specificity of the l-CBA or because the fixation 
used in both IHC and f-CBA masks some epitopes bound by a population of 
serum antibodies which are not present in the CSF. 
There was a comparison of Euf-CBA and Eu-IHC with results from the 
Barcelona laboratory f-CBA and IHC (Wandinger et al., 2011). 100% 
concordance between Euf-CBA and the Barcelona f-CBA and IHC was found in 
a study of 66 serum and CSF NMDAR-Ab-positive samples and 381 control 
samples (Wandinger et al., 2011). The same result was obtained with Eu-IHC, 
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although the control samples from patients with other antibody-mediated 
encephalitides also produced hippocampal and cerebellar staining, albeit in a 
different pattern to NMDAR-Abs. However, previous experience in the Oxford 
laboratory (Vincent, unpublished) did not support the 100% sensitivity of the 
Euf-CBA even in patients with definite disease and high titres with l-CBA. 
Other large studies using the Euf-CBA have found much higher prevalence of 
NMDAR-abs (about 10%) in the serum of healthy controls and patients with a 
number of neurological or psychiatric conditions including schizophrenia, 
affective disorders, Parkinson’s, stroke, and motor neurone disease (Steiner et 
al., 2013; Dahm et al., 2014; Steiner et al., 2014). However, IgA and IgM 
subclass antibodies, which are not specific to the NMDAR encephalitis 
syndrome and are of doubtful pathological relevance even when present in the 
CSF, were far more common than IgG (0.5% in schizophrenia and 0.6% in 
healthy controls in Steiner et al. (2014); 0.6% in schizophrenia and 1.2% in 
healthy controls in Dahm et al. (2014)). This rate of positivity in healthy and 
disease control populations has not been found in any of the Barcelona group 
studies discussed above using f-CBA and IHC, or in the original Oxford study 
using l-CBA (Irani et al., 2010b).  
These studies were large serum screening studies and did not investigate any 
differences in disease presentation or severity among the disease controls. 
Furthermore, the prevalence amongst healthy controls matched that of disease 
controls, arguing against a pathological role even of the IgG subclass 
antibodies. Indeed, the authors felt the detected antibodies were some of a 
large number of constitutively expressed antibodies against brain epitopes, 
which form a sort of “physiological autoimmunity”, which may modulate brain 
function in both health and disease (Dahm et al., 2014). The titres of IgG 
subclass NMDAR-Ab in these studies are also unclear but may have been 
rather low, so it is difficult to comment on whether a cut-off for pathogenicity 
could be established, or whether substantial CSF presence of NMDAR-abs 
could be predicted from the basic transfer rate of IgG across the BBB of 1:400 
of the serum IgG concentration. 
There are two other interesting observations to note from the Dahm et al. (2014) 
study: firstly, over 50% of the seropositive cases for each antibody investigated 
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(they also quantified seropositivity for 24 other brain antigens including CASPR-
2, LGI-1, GAD-65, amphiphysin, MOG, AQ4, AMPA and GABA R) were male, 
including in the healthy controls, whereas a female preponderance is usually 
expected in most autoimmune diseases or autoimmune diathesis. Secondly, 
seropositivity for any antibody of any Ig subclass was greater in the group of 
patients with schizophrenia compared to those with borderline personality 
disorder or those whose diagnosis was reclassified from schizophrenia to 
“mental illness not yet specified”. Is this relevant to schizophrenia 
pathophysiology in terms of its association with variations in Major 
Histocompatibility Complex (MHC) locus? Similarly, seropositivity was high for 
all antibodies in the group of patients with stroke, perhaps suggesting a 
secondary antibody response following the insult of the stroke and subsequent 
neurodegeneration (as perhaps seen in the patients with sporadic CJD 
discussed above). 
Overall, these studies suggest that IgG NMDAR-Ab, which is what hospital 
laboratories would test for upon receiving a request for NMDAR-Ab testing, are 
present in at most 1% of patients who do not appear to have NMDAR-Ab 
encephalitis using the Euf-CBA. It is not yet clear if this is the false-positivity 
rate of the Euf-CBA in serum caused by difficulties in reading it (see later 
discussion), which could be resolved by re-testing these same samples using l-
CBA/f-CBA and IHC, or whether it reflects the rate of presence of these 
antibodies in the general population. In the latter case further information 
regarding titres and presence in CSF would need to be obtained in order to 
determine if a cut-off for pathogenicity exists, as is the case with some other 
autoantibodies. 
3.1.3 Aims 
The arguments put forward by the Barcelona group would suggest that l-CBA is 
both less sensitive and less specific than f-CBA or IHC. Furthermore, Euf-CBA 
and Eu-IHC have not been compared to l-CBA directly.  
A comparison of l-CBA, f-CBA, ICH and Euf-CBA was therefore undertaken 
using serum and paired CSF samples, when available, stored at the Oxford 
Neuroimmunology laboratory. L-CBA-positive serum samples or negative serum 
samples from previously positive patients were chosen with no knowledge of 
 77
the final diagnosis, as well as a number of control samples from patients with 
other diagnoses including limbic encephalitis syndromes. Once all assays had 
been performed and scored, clinical data acquisition (still on-going) 
commenced, with the aim of correlating test results with final diagnosis.  
This sampling method was chosen as it offered some advantages over the 
methods in Gresa-Arribas et al. (2014). Firstly, by not limiting the study to 
clinically clear cases of NMDAR encephalitis, the presence of NMDAR-Abs in 
other conditions, and whether these can be detected by f-CBA, IHC or Euf-CBA, 
might be highlighted. Secondly, it would allow inclusion of l-CBA false-positives 
and comparison of the false-positive rates across tests. Thirdly, the results of 
repeat samples from previously NMDAR-Ab-positive patients might provide a 
hint at the detection thresholds of each test. Finally, whether different detection 
thresholds for CSF NMDAR-Abs for each test explain the discrepancy in 
published CSF-serum pairs between Oxford and Barcelona might also be 
addressed. 
This study was performed in the Neuroimmunology laboratory at the Nuffield 
Department for Clinical Neuroscience in Oxford with the assistance of Dr Matteo 
Gastaldi, a visiting clinical fellow from Pavia, Italy. 
3.2 Methods 
3.2.1 Live CBA 
L-CBA was performed according to the Oxford neurosciences group protocol 
described in Chapter 2 (Irani et al., 2010b). Cells were transfected with 
untagged NR1 and NR2B cDNA at a 3:1 ratio as well as a eGFP expression 
vector to visualise transfection using polyethylenimine (PEI). Serum samples 
were diluted 1:40 in DMEM-HEPES with 1% bovine serum albumin (BSA; note 
Oxford standard protocol for clinical diagnosis uses 1:20 dilution but 1:40 
dilution was used to standardise across tests). CSF samples were diluted 1:10 
(Oxford uses CSF diluted 1:2, but only small quantities of CSF were available 
and had to suffice for 4 diagnostic tests so dilution had to be increased). After 
incubation with patient samples, cells were fixed with 4% PFA in PBS. Binding 
of human IgG to surface NMDAR was detected using goat anti-human IgG H+L 
antibody AlexaFluor 568. Coverslips were examined using a fluorescent 
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microscope and scored independently by Dr Gastaldi and myself, using the 
semi-quantitative scoring system devised by Oxford. Some samples were 
diluted further to determine endpoint titration. 
CBA scoring 
The semi-quantitative scoring system used here was developed at the Oxford 
Neuroimmunology service (Leite et al., 2008). Scores from 0-4 are given as 
follows: 
 0: no labelling 
 0.5: weak labelling of a few transfected cells with no obvious GFP co-
localisation 
 1: weak labelling of some of the transfected cells with precise co-
localisation 
 2: moderate labelling of some (~20-50%) of the transfected cells, with 
precise co-localisation 
 3: moderate/strong labelling of 50-80% of the transfected cells, with 
precise co-localisation 
 4: strong labelling of virtually all transfected cells with precise co-
localisation 
This scoring system is not linear, and scores depend on transfection efficiency 
as well as NMDAR-Ab concentration in the sample assayed. To more 
accurately compare NMDAR-Ab concentration between different samples, serial 
dilutions of samples to determine end-titres would be more useful. Our early 
assays were also independently scored by experienced research assistants 
usually responsible for scoring diagnostic assays. This allowed us to validate 
our scores. 
3.2.2 Fixed CBA 
The Barcelona f-CBA was performed as closely as possible to the method 
described in Gresa-Arribas et al. (2014). Only the differences from l-CBA are 
noted here: HEK293 cells were transfected with NR1 and NR2B cDNA in 
equimolar ratio with no EGFP (rather than 3:1 with untagged EGFP). Cells were 
fixed with 4% PFA and permeabilised in 0.1% Triton-X100 before the start of 
the assay (rather than fixation occurring after exposure to patient samples). 
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1:40 serum or 1:10 CSF diluted in PBS with 1% BSA were used (rather than 
using DMEM-HEPES with 1% BSA). Coverlips were also incubated with a 
mouse monoclonal antibody against the extracellular loop of NR1 to allow 
colocalisation with any bound human IgG, before incubation with the two 
secondary antibodies. Scoring was done as above. Some samples were diluted 
further to determine endpoint titration. 
3.2.3 Euroimmun CBA 
Euroimmun slides were used according to the instruction manual supplied 
(EUROIMMUN Medizinische Labordiagnostika AG, 2011) as described in 
Chapter 2. Serum was diluted 1:10 using the PBS-tween supplied in the pack, 
and CSF was not diluted as suggested in the instructions. Results are normally 
reported as positive or negative, but here, a visual scoring system similar to the 
one for l-CBA was used in order to correlate Euroimmun results with l-CBA and 
f-CBA results. Some samples were diluted further to determine endpoint 
titration. The procedure for Eu-IHC was exactly the same. 
3.2.4 Immunohistochemistry 
IHC was performed as described in the most recent publications from the 
Barcelona group (Gresa-Arribas et al., 2014; Planagumà et al., 2014) except 
that TBS was used instead of PBS. Patient serum was diluted to 1:120 in TBS 
with 3% NGS and CSF to 1:10 in TBS with 3% NGS. Staining was scored 
visually from 0 to 4 as for l-CBA at 1:120 for serum and 1:10 for CSF. Some 
samples were diluted further to determine endpoint titration. 
3.3 Results 
3.3.1 Comparison of l-CBA with original l-CBA results 
Ninety-one serum and twenty-six CSF samples sent to the Neuroimmunology 
laboratory at Oxford from 2012-2014 were selected by AV for use in this study. 
For some patients, samples were available from different time points such that 
the serum of 80 patients and the CSF of 25 patients were tested (see Figure 
3.1). Of the 25 patients with available CSF, 8 had no serum available for study. 
The total number of patients in the study was therefore 88. For the CSF 
samples, 10 were paired with serum samples, 8 had been obtained separately 
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from serum (2 samples from 1 patient), and 8 were from patients for whom 
there were no serum samples available. The major barrier to finding paired 
serum and CSF samples was the number of empty or insufficient CSF samples 
available after routine diagnostics since the amounts provided by the referring 
laboratories are highly variable. 
L-CBA was repeated in all serum (1:40) and CSF (1:10) samples, and scored 
independently by AT and MG blind to the original result (done at 1:20 serum; 
1:2 CSF by Dr Jacobson, Oxford University). Examples of serum and CSF 
samples scoring 0-4 are shown in Figure 3.2. Although the cells were co-
transfected with eGFP as well as the NMDAR subunits, there was often poor 
co-localisation of human IgG with eGFP in l-CBA, since the NR1, NR2B and 
EGFP are on independent plasmids and the eGFP is mainly used to 
demonstrate successful overall transfection. In the l-CBA, scores of 0.5 and 1 
are given when only a few cells are weakly labelled, with some co-localisation 
with eGFP required for a score of 1. These scores are reported as negative, but 
they can indicate emerging or decreasing positivity. L-CBA reporting has been 
under continuous review by the Oxford laboratory, and the cut-off for positivity 
was adjusted to 1.5 based on audits of the clinical relevance of positive results 
(M. S. Zandi et al., 2015). Similar information or qualitative data have not been 
reported for the other assays. This does not apply to CSF, however, and any 
score of 0.5 or above is reported as positive. 
The results of the original l-CBA were positive for 70 serum samples (61 
patients) and negative in 21 serum samples (20 patients; one patient had 1 
positive and one negative serum sample in this study). For CSF, 9 samples 
were positive in the original l-CBA and 17 were negative. 
Among the sera positive on the original l-CBA, scores on the new l-CBA were 
lower (see Table 3.1 and Figure 3.3 A), with twelve samples scoring 0, and 29 
samples now scoring below the usual cut-off for positivity (1.5). A small 
reduction in scores was expected as a higher dilution was used in this study, 
but the range of reduction varied widely, consistent with a loss of reactivity 
caused by antibody degradation during the prolonged storage period (-20C). 
The 12 serum samples whose scores had decreased from an original threshold 
score of 1.5 or more to 0 were therefore excluded from further analysis, leaving 
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58 sera from 50 patients. No serum samples originally scoring 0.5 or 1 were 
excluded however, as although these would have been reported as negative 
when originally tested, we wished to investigate the possibility that other 
techniques might be more sensitive than l-CBA. Moreover, a difference of 0.5 
points in the scoring at such low levels of binding can be hard to detect and it 
cannot be ruled out that our relative inexperience may have played a role in the 
variability in the lower scores obtained, as well as the higher dilution used. 
Despite excluding the 12 serum samples that had lost reactivity, the new serum 
scores remained lower than the original scores (see Figure 3.3 B). Most of the 
sera originally reported as negative (n=21) scored 0 in the new l-CBA, except 
for two samples, which scored 1.5 and 2, and had originally scored 1 (Figure 
3.3 C). Among the 9 originally positive CSF samples, scores on the current l-
CBA were generally lower, with three samples scoring 0, but this did not reach 
statistical significance (Table 3.1 and Figure 3.3 D). As these samples had 
originally scored 1, and the reduction in score may have been related to the 
increased dilution of the samples, they were not excluded from the study. All 
CSF samples scoring 0 in the original l-CBA remained negative in the new l-
CBA. 
Table 3.1 Comparison of original and new l-CBA scores among originally 
positive samples (>1.5 for serum; >0 for CSF) 
 Original l-CBA 
score (serum 1:20/ 
CSF 1:2) 
New l-CBA score 
(serum 1:40/ CSF 
1:10) 
Paired t-test 
 Mean S.D. Mean S.D. T, df P 
Serum1 
(n=70) 
2.27 0.947 1.5 1.129 7.556, 69 <0.0001 
Serum2 
(n=58) 
2.38 0.957 1.81 0.986 5.902, 57 <0.0001 
CSF 
(n=9) 
1.83 1.00 1.11 1.14 1.982, 8 0.083 
1 all originally positive serum samples 
2 originally positive serum samples that have lost reactivity completely excluded 
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Figure 3.1 Serum and CSF samples included in present study 
L-CBA: live cell-based assay; F-CBA: fixed cell-based assay; IHC: 
immunohistochemistry on frozen rat brain sections; Euf-CBA: Euroimmun biochip cell 
based assay. Numbers in brackets on bottom row for L-CBA denote the number of 
samples scoring 0, as serum scores of 0.5 and 1 are reported as negative. In all other 
tests any score above 0 was considered positive.  
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Figure 3.2 Examples of scores 0-4 on L-CBA 
Pictures in the first two rows illustrate serum samples scoring from 0-4 on live cell CBA. 
Magnification is x40 and scale bar represents 50m. Magnified (x2) insets are included 
for detail. The photographs show merged EGFP and AlexaFluor 568 anti-human IgG 
fluorescence. Coverslips with no human IgG-bound cells scored 0. If weak red 
fluorescence was present in isolated cells, a score of 0.5 was given, and if this weak 
labelling co-localised with EGFP a score of 1 was given. 1.5 was given in cases where 
the anti-human IgG fluorescence was weak but present in about 20% of cells, with 
some co-localisation with EGFP. Scores from 2-4 were assigned on the basis of 
increasing intensity of anti-human IgG immunofluorescence and increasing number of 
labelled cells. The criteria for co-localisation with EGFP was not strictly applied as only 
the minority of cells binding anti-human IgG also expressed EGFP. On l-CBA, non-
specific background staining with both serum and CSF (see bottom row for examples) 
was minimal, and the same scoring rules applied for both. 
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Figure 3.3 Comparison of scores in original l-CBA and current l-CBA 
The originally positive serum scores (1:20) were higher than the new serum scores 
(1:40), when compared before (Ai, mean ± S.D) and after (B, mean ±SD) exclusion of 
samples with loss of reactivity. The variability of change is shown in Aii. Originally 
negative serum samples remained so in the new l-CBA (C). There was no difference 
between original and new scores for positive (D) or negative (not shown) CSF 
samples. E shows the scores of serum and CSF pairs in the original and repeat l-CBA. 
CSF scores were usually lower than serum scores.
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Inter-observer agreement was high on first-pass scoring (92.5%, CI 84.39-97.2 
%; scores > 2 within 1 point of each other, and scores 0-1.5 within 0.5 of each 
other). If scores differed, the assay was re-scored independently. If this did not 
resolve the inter-observer variability the sample was re-tested. 
In the original l-CBA, six of the 10 serum-CSF pairs had lower scores in CSF 
than serum (of which three were 0 in CSF) and three had equal CSF and serum 
scores. Only one CSF scored higher than the paired serum. That CSF had been 
obtained from an intraventricular catheter in a patient with a very severe 
disease course. The distributions were similar in the new l-CBA (see Figure 3.3 
E). Four of the eight CSF samples that were associated but not paired with a 
serum sample had lower CSF scores (two were negative) and the remaining 
four had equal serum and CSF scores.  These scores, however, do not take 
into consideration the different dilutions used here. 
3.3.2 Developing the Barcelona fixed cell CBA 
In order to compare the results obtained with l-CBA with those that would be 
obtained with the Barcelona methods, a f-CBA protocol was developed based 
on the methods published by this group. This was not straightforward as the 
description of their CBA methodology was always brief and clearly evolved over 
publications (Table 3.2).  
In the first attempts the 3:1 NR1:NR2B ratio was maintained and EGFP was 
used to visualise transfection as this allowed transfection success to be rapidly 
checked prior to starting the CBA. Samples and secondary antibody were 
diluted in DMEM-HEPES with 1% BSA as in the l-CBA. Non-specific 
background staining was very high with serum samples in all these trials (Table 
3.3 and Figure 3.4 top panel), such that it was not possible to differentiate 
positive samples and negative controls. 
Background appeared much reduced once the dilutant had been switched to 
PBS with 1% BSA, and a 1-hour block with permeabilisation at 37C had been 
introduced, suggesting that DMEM-HEPES was perhaps more difficult to wash 
away in fixed and permeabilised cells, and that access of the 1% BSA as 
blocking agent to the intracellular compartment was helpful (Figure 3.4 middle 
panel). 
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Table 3.2 Comparison of f-CBA methods published by Dalmau’s group over time 
and with l-CBA. 
 Dalmau 
2007 
Dalmau 
2008 
Gleichma
n 20121 
Gresa-
Arribas 
2014 
Honnorat 
2015 
Unpub-
lished 
L-CBA 
NMDAR 
subunits 
NR1 = 
NR2A/B 
NR1 = 
NR2A/B 
NR1=NR2B NR1=NR2B NR1-EGFP 
and NR2B 
NR1:NR2
B 
3:1+EGFP 
Plasmids N/R N/R N/R N/R N/R NR1: 
pCDNA 
3.1+ 
NR2B: 
pCDNA 
3.1 hygro 
Invitrogen 
Total 
DNA 
concen-
tration 
N/R N/R 2g/ml 
medium 
N/R N/R 1.5g/ml 
medium 
Transfec
-tion 
method 
N/R N/R Calcium 
Phosph-ate 
N/R Lipofect-
amine 
Polyethyle
-nimine 
Post-
transfec-
tion 
Up to 24h 
500M 
ketamine 
Up to 24h 
500M 
ketamine 
Up to 24h 
500M 
ketamine 
Up to 24h 
500M 
ketamine 
Up to 24h 
500M 
ketamine 
Up to 24h 
500M 
ketamine 
Fixation Post 
incubation 
4% PFA-
PBS 
Pre 
incubatio
n 
4%PFA-
PBS  
Pre 
incubation 
4%PFA-
PBS 
Pre 
incubation 
4%PFA-PBS 
Pre 
incubation 
4% PFA-
PBS 
Post 
incubation 
4% 
formalde-
hyde-PBS 
Duration N/R N/R 10 min 
RT 
5 min 
RT 
10 min 10 min 
RT 
Permea-
bilisation 
N/R 0.3% 
Triton 
after fix 
0.3% Triton 
after fix 
0.3% Triton 
after fix 
0.1% Triton 
+ block  
No 
Duration  N/R 10 min 
RT 
5 min 
RT 
1h N/A 
Block N/R N/R 10% BSA-
PBS 
1h RT 
N/R 0.2% 
gelatin-PBS 
+triton 1h 
RT 
Samples 
diluted in 
DMEM-
HEPES 
w.1% BSA 
Samples       
Serum 
 
Max 1:400 1:200 N/A 1:40 1:5 1:20 
CSF Max 1:10 1:10 1:10-100 1:2 1:5 1:2 
Dilutant  N/R N/R PBS w.1% 
BSA 
N/R Saturation 
buffer 
DMEM-
HEPES w. 
1% BSA 
Duration N/R N/R ON 4C 2h RT 90 min 1h RT 
NMDAR N/R Anti-NR1 Anti-NR1 Anti-NR1 Ab4 NR1+EGFP EGFP-not 
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labelling Ab2 Ab3 conjugated conjugated
Duration N/R N/R ON 4C 1h RT N/A N/A 
2 
antibody 
N/R 
“appropriat
e 
fluorescent 
secondary 
abs” 
N/R AlexaFluor 
488 goat 
anti-human 
IgG 1:1000 
in PBS 
w.1% BSA 
Goat 
AlexaFluors
: 488 anti-
human IgG, 
1:1000 + 
594 anti-
mouse IgG, 
1:1000 
cy3-
conjugated 
anti-human 
IgG 
containing 
DAPI  
 
AlexaFluor 
568 goat 
anti-
human 
IgG 1:750 
Duration N/R N/R 2h 37C 1h RT N/R 45 min  
Dilutant N/R N/R PBS w. 1% 
BSA 
N/R N/R DMEM-
HEPES w. 
1% BSA 
Medium 
for 
washes 
N/R N/R PBS PBS PBS likely DMEM-
HEPES 
1 not diagnostic assay protocol, research protocol 
2 rabbit monoclonal anti NR1 1:10000, AB9864, Chemicon, C-terminus aa 909-938. 
3 mouse monoclonal anti-NR1 1:1000, 556308, BD Biosciences, against TM3-4 loop 
aa 660-811. 
4 mouse monoclonal anti-NR1 1:20000, MAB363 Millipore, against TM3-4 loop aa 660-
811. 
N/A not applicable; N/R not recorded; ON overnight; RT Room temperature; PBS 
phosphate buffered saline; BSA bovine serum albumin; DMEM-HEPES Dulbecco’s 
modified Eagle’s medium with HEPES. 
 
Non-specific background staining appeared to improve further when cells were 
transfected with equal concentrations of NR1 and NR2B with no EGFP (Table 
3.3, and Figure 3.4 bottom panel). However, it was noted that cells fixed more 
than 48 hours prior to CBA were generally in poor condition with very few cells 
adhering to the coverslips and a number of apparently lysed cells present, 
suggesting that storage of fixed cells in PBS at 4C was not advisable. There 
was no non-specific background with CSF samples in any of the methods 
tested, as for the l-CBA.
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Table 3.3 Results of initial trials of f-CBA 
Trial NR1:NR2B 
EGFP 
Dilutant Permeabilisation 
and block 
Result 
1 3:1 + EGFP DMEM-
HEPES + 
1% BSA 
0.3% Triton 
10min, no block 
Background 
++ 
unreadable 
2 3:1 + EGFP DMEM-
HEPES + 
1% BSA 
But PBS 
washes 
½ permeabilised 
with 0.1% Triton 
at each step; 
10% BSA block 1 
h in ½  
Background 
++ 
unreadable 
3 3:1 + EGFP PBS-1% 
BSA PBS 
washes ++ 
0.3% Triton 10 
min 
Background 
++ and no 
effect of 2Ab 
dilution 
No 
background if 
omit serum 
4 3:1 + EGFP PBS-1% 
BSA 
5% BSA + 5% 
NGS 1h  
0.1% Triton in 1/2 
background 
readable 
perm=no 
perm 
NB: few cells 
5 3:1 + EGFP 
½ coverslips 
untransfected 
PBS-1% 
BSA 
5% BSA + 5% 
NGS + 0.1% 
Triton 1h 
Untransfected 
cells aided 
interpretation 
6 1:1 PBS-1% 
BSA 
10% BSA + 0.1% 
Triton 1 h 
Anti-NR1 Ab 
labels ++ cells 
with minimal 
background 
background 
with serum 
easy readable 
7 1:1 PBS-1% 
BSA 
10% BSA + 0.1% 
Triton 1 h 
Fixed cells 
stored for 5 
days: in poor 
condition 
8+9 3:1+EGFP vs.  
1:1  
PBS-1% 
BSA 
10% BSA + 0.1% 
Triton 1 h 
Much less 
background in 
1:1 w/o EGFP 
 The final protocol used for the f-CBA was as follows: 
 Growing and seeding of HEK293 cells as for l-CBA 
 Transfection on day 2 with 1.5g each of NR1 and NR2B cDNA per well 
(total 1.5g/ml of medium). 
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 Change to medium containing 500M ketamine 16 hours after 
transfection 
 CBA performed on day four: 
o Cells fixed with 4% PFA in PBS for 5 minutes at room temperature 
followed by 6 rapid PBS washes 
o Cells incubated with 10% BSA and 0.1% TritonX-100 in PBS for 1 
hour at 37C followed by a single PBS wash 
o Serum samples diluted 1:40 and CSF 1:10 in PBS with 1% BSA 
(and further dilutions in steps of 3 if required) and transferred into 
24-well plates 
o Single coverslip added to each well (cell side up) and incubated 
for 2 hours at room temperature 
o 3 PBS washes 
o 1 hour incubation at room temperature with commercial anti-NR1 
antibody at 1:1000 in PBS with 1% BSA 
o 3 PBS washes 
o 90-minute incubation with fluorescently-labelled secondary 
antibodies at 1:1000 in PBS with 1% BSA at room temperature 
o 3 PBS washes 
o coverslips placed on microscope slides cell-side down in mounting 
medium with DAPI 
 90
 
 
Figure 3.4 Results of first attempts at f-CBA 
The first attempts at f-CBA, using 3:1 NR1:NR2 with untagged EGFP transfection and 
no specific blocking step yielded very high non-specific background (see 1st panel), 
with every cell (denoted by blue DAPI stain) being bound by anti-human IgG 
fluorescent antibody (red) such that no specific NMDAR staining could be detected. 
The introduction of a blocking step alone was not sufficient to reduce the background 
(1st row of second panel), but changing the dilutant for serum and CSF to PBS and 
permeabilising and blocking simultaneously for 1 hour at 37C appeared to markedly 
reduce background staining (middle and bottom row of second panel) such that 
specifically IgG-bound were detectable above background. Not using EGFP 
transfection and instead co-localising with a commercial NR1 antibody appeared to 
further reduce non-specific staining. Scale bar is 50m, pictures taken at x20 
magnification.
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Despite optimisation of the developed protocol, non-specific staining with serum 
was much stronger than in the l-CBA; nevertheless, detection of NMDAR-
antibody binding was still possible after optimisation, as this appeared in a very 
specific cell-membrane pattern, whilst the background staining was present at a 
lower intensity throughout the cytoplasm of the cells (see Figure 3.5). 
Additionally, there was good co-localisation with the commercial anti-NR1 
antibody (see bottom panel of Figure 3.5). The non-specific staining sometimes 
made interpretation of low-positives difficult at 1:40 dilution, in which case a 
higher dilution (1:120) helped clarify the results, as background staining was 
considerably weaker (Figure 3.5). Therefore, serum was always tested at both 
these dilutions for the f-CBA. For the analysis, the score at 1:40 was used.  
There was no background staining with CSF, as in the l-CBA, and CSF was 
therefore tested at 1:10 only and any value of 0.5 and above considered 
positive. Examples of serum and CSF scores 0 to 4 are shown in Figure 3.6 and 
Figure 3.7. 
All observed binding (scoring from 0.5) was considered positive. This was 
because, unlike for l-CBA results’ reporting, which has been under continuous 
review by the Oxford laboratory as was described above, f-CBA scoring and 
reporting information is not available in the literature. Additionally, co-
localisation of human IgG with commercial NR1 antibody staining was very 
consistent in the f-CBA, improving the confidence with which the result could be 
stated as positive, once non-specific binding to all cells has been taken into 
consideration.
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Figure 3.5 Non-specific background staining with serum in f-CBA. 
Non-specific background staining of cells in f-CBA with serum was marked in 
comparison to l-CBA (see Figure 3.2). The top panel shows three examples of results 
obtained with negative control serum samples. Background staining is present 
throughout the cytoplasm of all the cells (red), sometimes with variable intensity (e.g. 
middle and bottom row). Background staining reduced markedly at 1:120 dilution of 
serum. This pattern of staining can be distinguished from NMDAR-specific IgG binding 
(red, bottom panel), which is present in a cell-membrane pattern similar to that seen in 
l-CBA. NMDAR-specific human IgG binding (red) co-localised well with anti-commercial 
NR1antibody-binding (green), which appeared more diffusely present throughout the 
cytoplasm as well as in the cell membrane. NMDAR-specific human IgG binding 
remained present at 1:120 in the majority of samples tested, whilst non-specific 
background diminished markedly. Scale bar 50 m, pictures taken at x40 
magnification. 
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Figure 3.6 Scoring of f-CBA results for serum samples 
Pictures illustrate serum samples scoring from 0-4 on fixed cell CBA. Magnification is 
x20 in the top panel and x40 in the middle and bottom panels. Scale bar represents 
50m. Magnified (x2) insets are included for detail. The photographs show anti-human 
IgG staining alone (red) followed by merged anti-human IgG and anti-NR1 antibody 
(green) binding. Coverslips with background staining only scored 0. If weak red 
fluorescence was present in isolated cells in the correct pattern (confirmed by 
increasing signal:noise ratio at 1:120 dilution), a score of 0.5 was given (same sample 
shown at both dilutions here). Scores of 1-4 were given based on increasing intensity 
and density of bound cells. Unlike for l-CBA, colocalisation was important to 
determining the specificity of the binding. 
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Figure 3.7 Scoring of f-CBA results for CSF samples 
Magnification is x40. Scale bar represents 50m. Magnified (x2) insets are included for 
detail. The photographs show anti-human IgG staining alone (red) followed by merged 
anti-human IgG and anti-NR1 antibody (green) binding. Unlike with serum, there was 
no non-specific background staining. Coverslips with no binding scored 0. If weak red 
fluorescence was present in isolated cells in the correct cell-membrane pattern, a score 
of 0.5 was given. Scores of 1-4 were given based on increasing intensity and density of 
bound cells. Unlike for l-CBA, colocalisation was important to determining the 
specificity of the binding.
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3.3.3 Developing the Barcelona immunohistochemistry protocol 
used in this thesis 
The IHC protocol used here was based on the IHC methods optimised for cell-
surface antigens published by the Barcelona group (See Table 3.4 (Dalmau et 
al., 2007; Höftberger et al., 2013; Gresa-Arribas et al., 2014; Planagumà et al., 
2014)). 
Obtaining 7m sections after this brief fixation protocol proved difficult, with 
sections often crumpling or folding when collected onto microscope slides. 
Reducing the cryostat temperature to -25C alleviated the problem in some half 
brains but not others. Ensuring that freshly made PFA was used, careful 
washing after immersion in PFA and removal of excess sucrose solution prior to 
embedding in freezing medium did not improve slicing ease. A range of section 
thicknesses (7-12 m) was used here.
 96
Table 3.4 Published IHC methods 
 Dalmau 2007 Gresa-Arribas 
2014 
Höftberger 
2013 
Planaguma 
2015 
Kill Method Not given Not given CO2 CO2 
Perfusion No No No No 
Fixation Immersion 24h 
in 4% PFA 
Immersion in 
4% PFA at 4°C 
for 1h 
Immersion in 
4% PFA at 4°C 
for 1h 
Immersion in 
4% PFA at 4°C 
for 1h 
Freezing Immersion 40% 
sucrose 24h 
and snap 
frozen in 
isopentane 
chilled with 
liquid nitrogen 
(l-N2) 
Immersion in 
40% sucrose 
for 24h at 4°C, 
then 
embedded in 
freezing 
medium and 
snap frozen in 
isopentane 
chilled with l-N2
Immersion in 
40% sucrose 
for 48h at 4°C 
then 
embedded in 
freezing 
medium and 
snap frozen in 
isopentane 
chilled with l-N2
Immersion in 
40% sucrose 
for 48h 4°C, 
embedded in 
freezing 
medium then 
snap frozen in 
isopentane 
chilled with l-N2 
Section 
thickness 
7m 7m 7m 7m 
Antigen 
retrieval 
Yes (?only for 
paraffinised 
tissue) 
No No No 
 Endogenous 
peroxidase 
block 
0.3% H2O2 for 
20min 
N/R 0.3% H2O2 for 
15 min 
0.25% H2O2 for 
10 min at 4°C 
Protein block 10% normal 
goat serum 1h 
N/R 5% NGS for 1 
h 
5% NGS for 
15min at room 
T° 
Primary Serum 1:250 
CSF 1:10 
Overnight 4°C 
Serum 1:200 + 
dilutions 
CSF 1:2 + 
dilutions 
Overnight 4°C 
Serum 1:200 in 
PBS-5% NGS; 
CSF 1:2 
Overnight 4°C 
Animals 
received 
biventricular 
infusion of 
patient or 
control CSF for 
up to 14d 
Secondary “Appropriate” 
secondary Ab; 
1:2000 no time 
indication 
Biotinylated 
goat anti-
human IgG Ab 
1:2000 1h at 
RT 
Biotinylated 
goat anti-
human IgG Ab 
1:2000 in PBS-
5% NGS 1h at 
RT 
Biotynilated 
goat anti-
human IgG Ab 
1:2000 
overnight at 
4°C 
Development Avidin-biotin-
peroxidase 
Avidin-biotin-
peroxidase 
(Vector Labs) 
Avidin-biotin-
peroxidase 
1h RT 
Avidin-biotin-
peroxidase 
Chromogen N/R N/R DAB 7 min DAB 
Initial trials revealed high levels of non-specific background, making the 
interpretation of results difficult. Substituting PBS with 0.1M Tris-buffered saline 
markedly reduced the background staining and was particularly helpful in 
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negative samples as background staining often appeared somewhat stronger in 
HPC when PBS was used. The protocol was otherwise as described in 
Höftberger et al. (2013), except serum samples were diluted 1:120 and CSF 
1:10. For serum, a further dilution of 1:360 was also always tested. As 
expected, non-specific staining was higher with serum samples than CSF 
samples and decreased with increasing dilution. 
Positivity was defined as neuropil binding in the HPC with sparing of the granule 
cell layer in DG and CA1-3 pyramidal layers, according to the pattern previously 
described (see also Dalmau et al. (2007); Dalmau et al. (2008); Gresa-Arribas 
et al. (2014)). Cerebellar granule cell layer staining has not clearly been 
reported with positive samples in Dalmau’s papers but is defined as a specific 
finding by Euroimmun (Wandinger et al., 2011). It was therefore included in our 
criteria for positivity, albeit only if associated with the typical hippocampal 
distribution of binding, as nuclear staining with some samples occasionally gave 
rise to marked cerebellar granular layer staining. Faint staining was also seen in 
cerebral cortex and basal ganglia. Examples of scores 0-4 for serum and CSF 
samples are shown in Figure 3.8. 
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Figure 3.8 Scoring results of IHC for serum and CSF samples 
Results were scored visually, based on the strongest staining obtained from 0-1. Scale 
bar in the photographs in the first column is 1mm. Magnification is otherwise as 
indicated and scale bars represent 100m. The most marked anti-human IgG binding 
is found in the HPC, and dominates in the molecular layer of the dentate gyrus, sparing 
the hilus of the DG and the cell layers of CA1-3. Punctate staining was also present in 
the granule cell layer of the cerebellum in positive samples, with variable non-specific 
staining of the Purkinje cells. Background staining is more prominent with serum than 
CSF. 
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3.3.4 Gaining experience with the Euroimmun Biochips 
Cell-based assays for serum and CSF were carried out according to 
Euroimmun instructions. A visual scoring system similar to the one used in l-
CBAs was used, with the maximum score of 4 defined by the positive control 
provided by Euroimmun, which produced intense cytoplasmic punctate staining 
in most cells in the biochip. All scores over 0 were considered positive. 
Examples of scores 1-4 are shown in the top and middle panel of Figure 3.9. 
Unlike the cell-surface staining seen in l- and f-CBA, the binding pattern in Euf-
CBA was always cytoplasmic. 
Some serum samples produced ambiguous bright staining in a pattern not seen 
with the positive control provided by Euroimmun or other clearly positive 
samples. This staining was not punctate and present throughout the cytoplasm 
as with the positive samples, but also not entirely nuclear as was seen, for 
instance, in some negative samples with anti-nuclear antibodies (see Figure 3.9 
lower panel). In the case of these ambiguous samples, the neighbouring non-
transfected biochip, included by the company as a control, was not always 
helpful for determining positivity or negativity. This pattern of staining also led to 
the incorrect reporting of the presence of NMDAR-Abs in 2 of 319 (0.6%) 
patients with schizophrenia (de Witte et al., 2015); when the two sera were re-
tested by f-CBA and on a different batch of the Euroimmun biochips, NMDAR-
Abs were not detected. 
Adding a further brief incubation with mouse anti-NR1 antibody, and then 
double-staining with the human IgG antibody provided by Euroimmun and a 
goat anti-mouse IgG antibody eliminated the uncertainty, as the pattern of 
staining with the NR1 antibody replicated that seen with the positive control and 
allowed determination of co-localisation with the anti-human IgG antibody 
(Figure 3.9 lower panel). As expected, CSF samples produced clear, 
background-free results. 
Euroimmun slides containing rodent hippocampal tissue biochips were used for 
65 of 79 serum samples and 18 of 26 CSF samples. Surprisingly, incubating 
hippocampal tissue biochips with the specific anti-NR1 antibody used above did 
not produce any binding. There was a striking lack of consistency between the 
scores on the fixed cell biochips and hippocampal tissue biochips for the serum 
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samples (Spearman’s correlation r = 0.415 (moderate), p= 0.0006, n=65 pairs) 
although this was much better for CSF samples (Spearman’s correlation r = 
0.874 (very strong), p< 0.0001, n= 18 pairs). The typical pattern of hippocampal 
staining obtained with NMDAR-Abs in unfixed or PFA-fixed tissue described in 
section 3.3.3 above was not consistently seen in the hippocampal tissue 
biochips. The hilus of the dentate gyrus also appeared stained with some 
positive samples, and bright fluorescence sometimes appeared throughout the 
HPC (including the dentate gyrus hilus) of some negative samples (see Figure 
3.10). The Euroimmun tissue scores were therefore excluded from further 
analysis. 
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Figure 3.9 Scoring of Euf-CBA results and challenges of scoring 
The top two panels show examples of serum (top) and CSF (middle) samples scoring 
1-4 on Euroimmun CBA. If there was no difference between the chip with the 
transfected cells and the untransfected cells, a score of 0 was given. Positive scores 
were given if punctate cytoplasmic staining was present (see bottom right inset in lower 
panel). Increasing scores were given based on the number of cells bound and the 
intensity of the fluorescence. The bottom panel illustrates the challenges of scoring 
Euf-CBA: sometimes brightly stained cells could be seen, but the staining was not 
punctate as seen in the small bottom right picture, and did not extend throughout the 
cell cytoplasm as seen in the bottom left picture. An additional incubation with anti-NR1 
and a red fluorescent secondary allowed determination of colocalisation, which helped 
determine positivity (bottom right) or negativity (top right). Magnification x40 (x20 in 
middle panel). Scale bar 50m. 
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Figure 3.10 Results obtained with biochips containing fixed hippocampal tissue. 
Variable results were obtained with the biochips containing fixed hippocampal tissue. 
Incubation with negative controls either gave rise to no binding as expected (negative 
control 1) or to a pattern that looked indistinguishable from some positive samples with 
apparent fluorescent present in the molecular and hilar layers of the dentate gyrus (e.g. 
negative control 2). Some samples that gave strongly positive results on the biochips 
containing cells were not associated with any detectable hippocampal staining (e.g. 
strong positive 1). Other positive samples gave rise to detectable fluorescence, but the 
pattern was not always clearly similar to that seen by IHC, with only subtly increased 
molecular layer binding compared to hilus (e.g. strong positive 2).
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3.3.5 Comparison of scores in all assays 
To compare score results across assays, the scores in the current l-CBA were 
used as these were obtained contemporaneously to the other assays. The 
samples that were positive in the original l-CBA were analysed separately from 
the originally negative samples, and the samples that had lost reactivity were 
excluded.  
Samples positive in original l-CBA 
There were 58 serum samples from 50 patients with a positive score in the 
original l-CBA, but 2 serum samples had to be excluded as the result of one of 
the assay methods was missing for each of these (due to insufficient sample 
volume). This therefore left full data from 56 positive samples from 49 patients 
(one of the excluded samples was from a patient with 2 samples available).  
The serum scores in the repeat l-CBA were generally higher than with the other 
assay methods (Friedman test, F=39.11, p< 0.0001, n=56 originally positive 
samples, Figure 3.11 A). As mentioned above, only the f-CBA was performed at 
the same dilution as the l-CBA (1:40), the IHC having been scored at the 1:120 
dilution and Euf-CBA at 1:10. Nevertheless, the IHC score median was slightly 
higher than that of f-CBA, and the Euf-CBA scores were the lowest despite 
being done at the lowest dilution. 27, 24 and 28 samples scored 0 in f-CBA, 
IHC, and Euf-CBA respectively, whilst none scored 0 in the repeat l-CBA. Most 
of the samples that scored 0 in the f-CBA and IHC had scored from 0.5-1.5 in 
the l-CBA, whilst a similar proportion of samples scoring 0.5-1.5 and 2-4 in l-
CBA scored 0 in Euf-CBA (Figure 3.11 Bi), perhaps suggesting lower sensitivity 
of this method. 
Among previously positive serum samples, scores in f-CBA were strongly 
correlated to l-CBA scores (Spearman r= 0.681, p<0.0001), and scores in IHC 
were moderately correlated with l-CBA scores (Spearman r=0.412, p=0.002). 
As would be expected from the results above, Euf-CBA only correlated weakly 
with l-CBA scores (Spearman r=0.287, p=0.032, Figure 3.11 Bii)). 
Nine CSF samples were positive in the original l-CBA, but three of these scored 
0 in the repeat l-CBA. There was no difference between scores on the four 
assays (RM one-way ANOVA, F(2.39, 16.72)=2.22, p=0.133, Figure 3.12 A). 
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Four scored 0 in the f-CBA (scores of 0-0.5 in l-CBA), only one scored 0 in IHC 
(scored 0 in l-CBA and f-CBA and 1 in original l-CBA), and two scored 0 in Euf-
CBA (both scored 0 in l-CBA). 
Samples negative on l-CBA 
21 serum samples from 20 patients had been negative on the original l-CBA 
(three scores of 1, one score of 0.5, seventeen score of 0). There was a 
significant difference in scores between the four different assays (Friedman test, 
F=9.57, p = 0.023) although Dunn’s multiple comparisons test could not 
determine which groups were different (Figure 3.11 C). All but two of the 
negative samples remained negative in the repeat l-CBA (both had scored 1 in 
original l-CBA). All 21 samples were negative in f-CBA and Euf-CBA, but 5 were 
positive in IHC (all scored 0 in both original and new l-CBA, and in f-CBA and 
Euf-CBA) and this is likely to be the cause of the statistical difference. It is 
possible that these IHC-positive samples were from patients with other neuronal 
cell-surface antibodies and alternative LE diagnoses. The pattern of binding 
was consistent with NMDAR-Abs however, and the clinical details that became 
available for two of these five samples revealed the samples had been taken 
following clinical recovery from NMDAR-Ab encephalitis. No clinical information 
is available for the other three samples. 
Seventeen CSF samples were negative in the original l-CBA. All but two 
remained negative in all other assays (one score of 1 in f-CBA; one score of 2 in 
Euf-CBA, Figure 3.12 B). 
3.3.6 Effect of dilutions in the four assay methods 
Serial titration was performed in four serum samples and two of their paired 
CSF samples (Figure 3.13 A and B). The last dilution at which reactivity was 
visible was recorded for each assay as the end-titration for that sample (Figure 
3.13 C). For serum, the highest end-titres were found with IHC, and Euf-CBA 
reactivity was lost earliest. In CSF, IHC and Euf-CBA gave the highest end-
titres. The number of samples studied is too small to draw any firm conclusions.
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Figure 3.11 Comparison of serum sample scores in all assays. 
L-CBA (1:40) scores were higher than f-CBA (1:40), IHC (1:120) and Euf-CBA (1:10) 
scores in samples that had previously been reported as positive by l-CBA (A, Friedman 
test with Dunn’s multiple comparisons test). 27 of these samples scored 0 on f-CBA, 24 
on IHC and 28 on Euf-CBA. For f-CBA and IHC, most of the samples scoring 0 had 
scored 0.5-1.5 on the new l-CBA, but many of the Euf-CBA-negative samples had 
scored positively in l-CBA (Bi). F-CBA scores were strongly correlated to l-CBA scores, 
IHC scores moderately correlated and Euf-CBA weakly correlated (Bii). Originally 
negative serum samples generally remained negative on all assays, except for 5 
samples, which scored positively on IHC.
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Figure 3.12 Comparison of CSF sample scores in all assays 
There was no difference between scores on the repeat l-CBA (1:10), f-CBA (1:10), IHC 
(1:10) and Euf-CBA (1:1) in CSF samples that scored positively (>0) on the original l-
CBA (1:2) (Ai). Only f-CBA and l-CBA scores were strongly correlated, with IHC scores 
weakly and Euf-CBA scores moderately correlated to l-CBA scores (Aii). Two samples 
scoring 0 in the original l-CBA scored positively in other assays (one each in f-CBA and 
Euf-CBA) but the remaining 15 samples scored negatively in all assays. 
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Figure 3.13 End-titration results in serum and CSF for the four assay methods. 
The scores for each dilution of four serum samples and two CSF samples are graphed 
in Ai-iv and Bi-ii respectively for each method. The end-titration (the last dilution at 
which binding was still visible) for each assay method is shown in C. 
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3.3.7 Correlation with clinical details 
Clinical details have so far been obtained on 44 of the 88 patients whose serum 
and/or CSF samples were included in the study, and the results of their assays 
are shown in Table 3.5. Treating physicians were contacted and asked to define 
the patients’ illness as definite, probable, possible, or unlikely NMDAR-Ab 
encephalitis based on their clinical syndrome and response to immunotherapy. 
No antibody-independent criteria are available at present; the clinician was 
therefore asked to give their diagnosis based on their experience with treating 
similar patients. The diagnoses included 23 definite, 1 probable, 6 possible and 
14 unlikely. The range of scores obtained in each diagnostic classification are 
shown in Figure 3.14 (A, B, C, left panel) for serum samples (n=49 samples 
from 40 patients, 3 “definite” and 1 “possible” patients excluded as samples 
taken after recovery and therefore negative), and for CSF samples from 
patients with definite NMDAR-Ab encephalitis (n=6, Figure 3.15). Clinical details 
were available for a further 3 patients with CSF samples (2 possible NMDAR-Ab 
encephalitis and 1 unlikely NMDAR-Ab encephalitis) and all 3 scored 0 in all 
assays and hence have not been shown.  
In serum, in the “definite” category, the highest scores were obtained using l-
CBA (original l-CBA median 2.5, IQR 1.5-4, new l-CBA median 2.0, IQR 1-
2.88), followed by f-CBA (median 2.25, IQR 0-3), and then IHC (median 1.5, 
IQR 1-2.5) and Euf-CBA (median 1.5, IQR 0-3, Figure 3.14 A left panel). 
Statistical comparison was not carried out as different dilutions were used in 
different assays. A similar trend was noted in the “possible”/”probable” (Figure 
3.14 B left panel) as well as “unlikely” categories (Figure 3.14 C left panel), 
where l-CBA tended to score positively whilst f-CBA, IHC and Euf-CBA scored 
negative in the majority of the samples
  
Table 3.5 Results of each assay in patients with available clinical diagnosis 
Patient 
identifier 
CSF or 
serum 
Paired or 
unpaired 
CSF 
Original  
l-CBA 
(serum 1:20; 
CSF 1:2) 
Current   
l-CBA 
(serum 1:40; 
CSF 1:10) 
IHC  
(serum 
1:120; CSF 
1:10) 
f-CBA 
(serum 1:40; 
CSF 1:10) 
Euf-CBA 
(Serum 1:10; 
CSF 1:1) 
Final 
Clinical 
Diagnosis 
Comment 
41 Serum 1   4 1 0.5 2.5 1 Definite   
83 Serum 2   3 2 1.5 3.5 0   Further sample 
26 Serum 1   4 2 2.5 4 3 Definite   
10 Serum 2  2.5 2.5 2.5 4 2.5   Further sample 
38 Serum 3   4 4 1.5 2.5 4 Further sample 
12 Serum Unpaired 4 3 1.5 2 0 Definite   
12A CSF Unpaired 1 3 1.5 1 2    
47 Serum 1 Paired 4 4 2.5 3.5 3.5 Definite   
47A CSF Paired 2.5 1 2.5 1.5 4    
88 Serum 2 4 4 3.5 3 3.5 Further sample 
110 Serum 3 4 4 3 3.5 3.5 Further sample 
24 Serum   4 4 3 4 4 Definite   
25 Serum 1   4 2.5 2 3 3 Definite   
68 Serum 2  1.5 0.5 0 0 Insufficient   Further sample 
50 Serum   3.5 3 1 0 1 Definite   
9 Serum 1   2.5 2.5 2 2.5 0 Definite   
61 Serum 2  1.5 1.5 1.5 2 0.5  Further sample 
2552 Serum Paired 2.5 2.5 2.5 2 4 Definite   
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2150 CSF Paired 4 2.5 1 3 4    
53 Serum 1   2.5 1 0.5 0 2 Definite   
76 Serum 2   1.5 1 1.5 0 2   Further sample 
11 Serum Paired 2 2 0 2.5 0 Definite   
11A CSF Paired 1 0 0 0 2    
56 Serum  Unpaired 1.5 2 1.5 1.5 1.5 Definite   
27 CSF Unpaired 1.5 0 0 1.5 0    
108 Serum 1.5 1 1.5 0 1 Definite   
105 Serum   1.5 2 1 2 0 Definite   
36 Serum   1.5 2.5 2.5 3 0 Definite   
66 Serum   1.5 0.5 0 0 0 Definite   
78 Serum   1.5 2 1.5 3 0.5 Definite   
67 Serum   1.5 1.5 3 0 1 Definite   
69 Serum   1.5 0.5 0 1.5 1.5 Definite   
13 Serum Paired 1.5 0.5 2.5 0 2 Definite   
13A CSF Paired 1.5 1 1.5 3.5 2    
71§ Serum 1 0 0 0 0 Definite  post treatment 
93§ Serum   0 0 0.5 0 0 Definite  other samples + 
104§ Serum   0 0 1 0 0 Definite  Post‐recovery 
40 Serum   2 1.5 0 0 0 Probable   
18 Serum   2.5 1.5 0 0 0.5 Possible   
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51 Serum   2.5 2 0 1.5 0 Possible   
23§ Serum Unpaired 2.5 0.5 0 0 0 Possible  Post‐recovery 
23A§ CSF Unpaired 0 0 0 Possible  Post‐recovery 
44 Serum   2 1.5 0 0 0 Possible   
79 Serum   1.5 1 0.5 0 1 Possible   
65† Serum 1 Paired 1.5 0 0 0 0 Possible   
65A CSF Paired 0 0 0 0 0    
89 Serum 2 0 0 0 0 0 Possible  Further sample 
39 Serum   3.5 2.5 0 0 0 Unlikely   
42 Serum   3 2 0 0 0 Unlikely   
48 Serum   2.5 3 0 2.5 0.5 Unlikely   
37 Serum   2 2 0 0.5 0 Unlikely   
45 Serum   2 1 0 0 0 Unlikely   
8 Serum   1.5 1.5 0 0 0 Unlikely   
4 Serum Paired 1.5 1.5 0 0 0 Unlikely   
4A CSF Paired 0 0 0 0 0  
77 Serum   1.5 0.5 0 0 0 Unlikely   
70 Serum   1.5 1.5 0 0 0 Unlikely   
98 Serum   1 2 0 0 0 Unlikely   
92 Serum   0 0 0 0 0 Unlikely   
99 Serum   0 0 0 0 0 Unlikely   
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100 Serum   0 0 0 0 0 Unlikely   
21 Serum   0 0 0 0 0 Unlikely   
§ excluded from analysis as samples taken after clinical recovery/post-treatment and would therefore introduce bias by increasing false-negative rate. 
† excluded as reactivity lost during storage (score 1.5 or above in original l-CBA and 0 in new l-CBA). 
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The CSF samples from patients with definite NMDAR-Ab encephalitis were all 
positive in the original l-CBA (1:2 dilution, Figure 3.15 A). Two of these samples 
scored 0 in the new l-CBA (1:10 dilution) and both scored 0 in two of three other 
assays (one in IHC and f-CBA, and the other in f-CBA and Euf-CBA), 
suggesting the higher dilution and prolonged storage were perhaps the cause of 
the loss of reactivity. 
Contingency tables were then built for each diagnostic classification listing the 
outcome of each serum assay as positive or negative (Figure 3.14 A, B, C right 
panel). For the original l-CBA, the cut-off of 1.5 for positivity in serum was 
maintained, but for all other assays (including the new l-CBA) samples scoring 
0.5 and above were considered positive in order not to bias the results as a 
consequence of loss of reactivity over time. The small number of CSF samples 
with diagnostic information rendered statistical analysis futile, and thus, similar 
contingency tables were not built. 
Twenty-eight serum samples were available from 20 patients with definite 
NMDAR-Ab encephalitis (4 patients with 2 samples and 2 patients with 3 
samples). Seven serum samples were available from 7 patients with possible 
(n=6) or probable (n=1) NMDAR-Ab encephalitis. Fourteen patients (14 
samples) had been classified as unlikely to have NMDAR-Ab encephalitis. 
For samples from patients with definite NMDAR-Ab encephalitis, f-CBA and 
Euf-CBA were more likely to be negative than l-CBA (Fisher’s exact test, p= 
0.004 for both, Figure 3.14 A right panel), and there was no difference in rates 
of positivity and negativity between l-CBA and IHC (Fisher’s exact test, p= 
0.11). 
In patients felt not to have NMDAR-Ab encephalitis, f-CBA, IHC and Euf-CBA 
were all more likely to be negative than l-CBA (Fisher’s exact tests, p= 0.006, 
0.0002, and 0.001 respectively, n=14, Figure 3.14 C right panel). For those 
patients with a possible or probable diagnosis of NMDAR-Abs encephalitis, l-
CBA appeared more likely to be positive and the other assays more likely to be 
negative (Figure 3.14 B right panel, no statistical analysis due to low numbers). 
Contingency tables were then built for each diagnostic assay to determine their 
sensitivity and specificity. For this, the patients classified as probable or 
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possible NMDAR-Ab encephalitis were excluded. The results are listed below in 
Table 3.6. It is worth noting that the population for which these data were 
available was biased: some of the positive serum samples included were known 
to be from patients who did not have NMDAR-Ab encephalitis. When compared 
to a more naturalistic control group or to the referral population, such patients 
were over-represented in the small sample of patients for whom clinical details 
were available. 
Table 3.6 Sensitivity and specificity of the three diagnostic approaches studied. 
 l-CBA f-CBA IHC Euf-CBA 
 + - + - + - + - 
Definite 
NMDAR-Ab 
encephalitis 
28 0 20 8 24 4 20 7 
Unlikely 
NMDAR-Ab 
encephalitis 
10 4 2 12 0 14 1 13 
Sensitivity1 
(95% CI) 
100%       
(87.7-100) 
71.43%   
(51.33-86.78) 
85.71%  
(67.33-95.97) 
74.04%  
(53.72-88.89) 
Specificity2 
(95% CI) 
28.57%    
(8.39-58.1) 
85.71%  
(57.19-98.22) 
100%     
(76.84-100) 
92.86%  
(66.13-99.82) 
PPV3   
(95% CI) 
73.68%    
(56.9-86.6) 
90.91%  
(70.84-98.88) 
100%     
(85.75-100) 
95.24%  
(76.18-99.88) 
NPV4    
(95% CI) 
100%     
(39.76-100) 
60%       
(36.05-80.88) 
77.78%  
(52.36-93.59) 
65%       
(40.78-84.61) 
1 Probability that a test result will be positive when the disease is present (true positive 
rate) 
2 Probability that a test result will be negative when the disease is not present (true 
negative rate) 
3 Positive predictive value: probability that the disease is present when the test is 
positive 
4 Negative predictive value: probability that the disease is not present when the test is 
negative 
 
Serum l-CBA was the most sensitive test but had poor specificity, with a high 
rate of “unlikely” diagnoses scoring positively. The calculated specificity value 
for l-CBA is, however, an underestimate. As mentioned above, patients known 
to have non-immune pathology but positive (usually low-positive) NMDAR-Abs 
by l-CBA were over-represented in the sample of patients for whom clinical 
details were available, and in this study population as a whole. The specificity of 
l-CBA would be better if an unselected referral population had been used. IHC, 
by comparison, was the next most sensitive test in serum and was also 100% 
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specific, meaning that, in the patients tested, IHC was negative in all patients 
who were unlikely to have NMDAR-Ab encephalitis. F-CBA and Euf-CBA both 
had moderate sensitivity, but good specificity. 
Sensitivity and specificity for CSF were not calculated, as the number of 
samples with available clinical data was too small. 
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Figure 3.14 Score range in the four assays for serum samples in each diagnostic 
category. 
The serum samples from patients with clinically definite NMDAR-Ab encephalitis (n=28, 
A) all scored positively in l-CBA (black and red) although the scores in the current l-
CBA, done at a higher dilution were slightly lower (median ± IQR, red). In the other 
three assays median scores were comparable but some samples scored negatively. 
The serum samples from patients with possible (n=6) and probable (n=1) NMDAR-Ab 
encephalitis (B) scored mostly positively on l-CBA and mostly negatively on the other 
assays. This was also the case for serum samples from patients unlikely to have 
NMDAR-Ab encephalitis (n=14, C). 
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Figure 3.15 Score range in the four assays for CSF samples from patients with 
definite NMDAR-Ab encephalitis and graphic representation of contingency 
tables for each assay in serum samples. 
The range of scores obtained for CSF samples of patients with definite NMDAR-Ab 
encephalitis in each assay is shown in A (n=6). All scored positive in the original l-CBA 
but some samples appeared to have lost reactivity or were negative at the higher 
dilution used in the current assays. In B, the rates of positivity (0.5) and negativity (0) 
for each assay are compared for serum samples from patients with clinically definite 
and unlikely NMDAR-Ab encephalitis. These numbers have been used in the sensitivity 
and specificity calculations in Table 3.6.  
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3.4 Conclusion 
For some time it has been clear that the l-CBA that Oxford has been running 
since 2008 is sensitive but may identify low positivity in patients who are 
unlikely to have an antibody-mediated disease (Mackay et al., 2012; M. S. 
Zandi et al., 2015). By contrast, the Barcelona CBA and the Euroimmun CBA 
use fixed cells, raising concerns about sensitivity and possibly specificity, since 
the fixative might mask extracellular epitopes and intracellular epitopes might be 
detected because of permeabilisation.  This was the first time that a full 
comparison between the three CBAs and with the IHC also used by Barcelona 
has been made. The results confirm the high sensitivity of the Oxford l-CBA with 
its relative lack of specificity, and some improvement in the specificity could be 
attempted by using a two-step assay in positive patients as discussed below. 
L-CBA scores in the repeat assay, performed contemporaneously with the other 
assays, were higher than those obtained in f-CBA, IHC, and Euf-CBA (median 
of 1.5 for l-CBA and around 0.5 for the other assays). The large proportion of l-
CBA-positive samples scoring 0 in f-CBA, IHC and Euf-CBA influenced the 
median scores in these assays. This difference would suggest either a higher 
sensitivity or a lower specificity of the l-CBA compared to the other tests, both of 
which were found to be true when the clinical data were analysed. The fact that 
most of the samples scoring 0 in f-CBA and IHC scored 0.5-1.5 in l-CBA would 
also support this conclusion. Looking at the diagnostic classification in the 
samples scoring positively in l-CBA but negatively in IHC (the second-most 
sensitive method in this study) suggests these low positive results are more 
likely to be false-positives: there were 16 patients with clinical details (23 in 
total) whose samples scored positive in l-CBA and negative in IHC, and 8 of 
these were classified as unlikely to have NMDAR-Ab encephalitis, 5 as possible 
and only 3 as definite NMDAR-Ab encephalitis (of these, 2 samples were 
positive by f-CBA ± Euf-CBA). Nevertheless, it also suggests that serum IHC is 
not positive in all NMDAR-Ab encephalitis patients, as found by Gresa-Arribas 
et al. (2014). 
In Euf-CBA, the negative scores came equally from low-positive and high-
positive samples, suggesting that this assay may not be very sensitive, and this 
was confirmed by the analysis of clinical data as well as the findings of the small 
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dilution study, which showed low end-titres in Euf-CBA. The pattern of binding 
in Euf-CBA was also different to that seen in the l-CBA and f-CBA. In Euf-CBA, 
the binding was punctate and intra-cytoplasmic. This difference is presumably 
related to the fixation protocol used by Euroimmun. Euroimmun uses covalent 
bonding (aldehyde fixation) to increase adhesion of cells to the glass surface of 
the biochips. The intensity of the fixation process is not described, but is likely to 
be high to avoid loss of substrate from the biochips. Formaldehyde fixation 
breaks down the normally impermeable cell membrane and denatures proteins 
by forming cross-linking methylene bridges; however, the structure of 
intracytoplasmic proteins tends to be well-preserved and the proteinaceous 
network formed in the cytoplasm has relatively low permeability to 
macromolecules. Overall, this increased permeability also contributes to 
increased non-specific “background” staining, and fixation is a compromise 
between preservation and introduction of artefact by denaturing proteins. The 
duration of formaldehyde fixation is paramount to the quality of the cytological 
preservation and immunolocalisation, and the longer the contact with the 
fixative, the more antigen masking is likely to occur (Farmilo and Stead, 2001). 
It is therefore possible that a portion of the surface epitopes in the Euroimmun 
biochips are masked and that the cell membranes are relatively permeable, 
such that the NMDAR-Abs can access NR1 subunits that have not yet been 
expressed on the cell membrane. This surface epitope loss may be responsible 
for the lower sensitivity of Euf-CBA. 
It is not clear why binding in f-CBA was not intra-cytoplasmic like that seen in 
Euf-CBA, as cells have been fixed and permeabilised. Perhaps the fixation 
method used (10 minutes of 4% PFA followed by gentle permeabilisation for 
one hour) does not cause the same degree of surface epitope cross-linking, 
and therefore masking and loss, as the Euf-CBA fixation method, leaving 
enough cell-membrane-expressed NR1 subunits to result in the cell-surface 
binding pattern observed. 
The aim of the study was to compare the l-CBA to the currently used f-CBA as 
well as other methods. Unfortunately, it was not possible to use the same 
protocol for f-CBA as that used in Barcelona, putting into question the validity of 
the comparison performed here. Indeed, results may have been different if 
samples had been sent to Barcelona for testing instead of developing an in-
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house f-CBA. However, we had no experience of using fixed cells in CBAs and 
no access to the Barcelona protocol other than what could be gleaned from 
publications. A step-wise approach to replicating the Barcelona protocol was 
therefore taken. Once a very similar working protocol had been established, it 
became apparent that the results of serum assays were difficult to interpret 
because of non-specific background staining. Further steps and variations from 
the protocol therefore had to be put in place in order to obtain usable results. 
However, the basic principles of the Barcelona f-CBA (1:1 NR1:NR2 
transfection, fixation and permeabilisation of cells, co-localisation with a 
commercial anti-NR1 antibody) were respected, and it is reassuring that our 
results in serum from patients with NMDAR-Ab encephalitis are not dissimilar to 
those of Gresa-Arribas et al. (2014) (71.43% sensitivity in our f-CBA and 86.8% 
in Barcelona f-CBA), bolstering the validity of our comparison. 
The analysis performed once the clinical data was available revealed that, in 
patients with clinically definite NMDAR-Ab encephalitis, l-CBA and f-CBA 
resulted in similar scores, and lower scores were found with IHC, as expected 
since it was performed at a higher dilution. Euf-CBA scores were the lowest, 
despite being performed at the lowest dilution, and this is in keeping with the 
possible epitope loss and resultant lower sensitivity as discussed above. 
Despite the lower scores in IHC, this method still proved to be sensitive 
(85.71%). Additional support for its good sensitivity comes from the fact that the 
highest end-titres were found with IHC in both serum and CSF samples in the 
small titration study performed here. Furthermore, 2 of the 5 serum samples 
that were positive in IHC but negative in l-CBA were from patients with definite 
NMDAR-Ab encephalitis (no diagnosis available for the other 3). These samples 
had been excluded from the sensitivity and specificity analysis as they were 
taken after full recovery of the patient. 
The poor specificity of the l-CBA, albeit partly overestimated by the over-
representation of patients with known non-immune pathology and positive 
NMDAR-Abs by l-CBA in this study, is concerning and implies that serum 
testing alone using l-CBA in patients with suspected NDMAR-Ab encephalitis is 
not necessarily helpful. The results of this study would preliminarily support 
testing CSF as well, as maintained by Gresa-Arribas et al. (2014): all available 
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CSF samples of patients with definite NMDAR-Ab encephalitis were positive in 
the original l-CBA. However, the number of CSF results available was small and 
not all were from the patients at first presentation of their disease when the test 
is most commonly requested. Thus, further comparisons of serum and CSF at 
presentation of “definite” disease will be required to answer this issue. 
The poor specificity of the l-CBA is unexplained at present. One possibility is 
that non-specific or low-affinity antibodies (IgG and IgM) bind more readily to 
the membrane of live cells. Another possibility is that the fluorescent secondary 
antibody, which is directed against human IgG heavy and light chains and 
therefore reacts with other immunoglobulin classes as these share common 
light chains, is also binding to IgM antibodies present in the serum. The use of a 
secondary antibody with improved specificity for IgG, for example those directed 
at the Fc portion of IgG, would mitigate this effect, and this has now been 
adopted in the Oxford laboratory. However, this would be expected to cause 
non-specific binding to be present in all the cell-based assays studied here. 
Another possibility is that low levels of serum NMDAR-Abs do occur in some 
individuals with other diagnoses, as in the sCJD study (Mackay et al., 2012). 
Finally, a further control step for positive samples in the l-CBA may improve 
specificity: demonstration of colocalisation of anti-human IgG binding with 
binding to a commercial anti-NR1 antibody, as used in the f-CBA, would allow 
greater certainty in the reporting of positive results. 
In conclusion, a two-step protocol for the detection of NMDAR-Abs in serum 
may be proposed based on the results of this study. L-CBA was the most 
sensitive test and was also the least time-consuming assay (except for Euf-CBA 
but this has very poor sensitivity), and should therefore be part of the diagnostic 
assay, especially if improved specificity can be demonstrated by adding a step 
to demonstrate co-localisation with commercial anti-NR1. It should nevertheless 
be supplemented with IHC, which was also very sensitive and 100% specific. 
Whether CSF testing is necessary to make a diagnosis was not clear in this 
study, because of the low number of CSF samples, and this requires further 
study. 
The findings of this study require confirmation in a prospective study using a 
representational control group or a naturalistic referral population. Additionally, 
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the prolonged storage of some of the samples used here and consequent 
reduction in reactivity probably caused some of the variability of the results in 
the different assays. This may underlie the lower sensitivity values found here 
for serum f-CBA and IHC in comparison to the Gresa-Arribas et al. (2014) study 
(f-CBA: 71.43% versus 86.8%; IHC: 85.71% versus 91.6%). However, this 
study clearly does not support the proposition that the commercially available 
assay from Euroimmun is as sensitive and specific as the combination of f-CBA 
and IHC (Wandinger et al., 2011). Insufficient CSF samples were available for a 
valid discussion of the requirement for CSF testing, as suggested by Dalmau’s 
group (Gresa-Arribas et al., 2014). 
Developing the protocols and learning to interpret the results of the f-CBA, IHC 
and Euf-CBA was more complex than anticipated. Whilst the relatively 
consistent co-localisation with anti-NR1 immunofluorescence in f-CBA was an 
advantage when interpreting the results, a high level of non-specific background 
persisted despite optimisation at several steps of the protocol. This high 
background has been acknowledged by other groups that perform in-house f-
CBA (J. Honnorat, personal communication), and it is noteworthy that 
publications by Dalmau’s group show the results of f-CBAs performed with CSF, 
where background staining is absent.  
Similarly, IHC results can also be difficult to score for serum samples with low 
NMDAR-Ab titres, especially if non-specific background is present. Serial 
dilutions are often helpful in these situations. Finally, Euf-CBA can also be 
challenging to interpret (see discussion of de Witte et al. (2015) above). 
Differentiating very low positives from background staining with serum was 
sometimes difficult and necessitated addition of a commercial NR1 antibody for 
co-localisation. It was essential to pay close attention to the pattern of staining, 
which had to be punctate, rather than simply relying on the intensity of the 
staining.  
All of these challenges are avoided by use of CSF, which produced essentially 
background-free results. The other advantage of finding NMDAR-Abs in the 
CSF of a patient with presumed NMDAR-Ab encephalitis is that this establishes 
beyond doubt their access to the brain and thus bolsters their claim to 
pathogenicity. However, the ease with which serum can be obtained is a 
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definite advantage when designing a diagnostic test. Furthermore, the immune 
response and antibody production is likely to be initiated peripherally in the 
great majority of patients with NMDAR-Ab encephalitis (Irani et al., 2010b; 
Kreye et al., 2016) (with the exception of patients who develop NMDAR-Ab 
encephalitis after HSV encephalitis), so that antibodies should always be 
present in blood and at a higher titre than in CSF. Along those lines, the Oxford 
laboratory experience so far, was that serum assays are sufficient for NMDAR-
Ab detection in patients with the suspected disorder (Vincent and Bien, 2008; 
Irani et al., 2010b). It is also worth noting that intrathecal antibody responses 
following neurotropic infections such as HSVE and neurosyphilis, tend to persist 
much longer than systemic responses, often outlasting the infective episode by 
years (Reiber, 1998). If this is the case for autoimmune disorders as well, then 
the presence of CSF antibodies against NR1 may not necessarily represent 
active NMDAR-Ab encephalitis. Insufficient paired serum and CSF samples 
were available for this study to examine whether serum testing alone is 
sufficient, but it is interesting that all the CSF samples from patients with definite 
NMDAR-Ab encephalitis in this study scored positively on the original l-CBA. 
High scores on serum assays (scores 3-4) were invariably associated with a 
clinical classification as “definite” NMDAR-Ab encephalitis. The patient samples 
used in the electrophysiological studies in the following chapters were all 
obtained from patients with scores of 4 on initial l-CBA and the samples diluted 
to demonstrate their titres. The presence of NMDAR-Abs was also confirmed 
using IHC. 
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4.1 Introduction 
The onset of NMDAR-Ab encephalitis is characterised by the subacute 
development of confusion, anterograde memory loss, which can become 
dense, seizures and psychiatric symptoms. The latter range from anxiety and 
depression-like symptoms to florid psychosis with hallucinations. Such 
symptoms can be recapitulated in healthy subjects by acute administration of 
NMDAR antagonists such as ketamine (Krystal et al., 1994; Lahti et al., 2001). 
Furthermore, in volunteers with schizophrenia, ketamine caused a brief 
increase in positive symptoms including delusions similar to those they had 
experienced in a previous psychotic phase, formed visual or auditory 
hallucinations and thought disorder (Lahti et al., 1995; Lahti et al., 2001). This 
early evidence in support of the NMDAR hypofunction model of schizophrenia 
led to the development of several animal models of NMDAR hypofunction, each 
exhibiting some cellular, anatomical or behavioural correlate of schizophrenia in 
humans (e.g. (Mohn et al., 1999; Keilhoff et al., 2004; Rujescu et al., 2006; 
Belforte et al., 2010; Gandal et al., 2012), and for review(Inta et al., 2010)). 
One commonly reported effect of NMDAR antagonism or partial NMDAR 
ablation was a selective reduction in parvalbumin-positive interneurons in 
several areas including pre-frontal cortex and hippocampus (Keilhoff et al., 
2004; Rujescu et al., 2006; Gandal et al., 2012), and resultant deficits in 
inhibitory synaptic transmission (Rujescu et al., 2006; Gandal et al., 2012). 
Gamma-frequency oscillations (-oscillations) are associated with sensory 
processing and memory as discussed in chapter 1. They result from the 
synchronised interplay of excitatory principal cell and inhibitory interneuron 
firing. They can be pharmacologically generated in live brain slices, in which 
case they are stable for several hours (Cunningham et al., 2003b). 
Parvalbumin-positive fast-spiking interneurons provide the most powerful 
inhibitory input to principal cells by targeting their perisomatic region and have 
been shown to be the principal interneuron subtype involved in the generation 
of -oscillations (Pouille and Scanziani, 2001; Hájos et al., 2004; Fuchs et al., 
2007; Strüber et al., 2015).  
In the hippocampus, both cholinergically and kainate-induced -oscillations are 
dependent on excitatory activity mediated by ionotropic non-NMDA glutamate 
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receptors, but there is no NMDAR component to the excitatory drive, as shown 
by the lack of effect of NMDAR antagonists D-AP5 and ketamine on the power 
or frequency of these oscillations (A Fisahn et al., 1998; Cunningham et al., 
2006). This may be related to the remarkably low synaptic NMDA receptor 
content of parvalbumin-positive interneuron in the hippocampus (NyÍri et al., 
2003). 
In the superficial layers of the medial entorhinal cortex, however, NMDAR-
mediated excitation is an important component of the drive to the fast-spiking 
interneurons that are generating the -rhythms (Jones and Buhl, 1993; 
Cunningham et al., 2006). Acute application of the NMDAR antagonist ketamine 
has been shown to reduce both the power and frequency of layer II and III -
oscillations in the mEC (Cunningham et al., 2006; Middleton et al., 2008). 
There is some evidence to suggest NMDAR-Abs may have an acute 
antagonistic effect on NMDAR-mediated neurotransmission: brief exposure (in 
the range of minutes) to NMDAR-Ab-containing CSF prevented NMDA-
mediated Ca2+ entry into cultured cerebellar neurons (Rubio-Agustí et al., 2011) 
and blocked the induction of hippocampal LTP in mouse slices (Q. Zhang et al., 
2012). The effect of acute exposure to NMDAR antibodies on superficial mEC 
and hippocampus field -oscillations in vitro will therefore be investigated in this 
chapter, to test the hypothesis that, in this slice preparation, NMDAR-Abs may 
selectively impair oscillations in the mEC. 
4.2 Methods 
Horizontal hippocampal-entorhinal rat brain slices were prepared and 
maintained as described in the general methods. The extracellular local field 
potential was recorded using blunt glass electrodes filled with artificial CSF. -
oscillations were generated by adding 400nM kainate (KA) to the perfusion 
medium. The peak power, area power and frequency of the observed oscillation 
were obtained by applying a fast Fourier transform to a 60 second epoch of 
recording every 10-15 minutes. Oscillations were considered stable once the 
values obtained for each of these characteristics varied by less that 20% over 
four consecutive 10-minute periods. Pharmacological experiments were 
performed by bath application of ketamine or D-AP5 for 40 minutes to1 hour, 
followed by a 30-minute washout phase in aCSF and KA (vehicle). Purified 
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immunoglobulin G (IgG) from three patients with NMDAR Ab encephalitis and 
high titre NMDAR antibodies, two healthy controls, and one patient with voltage-
gated potassium channel complex antibodies (VGKC-complex abs) was used to 
investigate the effect of NMDAR antibodies on superficial mEC -oscillations. 
These were initially diluted to 10g/ml in vehicle (aCSF+400nM KA) and bath 
applied to the slices. Because only small volumes of purified IgG were 
available, it was diluted in no more than 25ml of vehicle. To control for this 
significant reduction in the volume of the circulating perfusion medium, control 
experiments using vehicle only were also performed with this lower volume of 
perfusion medium. The concentration of 10g/ml was chosen based on findings 
from a preliminary study by a previous MRes student (Lawley, 2009). A 
significant effect on both power and frequency of -oscillations in mEC had 
been demonstrated at 5, 10 and 20g/ml concentrations of IgG from a patient 
with NMDAR-Ab encephalitis. Later, some experiments with patient IgG were 
also performed at a concentration of 30g/ml as discussion with members of 
the neuroimmunology groups at Oxford University revealed they were using 
purified IgG diluted 1:250 to 1:500 in their staining experiments (corresponding 
to 48 and 24g/ml concentration). Because of time constraints it was not 
possible to test all IgG samples at both concentrations. 
4.3 Results 
4.3.1 Pharmacological blockade of NMDA receptors disrupts -
oscillations in mEC 
Ketamine 
The effect of bath application of 25M ketamine was examined in 6 slices from 
4 rats. Kainate perfusion (400nM) generated oscillations in mEC layer II or III 
with a peak power of 48.44 ± 49.29 V2/Hz, area power of 0.424 ± 0.535 
V2/Hz.kHz, and frequency of 43.25 ± 6.45 Hz. Because of the wide variation in 
baseline power from one slice to the next, the values for power and frequency 
in each experiment have been normalised to the average of the values 
recorded during the 40-minute stable period (all values within 20% of each 
other) prior to addition of ketamine, such that the baseline period always has a 
power and frequency of 100% in each slice. Ketamine caused a partially 
  130
reversible reduction in power and frequency, but only the change in peak power 
reached statistical significance (see Table 4.1 and Figure 4.1).  
Table 4.1 Effect of ketamine on mEC -oscillations 
 Reduction at 1 
hour (%) 
RM ANOVA P value 
Peak power 61.07 ± 16.36 F (1.890, 5.671) = 
6.293 
0.0372 
Area power 35.58 ±25.18 F (2.237, 6.712) = 
2.980 
0.1160 
Frequency 8.89 ±4.78 F (2.587, 7.760) = 
3.974 
0.0581 
D-AP5 
The effect of bath application of 50M D-AP5 was examined in 9 slices from 5 
rats. The effect of ketamine had been investigated because this was the drug 
used by most animal and human studies described above, but ketamine also 
has non-NMDAR-mediated effects. D-AP5, a selective NMDAR antagonist was 
used to confirm the effects were NMDAR-mediated. Kainate perfusion 
generated oscillations in mEC layer II or III with a peak power of 137.7 ± 197.9 
V2/Hz, area power of 1.085 ± 1.435 V2/Hz.kHz, and frequency of 45.48 ± 6.8 
Hz. As above, the values for power and frequency in each experiment were 
normalised, with the average of the values at for power and frequency during 
the stable baseline period being defined as 100%. D-AP5 caused a partially 
reversible reduction in peak power and frequency (see Table 4.2 and Figure 
4.1). These decreases occurred in the first 20 minutes of D-AP5 perfusion and 
the oscillations then remained stable at the new lower level. 
Table 4.2 Effect of D-AP5 on mEC -oscillations 
 Reduction at 1 
hour (%) 
RM ANOVA P value 
Peak power 52.7 ± 32.44 F (2.611, 20.89)= 
7.529 
0.0019 
Area power 35.04 ±39.78 F (2.636, 21.09) = 
2.711 
0.0769 
Frequency 10.76 ± 9.74 F (2.730, 21.84)= 
3.196 
0.047 
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Figure 4.1 The effects of ketamine and D-AP5 on mEC layer II/III -oscillation. 
Ai and Ci show examples of LII/III mEC extracellular field recording from a single 
slice during the initial stable period, at the end of the ketamine or D-AP5 perfusion 
(red) and at the end of a 30-minute washout period (grey). The corresponding power 
spectra are shown in Aii and Cii, illustrating the marked reduction in power and small 
reduction in frequency. Bi and ii and Di and ii show the gradual reduction in peak and 
area power (i) and frequency (ii) over the course of the experiments (mean ± S.D.). 
Note the apparent partial recovery of power and frequency during the washout 
period. * p<0.05, **p<0.01.
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4.3.2 Naïve control 
To test the stability of -frequency oscillations over time, -frequency oscillations 
deemed stable over the required 40-minute period were followed for the 
duration of a typical pharmacological experiment, i.e. 90 minutes (60 minutes 
drug application and 30 minutes drug washout). For these experiments (n=8, 7 
animals) the perfusion medium was changed to a smaller container (25ml) of 
the same perfusion medium to mimic the conditions in other experiments 
(where drug or immunoglobulin are diluted in a 20-25ml volume of the 
circulating aCSF).  
Kainate perfusion generated oscillations in layer II or III of the mEC with a peak 
power of 76.54 ± 51.94 V2/Hz, area power of 0.58 ± 0.349 V2/Hz.kHz, and 
frequency of 46.08 ± 4.27 Hz. The values for power and frequency in each 
experiment have been normalised as described above. Oscillation power 
declined progressively from about 40 minutes into the experiments, reaching 
significantly lower peak power values after 90 minutes (see Table 4.3 and 
Figure 4.2 right panel). There were parallel but less marked reductions in area 
power, whilst frequency remained stable throughout the 90-minute experimental 
period.
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Table 4.3 Change in mEC -oscillations over time in vehicle. 
 Reduction 
at 1 hour 
(%) 
Reduction 
at 90 
minutes 
(%) 
RM 
ANOVA 
P 
value 
Significant 
Dunnett’s 
multiple 
comparison 
test 
P 
value 
Peak 
power 
17.24 
±35.49 
35.47 
±25.72 
F(1.735, 
12.15) = 
5.505 
0.0229 90min vs. 
baseline 
0.011 
Area 
power 
5.14 
±40.61 
17.83 
±32.94 
F(1.177, 
8.237) = 
1.365 
0.2844   
Frequency -0.24 
±4.65 
-2.24 ±5.8 F(1.217, 
8.518) = 
1.191 
0.3191   
 
Figure 4.2 Power and frequency of -oscillations over time in vehicle in 
superficial layers of mEC.  
The left panel shows examples of extracellular field recordings from LII mEC from a 
single experiment. The top excerpt is from the baseline period of stability, the middle 
excerpt from a recording 60 minutes later and the bottom excerpt from a recording 
90 minutes after baseline. The corresponding power spectra are shown in the middle 
panel. The black line corresponds to the baseline oscillation, the red line to 60 
minutes and the grey line to 90 minutes after baseline. Note the slight increase in 
power at 60 minutes, followed by a decrease in power at 90 minutes. The right panel 
shows the mean ±S.D. for the 8 experiments for peak power (blue), area power 
(orange), and frequency (green). Peak power decreases gradually after about 40 
minutes of the experiments and the reduction is significant after 90 minutes. Area 
power follows a similar but less pronounced course and frequency remain stable 
throughout the experiments.
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4.3.3 Negative controls – Healthy control IgG 
Two healthy control purified IgG samples have been used in this thesis. HC1 
IgG was obtained from pooled serum samples from healthy individuals and HC2 
IgG was purified from the serum of a single healthy individual with no 
neurological symptoms. No binding to the surface of HEK293 cells expressing 
NR1 and NR2B was detected by cell-based assay at either the concentration 
used in the electrophysiological experiments (10g/ml) or at a ten times higher 
concentration (see  
Figure 4.3). 
Medial entorhinal cortex 
Slices exhibiting stable gamma-frequency oscillations were exposed to purified 
HC1 or HC2 IgG at 10µg/ml for one hour followed by a 30-minute wash.  
Kainate perfusion (400nM) generated oscillations in layer II or III with average 
peak power of 55.61 ± 28.26 V2/Hz, area power of 0.57 ± 0.19 V2/Hz.kHz, 
and frequency of 48.08 ± 2.10 Hz in the slices subsequently exposed to HC1 
IgG (n=6 slices from 3 animals). In the slices exposed to HC2 (n=7 slices from 6 
animals), baseline peak power was 73.30 ±29.47 V2/Hz, area power was 0.77 
±0.28 V2/Hz.kHz, and frequency was 46.54 ±1.55 Hz. Because of the wide 
variation in baseline power, the values for power and frequency in each 
experiment have been normalised as described above.  
Over time, there were reductions in peak power and area power very similar to 
those seen in vehicle. Table 4.4 lists the normalised values obtained from the 
healthy control experiments.  
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Table 4.4 Peak power, frequency and area power in slices exposed to HC1 and 
HC2 IgG at a concentration of 10µg/ml in mEC. 
 HC1 10g/ml (n=6) HC2 10g/ml (n=7) 
 Base-
line 
60min 
IgG 
30 min 
washout 
Base-
line 
60min 
IgG 
30 min 
washout 
Peak 
power 
(% of 
baseline) 
100 
(55.61 
±28.26 
V2/Hz) 
 
82.72 
±14.5 
77.79 
±12.26 
100 
(73.30 
±29.47 
V2/Hz) 
76.42 
±10.73 
55.89** 
±11.75 
Frequen-
cy (% of 
baseline) 
100 
(48.08 
±2.10 
Hz) 
95.07 
±2.17 
95.21 
±2.15 
100 
(46.54 
±1.55 
Hz) 
97.99 
±1.32 
100 
±1.93 
Area 
power 
(% of 
baseline 
100 
(0.57 
±0.19 
V2/Hz.k
Hz) 
82.65 
±8.82 
76.67 
±10.68 
100 
(0.77 
±0.28 
V2/Hz.k
Hz) 
75.32** 
±6.97 
58.32**** 
±4.28 
There was a statistically significant reduction in peak power in slices exposed to 
HC2 at the end of the washout period (RM ANOVA, F(1.979, 11.87) = 7.674, p 
= 0.0074; Dunnett’s multiple comparisons test 90 minutes vs. baseline 
p=0.0168, see Figure 4.4). Similarly, the reduction in area power was 
statistically significant for the HC2 group at both 60 minutes (end of HC2 IgG 
perfusion) and 90 minutes (end of washout, RM ANOVA, F(1.533, 9.199) = 
21.80, p=0.0005; Dunnett’s multiple comparisons test baseline vs. 60’ p=0.022, 
baseline vs. 90’ p=0.0001). 
As for the experiments in aCSF and KA, frequency remained stable over the 90-
minute period of observation. 
As expected, there were no statistically significant differences between the 
changes in power and frequency of -oscillations in the two healthy control 
groups at either of the two endpoints (60 minutes of perfusion with IgG and 30 
minutes after washout, see Table 4.5 and Figure 4.4 Bii, Cii, Dii) and these were 
therefore pooled to form a larger control IgG group (cIgG n=13, see Figure 4.5). 
No significant differences in power or frequency at 60 minutes and 90 minutes 
(30 minutes washout) were found between the vehicle and cIgG groups (see 
Table 4.6). 
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Table 4.5 HC1 and HC2 IgG have similar effects on mEC -oscillations 
 Mean 
Difference 
at 60 
minutes (± 
S.E.M) 
Unpaired 
t-test 
P 
value 
Mean 
Difference 
at 90 
minutes 
(95% CI) 
Unpaired 
t-test 
P 
value 
Peak 
Power (%) 
6.303 
±17.71 
T (11) = 
0.356 
0.729 21.90 
±17.03 
T (11) = 
1.286 
0.225 
Area 
Power (%) 
7.33 
±11.09 
T (11) = 
0.661 
0.522 18.35       
± 10.86 
T (11) = 
1.69 
0.119 
Frequency 
(%) 
-2.92        
± 2.45 
T (11) = 
1.190 
0.259 -4.82       
± 2.88 
T (11) = 
1.672 
0.123 
Table 4.6 The pooled cIgG group of slices behaves similarly to slices exposed to 
vehicle only. 
 Mean 
Difference 
at 60 
minutes (± 
S.E.M) 
Unpaired 
t-test 
P 
value 
Mean 
Difference 
at 90 
minutes 
(95% CI) 
Unpaired 
t-test 
P 
value 
Peak 
Power (%) 
-3.438 ± 
14.61 
t=0.2353 
df=19 
0.816 1.472 ± 
13.24 
t=0.1112 
df=19 
0.913 
Area 
Power (%) 
-16.16 ± 
15.34 
t=1.053 
df=9.014 
0.319 -15.38 ± 
11.70 
t=1.315 
df=19 
0.204 
Frequency 
(%) 
-3.603 ± 
2.043 
t=1.763 
df=19 
0.094 -4.434 ± 
2.536 
t=1.748 
df=19 
0.096 
Hippocampus 
Bath application of 50nM kainic acid generated oscillations in the CA3 subfield 
of the hippocampus. These were of somewhat slower frequency than in the 
mEC (see Table 4.7) but in line with previous published observations. As the 
baseline power of these oscillations was much less variable than that of mEC 
oscillations, normalisation of the data was not carried out. Perfusion for one 
hour with either 10µg/ml HC1 IgG or HC2 IgG did not affect the peak power or 
area power of hippocampal gamma-frequency oscillations (see Table 4.7 and 
Figure 4.6). For both IgG samples there was a small reduction in oscillation 
frequency at peak power over the course of the 90-minute experiment. This is 
consistent with published observations on the natural history of 
pharmacologically evoked hippocampal gamma-oscillations (Pietersen et al., 
2009). For HC1, this reduction in frequency reached statistical significance at 
the end of the washout phase (baseline frequency 37.39 ±1.58 Hz vs. WO 
frequency 34.52 ±1.36Hz, RM ANOVA F(1.470, 8.823)= 13.94, p= 0.003; 
Dunnett’s multiple comparison test baseline vs. 90 minutes p=0.009). However, 
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in view of the known downward trend in HPC kainate-induced gamma-
frequency oscillation, it is unlikely that this reduction was due to the perfusion 
with IgG. 
Table 4.7 Effect of control IgG samples HC1 and HC2 on parameters of 
hippocampal gamma-frequency oscillations.  
 HC1 10g/ml (n=7) HC2 10g/ml (n=6) 
 Base-
line 
(mean 
±SEM) 
60 
minutes 
IgG 
30 
minutes 
washout
Base-
line 
(mean 
±SEM) 
60 
minutes 
IgG 
30 
minutes 
washout
Peak 
Power 
(µV2/Hz) 
54.92 
±12.58 
49.77 
±11.57 
56.75 
±13.06 
61.34 
±22.12 
51.65 
±14.85 
48.71 
±16.96 
Frequen
-cy (Hz) 
37.39 
±1.58 
36.60 
±1.21 
34.52 
±1.36 
42.10 
±1.5 
40.21 
±2.24 
39.20 
±1.96 
Area 
Power 
(µV2/Hz.k
Hz) 
0.606 
±0.162 
0.485 
±0.128 
0.624 
±0.202 
0.933 
±0.357 
0.799 
±0.311 
0.782 
±0.36 
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Figure 4.3 Cell-based assay results of HC1 and HC2 IgG 
HC1 and HC2 IgG do not bind to NMDAR (NR1 and NR2B subunits coexpressed with 
EGFP) expressing HEK cells. NMDAR (+EGFP) transfected HEK cells (green) can be 
visualised in the first column. If serum autoantibodies to NMDAR are present, they bind 
to NMDAR (+EGFP) transfected cells (red, e.g. row 2) and co-localisation of serum 
autoantibody binding and NMDAR (+EGFP) expression can sometimes be seen 
(merge). No red fluorescence is detected on coverslips incubated with HC1 and 2 at 2 
concentrations, indicating that no binding to surface NMDAR has occurred. 
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Control	
1:20 
HC1	IgG	
10μg/ml	
(≈1:1000) 
NMDAR+EGFP SERUM	BINDING MERGE 
NMDAR	
Positive	
Control	 
1:20 
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(≈1:100) 
HC2	IgG	
10μg/ml 
HC2	IgG	
100μg/ml 
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Figure 4.4 The effect of HC1 and 2 IgG on -oscillations in mEC.  
Examples of field recordings from a single experiment in a slice exposed to HC1 are 
shown in Ai with the corresponding power spectra in ii, illustrating the small decline in 
peak power over the course of the experiment. Time course of power and frequency 
are shown in Bi, Ci, and Di (mean ± SD). Peak and area power decrease significantly 
in slices exposed to HC2 (Bi and Ci), and frequency remains stable for both IgG 
preparations (Ci). When power and frequency of the oscillations in the two groups of 
slices are compared at the relevant time points, no statistical differences are found (Bii, 
Cii, Dii, mean ± SEM). 
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Figure 4.5 Comparison of mEC -oscillations in slices exposed to cIgG or 
vehicle.  
There is a decline in peak power in slices exposed to either cIgG or vehicle (Ai, mean ± 
SD). Although area power also decreases in both groups, only the decrease in cIgG is 
significant (Bi, mean ± SD). Frequency remains stable in both groups of slices (Ci, 
mean ± SD). There are no significant differences when power and frequency in the two 
groups are directly compared at the end of the IgG perfusion period and at the end of 
washout (mean ± SEM). 
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Figure 4.6 -oscillation power and frequency in CA3 of slices exposed to HC1 or 
HC2.  
Ai shows examples of extracellular field recordings in CA3 from a single experiment 
with HC1, and the corresponding power spectra are shown in Aii. Note the very stable 
appearance of the oscillation with essentially superimposed power spectra at the three 
time points. The graphs in B show the time course of peak power (i), area power (ii) 
and frequency (iii) for the two control IgG samples as mean ± S.E.M
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4.3.4 Disease Control 
IgG purified from the serum of a patient with autoimmune limbic encephalitis 
and VGKC-complex antibodies was used as a disease control (DC IgG) to 
ascertain the specificity of any findings with NMDAR-Ab positive IgG. DC IgG 
did not bind to NR1 and NR2B expressing HEK cells at the concentration used 
(10g/ml) or at a tenfold higher concentration (100g/ml, see Figure 4.7), which 
was always associated with binding of NMDAR-Ab positive samples, confirming 
there were no NMDAR antibodies in this IgG sample. 
mEC 
Slices exhibiting stable gamma-frequency oscillations were exposed to DC IgG 
at 10µg/ml for one hour followed by a 30-minute wash (n=4 slices from 4 
animals). Kainate perfusion generated oscillations in layer II or III with a peak 
power of 81.61 ± 36.27 V2/Hz, area power of 1.016 ± 0.539 V2/Hz.kHz, and 
frequency of 45.08 ± 7.27 Hz. There was no significant change in the 
normalised power or frequency of mEC -oscillations at one hour of exposure to 
DC IgG or 30 minutes after IgG washout (see Table 4.8 and Figure 4.8) 
There was no difference between the change in power and frequency of the 
oscillations exposed to DC and those in vehicle at 60 minutes or 90 minutes 
(after 30 minutes of DC washout, see Table 4.8 and Figure 4.8).
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Table 4.8 Effect of DC IgG on mEC -oscillations and comparison with vehicle 
 Reduction at 
60 mins (%) 
Reduction at 
90 mins (%) 
RM ANOVA P value 
Peak Power 33.45 ± 42.94 -1.855 ± 
30.86 
F (1.469, 
4.406) = 
1.374 
0.326 
Area Power 27.67 ±48.60 4.377 ± 25.25 F (1.546, 
4.639) = 
1.150 
0.373 
Frequency 2.93 ±3.08 -4.106 ± 
3.518 
F (2.206, 
8.826) = 
2.328 
0.152 
 DC IgG 
60min – 
vehicle 
60min (%) 
DC IgG WO – 
vehicle WO 
(%) 
ANOVA P value 
Peak Power 
Mean 
Difference 
(95% CI) 
-16.21 
(-65.68 to 
33.26) 
33.62 
(-15.85 to 
83.08 
) 
F (3, 20) = 
0.8289 
0.494 
 
Area Power 
Mean 
Difference 
(95% CI) 
-22.53 
(-72.05 to 
26.98) 
22.21 
(-27.31 to 
71.72) 
F (3, 20) = 
0.5986 
0.623 
Frequency 
Mean 
Difference 
(95% CI) 
-3.177 
(-9.714 to 
3.361) 
-6.346 
(-12.88 to 
0.1918) 
F (3, 22) = 
1.732 
0.19 
CA3 
DC IgG caused no significant change to -oscillation power (mean ± S.E.M.: 
peak power baseline 80.35 ±19.81 V2/Hz vs. 67.63 ±26.34 V2/Hz DC 60 
minutes, one-way ANOVA F (2.120, 8.479) = 0.964, p=0.425; area power 
baseline 0.645 ±0.335 V2/Hz.kHz vs. 0.495 ±0.296 V2/Hz.kHz DC 60 
minutes, F (1.34, 5.36)=1.133, p=0.358) or frequency (baseline 38.18 ±2.29 Hz 
vs. 38.34 ±2.16 Hz DC 60 minutes, F(2.68, 10.73)=0.65, p= 0.583) in the CA3 
subfield of the hippocampus in 5 slices examined (3 animals, see Figure 4.8).
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Figure 4.7 DC IgG does not bind to NMDAR (NR1 and NR2B subunits 
coexpressed with EGFP) expressing HEK cells.  
NMDAR (+EGFP) transfected HEK cells (green), serum autoantibodies bound to 
NMDAR (+EGFP) transfected cells (red) and co-localisation of serum autoantibody 
binding and NMDAR (+EGFP) expression (merge). The bottom row pertains to the 
disease control sample. The pictures shown are from coverslip exposed to 100g/ml 
DC IgG. 
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Figure 4.8 Power and frequency of -oscillation in mEC and CA3 of HPC in slices 
exposed to disease control IgG. 
In the mEC (n=4, graphs i and ii of each row) there is a gradual decline in power (Ai 
and Bi, mean ± SEM) comparable to that seen in the vehicle group (Aii and Bii, mean 
±SD). Frequency remains stable (Ci and ii). In the HPC (n=5), power (Aiii and Biii) and 
frequency (Ciii) remain unchanged (mean ± SEM). 
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4.3.5 Fab fragments from patient IgG 
Patient autoantibodies have been shown to cause the internalisation of 
NMDARs through divalent binding and cross-linking of surface receptors 
(Hughes et al., 2010). The antigen-binding region of an antibody (fragment 
antigen-binding or Fab) can be enzymatically cleaved from the immunoglobulin 
molecule, yielding two Fab fragments for each IgG molecule. Fab fragments 
prepared from patient IgG bind to surface NMDARs, but unlike the full IgG 
molecule, they do not cause a reduction in surface NMDAR clusters. Only when 
an anti-Fab secondary antibody is added, thus restoring the divalent 
conformation of a normal IgG molecule, is a reduction in surface NMDAR 
clusters seen (Hughes et al., 2010). This strongly suggests that any effect seen 
with patient IgG is a result of reduced surface NMDAR availability through 
internalisation. 
Fab fragments (Fab) prepared from NMDAR-Ab-positive patient IgG (gift of 
Professor Vincent, Oxford University) were used at a concentration of 10g/ml 
to determine whether any effect on -oscillations was mediated by NMDA 
receptor internalisation or through an acute antagonistic affect. Kainate 
perfusion generated oscillations in layer II or III of mEC with average peak 
power of 70.85 ± 51.69 V2/Hz, area power of 0.68 ± 0.32 V2/Hz.kHz, and 
frequency of 46.27 ± 8.39 Hz (n=11 slices from 9 animals). Because of the wide 
variation in baseline power, the values for power and frequency in each 
experiment have been normalised as described above. In the presence of Fab, 
there was a gradual decline in peak and area power similar to that seen in the 
vehicle group. Frequency remained unchanged (see Table 4.9 and Figure 4.9).
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Table 4.9 Effect of NMDAR-Ab Fab on mEC -oscillations (mean ± SD) 
 Reduction 
at 60 min 
(%) 
Reduction 
at 90 min 
(%) 
RM 
ANOVA 
P Significant 
multiple 
comparison 
test 
(Dunnett’s) 
P 
Peak 
Power 
17.88 
±27.48 
45.08 ± 
22.88 
F(1.616, 
16.16) = 
21.43 
<0.0001 Baseline vs. 
90 min 
p<0.001 
Area 
Power 
22.02 ± 
16.43 
33.56 ± 
20.31 
F(1.554, 
15.54) = 
22.92 
<0.0001 Baseline vs. 
60 min 
Baseline vs. 
90 min 
<0.01 
 
<0.001 
Frequen
-cy 
1.18 ± 5.47 0.87 ± 
5.37 
F 
(1.456, 
14.56) = 
0.368 
 
0.633 
 
  
 
When oscillation power and frequency in the Fab group (n=11), the vehicle 
group (n=8) and the cIgG group (n=13) were compared at the end of IgG 
perfusion and the end of washout, there were no significant differences 
between the groups (see Figure 4.9). 
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Figure 4.9 Power and frequency of -oscillations in the presence of purified Fab 
fragments from a patient with NMDAR-Abs (10g/ml).  
Examples of extracellular field recordings from three time points during an experiment 
in a single slice are shown in A. The corresponding power spectra at the far right 
illustrate the small reduction in peak power that occurs over the course of the 90-
minute experiment. The time course of peak power (B), area power (C) and frequency 
(D) are shown as mean ±S.D. in the left panel. Both peak and area power decline over 
the course of the experiments. However, these declines are similar to those seen in the 
vehicle and cIgG groups (right panel). 
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4.3.6 Patient Immunoglobulin preparations 
NMDAR-Ab positive purified IgG was obtained from three patients with 
NMDAR-Ab encephalitis and strongly positive NMDAR-Ab titres (scores 3-4 on 
cell-based assay, gift of Professor A. Vincent). Patient 1 IgG was used at 
10g/ml, and patients 2 and 3 at both 10 and 30 g/ml. Only patients 2 and 3 
IgG were tested in the hippocampus due to the limited availability of patient 1 
IgG. Clinical details of the three patients can be found in Appendix A 
Patient 1 
Purified IgG from patient 1 (Pt1) strongly bound to HEK cells expressing NR1, 
NR2B and EGFP at the standard dilution used for diagnostic cell-based assays 
(1:20, see Figure 4.10 bottom row). At the concentration used in the 
electrophysiological experiments below (10g/ml) binding was present but very 
subtle (see Figure 4.10 middle row), scoring 1/4. The CBA using Pt1 IgG at 
10g/ml was performed two years after its use for the electrophysiology 
experiments with an aliquot that had been stored at 4C and loss of activity may 
have occurred. 
Medial entorhinal cortex 
Slices exhibiting stable gamma-frequency oscillations were exposed to purified 
IgG from Pt1 at 10µg/ml for one hour followed by a 30-minute wash (n=7 slices 
from 7 rats). Kainate perfusion (400 nM) generated oscillations in layer II or III 
with a peak power of 56.23 ± 45.78 V2/Hz, area power of 0.51 ± 0.35 
V2/Hz.kHz, and frequency of 43.60 ± 6.79 Hz (mean ± SD). Because of the 
wide variation in baseline power, the values for power and frequency in each 
experiment have been normalised as described above. Over time, there were 
reductions in peak power and area power, which appeared more pronounced 
than those seen with vehicle or cIgG (see Figure 4.10). Peak power had 
decreased by 48.01 ±36.36% after 1 hour of perfusion with Pt1 IgG (RM 
ANOVA, F(1.918, 11.51)=14.86, p=0.007; Dunnett’s multiple comparisons test 
baseline vs. 1h p<0.05). No recovery after washout was seen. In fact peak 
power continued to decline (change in peak power 67.76 ±34.5% at end of 
washout, Dunnett’s multiple comparisons test baseline vs. 90 minutes p<0.01). 
Area power followed a similar course (decrease of 45.21 ±35.05% at 1 hour and 
63.65 ±31.96% at end of washout, F(1.913, 11.48)=12.08, p=0.0016; Dunnett’s 
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multiple comparisons test baseline vs. 1hr p<0.05, baseline vs. 90 minutes 
p<0.01). Frequency remained stable (decrease of 4.4±7.36% at 1 hour and 
1.07±14.96% at 90 minutes, F(1.386, 8.318) = 0.464, p= 0.576). 
When compared to the changes seen in vehicle and cIgG, only the change in 
area power at the end of the washout period was significantly greater in Pt1 IgG 
slices (one-way ANOVA, F(2, 25)=5.321, p=0.0119; Dunnett’s multiple 
comparisons test vehicle vs. Pt1 IgG p<0.01, cIgG vs. Pt1 IgG p<0.05, Figure 
4.10). 
Patient 2 
Purified IgG from patient 2 (Pt2) strongly bound to HEK cells expressing NR1, 
NR2B and EGFP at the standard dilution used for diagnostic cell-based assays 
(1:20, see Figure 4.11), scoring 4. At the concentrations used in the 
electrophysiological experiments below (10 and 30g/ml) binding was less 
pronounced but still clearly visible (see Figure 4.11), scoring 1.5/4. 
Medial entorhinal cortex 
Six slices from 5 animals were exposed to 10g/ml Pt2 IgG and 8 slices from 5 
animals to 30g/ml. There were significant reductions in power and also 
frequency of -oscillation in mEC after exposure to Pt2 IgG (see Table 4.10 and 
Figure 4.12).  
Table 4.10 Effect of Pt2 IgG on parameters of -frequency oscillations in mEC 
 Pt2 10µg/ml (n=6) Pt2 30 µg/ml (n=8) 
 Base-
line 
60 min 
IgG 
(mean 
±SEM) 
Wash
out 
(mean 
±SEM) 
Signifi
cance 
level 
(RM 
ANOVA) 
Base-
line 
60 min 
IgG 
(mean 
±SEM) 
Wash
out 
(mean 
±SEM) 
Signifi
cance 
level 
(RM 
ANOVA) 
Peak 
Power (%) 
100 70.3 
±8.43 
64.76 
±10.86 
F=7.619 
P=0.012 
100 64.45 
±8.99 
53.22 
±15.11 
F=9.534 
P=0.012 
Area 
Power (%) 
100 67.58 
±6.54 
68.46 
±6.9 
F=18.08 
P=0.001 
100 71.22 
±7.25 
49.37 
±13.48 
F=11.14 
P=0.005 
Frequency 
(%) 
100 95.01 
±0.6 
93.75 
±1.35 
F=20.44 
P=0.003 
100 97.75 
±2.09 
89.60 
±5.96 
F=2.873 
P=0.127 
There was a significant reduction in peak power over time in the presence of 
both 10 and 30µg/ml Pt2 IgG. The decrease was significant after 60 minutes 
(Dunnett’s multiple comparisons test IgG vs. baseline p=0.029 for 10µg/ml IgG 
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and p=0.0099 for 30µg/ml IgG). At both IgG concentrations, peak power 
continued to drop during the washout phase so that peak power at the end of 
the washout phase was significantly lower than during the baseline period 
(Dunnett’s multiple comparisons test p=0.039 for 10µg/ml IgG, p=0.031 for 
30µg/ml IgG). 
Area power also decreased significantly over time in both concentrations of IgG. 
The reductions were highly significant after 60 minutes of perfusion (Dunnett’s 
multiple comparisons test baseline vs. 60 minutes p=0.0075 for 10µg/ml and 
p=0.0097 for 30µg/ml) and significant at the end of the washout phase 
(Dunnett’s multiple comparisons test baseline vs. 90 minutes p=0.011 for 
10µg/ml and p=0.013 for 30µg/ml). 
Unexpectedly, there was a statistically significant decrease in frequency over 
time in slices perfused with 10µg/ml Pt2 IgG but not 30µg/ml Pt2 IgG (see Table 
4.10). The reduction for the slices perfused with 10µg/ml was significant at both 
time points (Dunnett’s multiple comparisons test baseline vs. 60’ IgG p=0.0007, 
baseline vs. washout p=0.0097). 
There was no statistical difference between the power and frequency at 1 hour 
and following washout for the two concentrations (see Table 4.11). Also, the 
changes were not significant when compared to the vehicle and cIgG groups 
(see Table 4.11). 
Table 4.11 Comparison of Pt2 IgG at 10 and 30 g/ml with vehicle and cIgG 
Peak Power (% of baseline) 
At 60 minutes Mean 1 Mean 2 Mean Diff. Tukey P 
Pt2(10)-60' vs. Pt2(30) -60' 70.31 64.45 5.859 0.983 
Pt2(10)-60' vs. vehicle 60' 70.31 82.76 -12.46 0.861 
Pt2(10)-60' vs. cIgG -60' 70.31 79.33 -9.019 0.924 
Pt 2(30) -60' vs. vehicle 60' 64.45 82.76 -18.32 0.603 
Pt2(30) -60' vs. cIgG -60' 64.45 79.33 -14.88 0.676 
vehicle 60' vs. cIgG -60' 82.76 79.33 3.438 0.994 
At 90 minutes Mean 1 Mean 2 Mean Diff. Tukey P 
Pt2(10)-WO vs. Pt2(30) -WO 64.76 53.22 11.53 0.913 
Pt2(10)-WO vs. vehicle 90’ 64.76 64.53 0.2250 0.999 
Pt2(10)-WO vs. cIgG -WO 64.76 66.00 -1.247 0.999 
Pt 2(30) -WO vs. vehicle 90' 53.22 64.53 -11.31 0.89 
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Pt2(30) -WO vs. cIgG -WO 53.22 66.00 -12.78 0.818 
vehicle 90' vs. cIgG -WO 64.53 66.00 -1.472 0.999 
Frequency (% of baseline) 
At 60 minutes Mean 1 Mean 2 Mean Diff. Tukey P 
Pt2(10)-60' vs. Pt2(30) -60' 100.2 96.64 3.603 0.315 
Pt2(10)-60' vs. vehicle 60' 100.2 95.01 5.236 0.169 
Pt2(10)-60' vs. cIgG -60' 100.2 97.75 2.490 0.699 
Pt 2(30) -60' vs. vehicle 60' 96.64 95.01 1.633 0.887 
Pt2(30) -60' vs. cIgG -60' 96.64 97.75 -1.113 0.948 
vehicle 60' vs. cIgG -60' 95.01 97.75 -2.746 0.685 
At 90 minutes Mean 1 Mean 2 Mean Diff. Tukey P 
Pt2(10)-WO vs. Pt2(30) -WO 102.2 97.81 4.434 0.711 
Pt2(10)-WO vs. vehicle 90’ 102.2 93.75 8.487 0.341 
Pt2(10)-WO vs. cIgG -WO 102.2 89.60 12.64 0.048 
Pt 2(30) -WO vs. vehicle 90' 97.81 93.75 4.053 0.811 
Pt2(30) -WO vs. cIgG -WO 97.81 89.60 8.210 0.218 
vehicle 90' vs. cIgG -WO 93.75 89.60 4.157 0.838 
 
CA3 hippocampus 
Hippocampal -oscillations were not affected by perfusion with Pt2 IgG at 
10g/ml for one hour (n=6 slices from 3 animals). There was a gradual and non-
significant increase peak power and area power, along with a progressive slow 
decline in frequency in keeping with findings in Pietersen et al. (2009) (see 
Table 4.12 and Figure 4.12B). 
Table 4.12 Effect of Pt2 IgG on HPC -oscillations 
 Baseline 60 
minutes 
Washout RM 
ANOVA 
P value 
Peak Power 
(µV2/Hz) 
127.2 
±39.61 
147.7 
±44.84 
160.8 
±38.20 
F (1.581, 
7.904) = 
3.309 
0.097 
Area Power 
(µV2/Hz.kHz) 
1.653 
±0.522 
1.603 
±0.462 
2.001 
±0.627 
F (1.243, 
6.214) = 
1.217 
0.327 
Frequency 
(Hz) 
39.44 
±1.35 
38.29 
±0.43 
37.49 
±0.92 
F (1.569, 
7.847) = 
2.091 
0.189 
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Patient 3 
Purified IgG from patient 3 (Pt3) strongly bound to HEK cells expressing NR1, 
NR2B and EGFP at the standard dilution used for diagnostic cell-based assays 
(1:20, see Figure 4.13), scoring 4/4. At 10g/ml binding was barely visible and 
therefore scored 0.5. At 30g/ml, the binding scored 1/4. 
Medial entorhinal cortex 
As for the Pt2 IgG, perfusion of purified Pt3 IgG was accompanied by a 
significant decline from baseline in peak power and area power of kainate-
induced mEC gamma-frequency oscillations, whilst frequency remained 
unchanged (see Table 4.13: RM ANOVAs: peak power 10g/ml F(1.535, 
7.677)=37.37, p=0.0002, 30g/ml F(1.639, 16.39)=8.331, p=0.0047; area power 
10g/ml F(1.257, 6.285)=39.07, p=0.0005, 30g/ml F(1.773, 15.96)=7.962, 
p=0.005). 
Table 4.13 MEC -oscillation parameters after perfusion with Pt3 IgG 
 Pt3 10µg/ml (n=6 slices, 5 
animals) 
Pt3 30 µg/ml (n=10 slices, 6 animals)
 Base-line 
60 min 
IgG 
(mean 
±S.D.) 
Wash-
out 
(mean 
±S.D.) 
Signifi-
cance 
level  
(RM 
ANOVA) 
Base-line 60 min 
IgG 
(mean 
±S.D.) 
Wash-
out 
(mean 
±S.D.) 
Signifi-
cance 
level 
(RM ANOVA) 
Peak 
Power 
(%) 
100 47.37 
±27.23 
22.59 
±16.23 
*** 
0.0002 
100 58.59 
±29.95 
64.78 
±42.76 
** 
0.005 
Area 
Power 
(%) 
100 58.34 
±8.23 
39.72 
±20.12 
*** 
0.0005 
100 66.06 
±24.72 
66.83 
±34.04 
** 
0.005 
Frequenc
y (%) 
100 93.82 
±6.08 
95.28 
±3.35 
ns 100 98.24 
±12.46 
98.88 
±10.65 
ns 
Peak power had decreased significantly compared to baseline at both 60 
minutes of perfusion with Pt3 IgG (Dunnett’s multiple comparisons tests 
baseline vs. 60 minutes 10µg/ml p=0.0091 and 30µg/ml p=0.001) and after 
washout (Dunnett’s multiple comparisons tests baseline vs. 90 minutes 10µg/ml 
p=0.0002, 30µg/ml p=0.038). 
Area power had also declined significantly at both time points (Dunnett’s 
multiple comparisons tests: 60 minutes vs. baseline: 10µg/ml p=0.0001, 
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30µg/ml p=0.0035; 90minutes vs. baseline: 10µg/ml p=0.0013, 30µg/ml 
p=0.024). Interestingly, the reductions are greater in slices exposed to 10µg/ml 
Pt3 IgG (50-80% reduction from baseline vs. 35-45% in those exposed to 
30µg/ml, see Table 4.13). This is likely to be a chance effect caused by two 
slices demonstrating very large reductions in power in the 10µg/ml Pt3 IgG 
group. 
When compared to equivalent time points in control experiments, peak power at 
the end of the washout phase in the 10g/ml group was significantly lower than 
in the vehicle, cIgG and 30g/ml Pt3 IgG groups (one-way ANOVA 
F(3,34)=2.886, p=0.0498; Uncorrected Fisher’s Least Significant Difference 
p<0.05 for Pt3 IgG 10g/ml vs. each of vehicle, cIgG, and Pt3 30g.ml (note 
that correcting for multiple comparisons, e.g. with Dunnett’s test, abolished any 
group differences). Similarly, area power in the Pt3 10 and 30g/ml groups was 
significantly lower than in the vehicle group at 60 minutes of IgG perfusion (one-
way ANOVA at 60 minutes perfusion F(3, 33) = 2.905 p=0.0493; Uncorrected 
Fisher’s LSD p<0.05 for vehicle vs. Pt3 10g/ml and Pt3 30 g/ml; note that 
correcting for multiple comparisons, e.g. with Dunnett’s test, obscured any 
group differences). Comparisons to area power in the cIgG group and 
comparisons after washout were not significant. Frequencies throughout the 
experiments were comparable in all four groups (see Figure 4.14). 
CA3 hippocampus 
Hippocampal -oscillations were not affected by perfusion with Pt3 IgG at 
30µg/ml (n= 7 slices from 3 animals, see Figure 4.14). 
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Figure 4.10 Effect of Pt1 IgG on -oscillations in superficial mEC.  
The top panel shows the results of a CBA performed with Pt1 IgG. When initially tested 
at standard CBA dilution (1:20, bottom row), there was strong binding to HEK293 cells 
expressing NR1 and NR2B. Some faint binding could still be detected at 10g/ml 3 
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years later (middle row). The bottom panel shows the electrophysiological results. 
Examples of field recordings from a single experiment are shown in Ai with 
corresponding power spectra in Aii, illustrating the decline in power at the end of the 
IgG perfusion period, which also continues during the washout phase. The averaged 
time-course of peak power, area power and frequency (mean ± S.D.) are shown in Bi, 
ii, and iii respectively. Despite the apparent marked reductions in peak and area power 
with Pt1 IgG, there is no significant difference between the peak and area power of 
vehicle, cIgG and Pt1 IgG oscillations at 1 hour of IgG perfusion. At the end of the 
washout period there is a significant difference in area power between the vehicle, 
cIgG and Pt 1 IgG groups. 
 
Figure 4.11 Results of CBA using Pt 2 IgG at 10, 30, and 100 g/ml. 
Cell-surface binding of IgG to HEK293 cells expressing NR1 and NR2B (with EGFP) is 
subtle but definite at both the concentrations used in electrophysiological experiments, 
scoring 1 and 1.5 on CBA. Stronger binding can be observed at 100g/ml and at 1:20, 
the usual diagnostic CBA dilution for serum. 
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Figure 4.12 The effect of Pt2 IgG on mEC and CA3 -oscillations.  
Example mEC and CA3 oscillations at baseline (black), 1h after Pt2 perfusion (red) and 
after 30 minutes IgG washout (grey) are shown in Ai and Bi. Horizontal scale bars : 
100ms, vertical scale bars: 20V in Ai, 50V in Bi. The corresponding power spectra 
demonstrate the reduction in power after IgG perfusion in mEC, which is maintained 
through the washout period. In CA3, there is a gradual increase in  during the 
experiment. In the mEC (Ai-iv) Pt2 IgG perfusion was associated with a reduction in 
peak power (ii) and area power (iii), however these were not significant when 
compared to vehicle and cIgG data (right panel). Although frequency appears to 
decrease in the 10g/ml group (iv, left panel), there is no significant difference when all 
groups are compared (iv, right panel). 10g/ml Pt 2 IgG has no effect on CA3 -
oscillations. 
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Figure 4.13 CBA results using Pt 3 IgG at 10, 30, and 100g/ml. 
Cell-surface binding of IgG to HEK293 cells expressing NR1 and NR2B (with EGFP) is 
very subtle at both the concentrations used in electrophysiological experiments, 
scoring 0.5 and 1 at 10 and 30g/ml respectively on CBA. Stronger binding can be 
observed at 100g/ml and at 1:20, the usual diagnostic CBA dilution for serum. 
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Figure 4.14 The effect of Pt3 IgG on mEC and CA3 -oscillations.  
In the mEC (first two graphs per row) Pt3 IgG perfusion was associated with a 
reduction in peak power (A) and area power (B). Peak power in the 10g/ml group was 
significantly lower than in the other groups at 90 minutes, and area power in both the 
10 and 30 g/ml groups was lower than in the vehicle group at 60 minutes (A and B 
middle graphs). Although frequency appears to decrease in the 10g/ml group (C, first 
graph), there is no significant difference when all groups are compared (middle graph). 
30g/ml Pt3 IgG has no effect on CA3 -oscillations. 
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4.3.7 Grouped patient IgG samples 
The results above raised the possibility that patient IgG may have an effect on 
-oscillation power in the mEC: although  power is clearly not stable over 
prolonged periods as indicated in the literature, the decline in power in the 
patient IgG groups appeared more pronounced than in the vehicle or control 
IgG groups. Also, in the slices exposed to Pt3 IgG, -power was significantly 
lower than in slices perfused only with vehicle or with cIgG. 
This possible effect should be related to the presence of NMDAR-Abs in the 
patient IgG samples, as control IgG had a less pronounced effect on -power. It 
is not possible to quantify the concentration of NMDAR-Ab in purified IgG 
samples, and this will be different in each preparation. Any effect of the 
NMDAR-Abs will be related to the total amount used in each experiment, which 
is unknown. Using set concentrations of 10 and 30g/ml may therefore have 
been rather artificial. As shown for Pt2 and 3 IgG, there were no statistically 
significant differences in power between the slices exposed to each of the IgG 
concentrations. This would suggest that at the two relatively low concentrations 
used here (1:500 and 1:1200 dilution, compared to 1:10 to 1:100 used by other 
groups (Hughes et al., 2010), no concentration-effect could be detected. The 
results of three patient samples have therefore been pooled to form a larger 
patient IgG group (pIgG, n=38). At the end of the one-hour perfusion with IgG, 
the reduction in peak power of -oscillations was greater in the pIgG group 
compared to the vehicle, cIgG and Fab groups (one-way ANOVA, F(4, 69) = 
2.513, p = 0.0494), but not the DC group (see Table 4.14). The latter is likely to 
be related to the small sample size and large variation of the SD group.
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Table 4.14 Change in mEC -oscillation power and frequency in the five groups 
studied. 
 P by 
ANOVA 
pIgG 
(n=38) 
 
Vehicle 
(n=8) 
P by 
uncorrected 
Fisher’s 
LSD vs. 
pIgG 
cIgG 
(n=13) 
P by 
uncorrected 
Fisher’s 
LSD vs. 
pIgG 
Fab 
(n=11) 
P by 
uncorrected 
Fisher’s 
LSD vs. 
pIgG 
DC 
(n=4) 
P by 
uncorrected 
Fisher’s 
LSD vs. 
pIgG 
Change 
in peak 
power 
(%) 
* 41.31 
±27.54
17.24 
±35.49 
* 
20.67 
±30.65 
* 
17.88 
±27.48 
* 
33.45 
±41.31 
Change 
in area 
power 
(%) 
* 35.96 
±22.82
5.13 
 ±40.61 
** 
21.30 
±19.46 
22.02 
±16.44 
27.67 
±33.0 
Change 
in 
frequency 
(%) 
ns 4.9 
±11.84
-0.24 
±4.65 
3.36 
±4.48 
1.18 
±5.47 
2.93 
±3.08 
 The decline in area power of -oscillations was greater in the pIgG group 
compared to vehicle only (one-way ANOVA, F(4, 68) = 3.115, p = 0.0205). 
Change in frequency was minimal and similar across groups (see Table 4.14 
and Figure 4.15Error! Reference source not found.). 
Changes in power and frequency at 90 minutes (at the end of a 30 minute 
washout period) were not compared across groups as the significant reduction 
in power at 90 minutes in the vehicle group suggests that deterioration in slice 
health might confound any effect of IgG. 
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Figure 4.15 Change in power and frequency of mEC -oscillations in slices 
exposed to vehicle, cIgG, Fab or pIgG.  
The average time course of peak power (Ai), area power (Bi) and frequency (Ci) are 
presented as mean ±S.D. Peak and area power decline in all groups during the active 
perfusion period. There is no recovery during the washout phase. Frequency remains 
stable. The change in peak power is greater in the pIgG group than in the other groups 
except disease control (DC) (Aii, mean ± S.D.). The change in area power in pIgG is 
greater only than that in vehicle (Bii). There is no difference in frequency change 
among groups.
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4.4 Discussion 
The first aim of this research project was to determine if NMDAR-Abs could 
disrupt -oscillations in the mEC in vitro in a manner similar to NMDAR 
antagonists. This would lend support to their pathogenic potential and suggest a 
possible mechanism for the neuropsychiatric symptoms experienced by patients 
with NMDAR encephalitis. One of the first findings of this study was a gradual 
decline in -oscillation power over time under normal conditions. Indeed, -
oscillations defined as stable by electrophysiological criteria over 40 minutes 
remained so for only a further 30-40 minutes. After this a visible reduction in 
peak and area power occurred, which became significant at 90 minutes for 
peak power. 
The power of -oscillations is predicted by the size and synchrony of the IPSPs 
impinging onto principal cells (and also inhibitory interneurons through recurrent 
inhibitory connections), and thus phase-locking their output (Cunningham et al., 
2003a; Cunningham et al., 2006). The size of these IPSPs is itself related to the 
excitatory drive, in the form of excitatory post-synaptic potentials (EPSPs) onto 
the fast-spiking interneurons that generate the oscillation. This excitatory drive 
has several sources. Activity in the gap-junctionally coupled axonal plexus of 
excitatory principal cells constitutes an important part (Cunningham et al., 
2004), but the relatively low frequency of phasic EPSPs recorded in fast-spiking 
interneurons suggests tonic drive is also required (Cunningham et al., 2003a). 
Thus, there are several mechanisms by which the power of an oscillation might 
decline even without pharmacological intervention. Significant cell death among 
either the principal neurons or interneurons in the slice would lead respectively 
to a reduction in the excitatory drive to interneurons or the size of the IPSPs 
invading principal cells. Endogenous adenosine, the levels of which increase 
with kainate application in the slice preparation used here, is also known to 
depress excitatory glutamatergic and cholinergic transmission and therefore 
reduces -oscillation power (Pietersen et al., 2009). 
The observed reduction in oscillation power in control conditions meant that it 
was not possible to simply compare power before and after perfusion with 
patient or control IgG. Instead, statistical comparisons were made with 
reference to relevant endpoints in control conditions (60 minutes after the onset 
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of perfusion with the active compound and after 30 minutes of active compound 
washout). 
When the results of the slices exposed to each of the three patient IgG samples 
were grouped, the decline in -oscillation power was greater than that related to 
factors endogenous to the slice preparation. Indeed the reduction in the pIgG 
slices was greater than the reduction in any of the other groups examined and 
there were no significant differences between vehicle, cIgG, Fab and DC IgG. 
This would suggest that the difference in reduction is related to the NMDAR-
Abs, which are unique to the pIgG group. Purification of the NMDAR-Abs from 
patient IgG has so far not been possible. This would be required for the 
definitive demonstration that the reduction in -oscillation power seen in these 
experiments was due to the NMDAR-Abs in the IgG. However, the patient 
serum from which the IgG was purified has been shown not to bind other 
neurotransmitter receptors and ion channels as part of the diagnostic process. 
The purification process will also have removed other putative agents such as 
anti-epileptic medication for example. Furthermore, to show that there were no 
other detectable neuronal surface antibodies in the IgG preparation, adsorption 
of the antibodies by NMDAR-expressing cells was shown for each of the IgG 
preparations (Pettingill, unpublished). 
As expected from the literature (Cunningham et al., 2006), NMDAR-Ab 
containing IgG had no effect on hippocampal -oscillations. 
Immunohistochemistry using CSF or serum containing NMDAR-abs reveals that 
staining is most intense in the HPC, and this is related to the very high 
concentration of NMDAR in this region (Moscato et al., 2014). In view of the 
effect of NMDAR-abs on mEC -oscillations shown above, and the likely 
pathogenic role of the antibodies, it is likely that a change in NMDAR-mediated 
neurotransmission in HPC would occur in vivo after exposure to NMDAR-abs. 
However, -oscillations the HPC-mEC slice preparation do not allow detection 
of such a change. Other electrophysiological measurements such as NMDAR-
mediated EPSP or LTP in the HPC are likely to be more conducive to this. 
The disease control IgG was purified from the serum of a patient with limbic 
encephalitis and antibodies to LGI-1. LGI-1 is a secreted protein that interacts 
with several synaptic scaffolding proteins and complexes with the Kv1.1 
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subtype of voltage-gated potassium channels, thereby preventing its 
inactivation (Schulte et al., 2006). Electrophysiological slice studies from LGI-1 
knockout mice have demonstrated increased frequency of miniature excitatory 
postsynaptic currents in hippocampal pyramidal cells compared to wild-type 
mice, reflecting increased glutamate release (Yu et al., 2010). Similar increases 
in neurotransmitter release and hyperexcitability have been demonstrated as a 
consequence of inactivation or loss of Kv1.1 potassium channels (Schulte et al., 
2006; Simeone et al., 2013), with consequent reduced spike-timing precision in 
pyramidal cells in the hippocampus of Kv1.1 knock-out mice (Simeone et al., 
2013). Pyramidal cell hyperexcitability, reduced spike-timing precision, and 
hyperglutamatergic states adversely affect network organisation into oscillatory 
patterns.  
It is therefore likely that the DC IgG used here would impair -oscillations and 
perhaps cause epileptiform activity to emerge as seen in other studies (Yu et 
al., 2010; Lalic et al., 2011). This would mitigate its usefulness as a control for 
the effects of NMDAR-abs. We did indeed observe an apparent reduction in -
power in the mEC but not the HPC, but no epileptiform activity was recorded. 
The ambivalent effect may be related to the high dilution and/or small sample 
size used in this study, in contrast to Lalic et al. (2011), where the concentration 
of IgG used was ten times higher. These points highlight the fact that -
oscillations are a sensitive assay of perturbations of neuronal function, synaptic 
transmission and the balance of inhibition and excitation, but not a very specific 
one. Indeed, -oscillations are impaired in a number of neuropsychiatric 
conditions. 
One of the limitations of this study is a lack of mechanistic explanation for the 
observed decrease in mEC -oscillation power. In pharmacological experiments 
using ketamine, reduction in -power is due to fewer and smaller IPSPs 
reaching principal cells, indicating a disruption in the -output of the 
interneurons that govern the locally recorded oscillations (Cunningham et al., 
2006; Middleton et al., 2008). In the acute setting, this is likely to be related to 
the loss of the powerful NMDAR-mediated drive to fast-spiking interneurons in 
layer II of the mEC (Jones and Buhl, 1993). To determine if this is the case with 
NMDAR-Abs, intracellular recordings from both principal cells and interneurons 
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during -oscillations would be required. I have not obtained sufficient good 
quality intracellular recordings from principal cells during -oscillations to justify 
their inclusion here, but it is at least reassuring that patient IgG did not cause 
cell death during intracellular recordings, ruling out a direct toxic effect. 
It is unlikely that NMDAR-Abs have a direct antagonistic effect at the NMDAR 
complex. Indeed, if that were the case, the experiments with patient Fab 
fragments should have yielded similar results to the pIgG experiments as the 
binding moiety of the antibody is preserved in Fab. However, there is a 
significant difference in oscillation power in slices exposed to Fab and pIgG. 
Furthermore, no acute antagonistic effect has been found using other methods: 
the amplitude of NMDAR-mediated currents in cultured hippocampal neurons is 
not affected by exposure to patient CSF for 30 minutes or purified patient Fab 
for 24 hours (Moscato et al., 2014). Instead, the proposed mechanism of action 
of NMDAR-Abs is by cross-linking bound receptors and causing their 
internalisation (Hughes et al., 2010). The observed lack of effect of Fab, which 
cannot crosslink antigen (Hughes et al., 2010), would support internalisation as 
the cause of the reduction seen here. However, the reported time frame for 
internalisation may be outwith the duration of our experiments. Indeed, 
significant loss of surface NR1 immunofluorescence due to NMDAR-Ab-
mediated internalisation in hippocampal neuron cultures only occurred after 12 
hours of exposure to patient CSF (Moscato et al., 2014). On the other hand, 
Mikasova et al. (2012) found that significant internalisation had occurred by two 
hours in cultures and also showed that patient antibodies removed synaptic 
NR2A-containing NMDAR from synapses and caused internalisation of extra-
synaptic NR2B-containing NMDAR within that time as well, significantly 
changing the functional cellular distribution of NMDARs. It could therefore be 
hypothesised, that small changes in surface and synaptic NMDAR density, 
particularly in the exquisitely NMDA-sensitive fast-spiking interneurons that 
generate -oscillations in the superficial mEC (Jones and Buhl, 1993), could 
have functionally relevant implications whilst remaining undetectable by 
immunofluorescence. 
Finally, one study has found that acute exposure to NMDAR-Abs in patient CSF 
prolongs the open time of NMDARs compared to control CSF in the presence of 
glutamate and glycine (Gleichman et al., 2012). The Abs are unlikely to cause 
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the channels to open as there was no effect on closed time. It is not clear what 
the functional effect of this prolonged opening time might be, especially as the 
same group found no difference in the amplitude of NMDAR-mediated current in 
cultured hippocampal neurons exposed to patient or control CSF (Moscato et 
al., 2014). An enhancement of NMDAR-mediated excitation is possible although 
unlikely in our slice preparation where NMDAR activity is already promoted by 
the use of low-Mg2+ aCSF and kainate-induced depolarisation of neuronal 
membrane potentials. Indeed, one study found that adding NMDA to the 
perfusion medium during kainate-induced oscillations had a concentration-
dependent effect with very low concentrations (1M) causing an increase in 
power whilst higher concentrations (2M and above) massively reduced -
oscillation power (Hall, 2012). It is therefore more likely that desensitisation 
would occur. NMDA receptors are characterised by their slow kinetics and slow 
and complex desensitisation mechanisms (Sun et al., 2002), such that small 
prolongations of opening time would not necessarily cause desensitisation. 
However, it is conceivable that calcium-dependent desensitisation could be 
increased by the Ab-mediated stabilisation of the open state. Additionally, even 
in non-calcium-dependent desensitisation, the rate of desensitisation is higher 
from the open state than the closed state (Lin and Stevens, 1994). 
The lack of effect of patient IgG on hippocampal -oscillations is in keeping with 
the literature (Cunningham et al., 2006) and also suggests that the effect in the 
mEC is not mediated through toxicity. 
 Unlike the changes caused by ketamine and D-AP5, the decrease in power 
observed with pIgG was not reversible with washout. Reversibility is a useful 
feature of pharmacological experiments, as it indicates the effect is specific to 
the drug used and not related to cell death or deterioration of the slice. There 
are a number of potential explanations for the lack of reversibility seen with 
pIgG: NMDAR-Abs in pIgG may have caused internalisation of surface 
NMDARs, with the duration of the washout phase insufficient for membrane 
insertion of new receptors (Nong et al., 2003). Alternatively, it may simply be 
that the antibodies are not easily washed out of the slice once bound to their 
antigen and so do not “free up” glutamate binding sites during the washout 
phase. Finally, it has been shown that intracerebral infusion of CSF from 
patients with NMDAR-Ab encephalitis increases the extracellular concentration 
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of glutamate in the hippocampus of rats in vivo. This was accompanied by a 
disruption of NMDA-mediated synaptic regulation of glutamate (Manto et al., 
2010). Hyperglutamatergic states are known to cause excitotoxicity and 
reduced neuronal excitability, which could responsible for the progressive 
reduction in -oscillations beyond the application of patient IgG. 
4.4.1 Further work 
There are two important weaknesses of the data presented here. Firstly, the 
effects seen with pIgG cannot be unequivocally linked to the presence of 
NMDAR-Abs. This is because purified IgG contains the whole range of 
antibodies found in a healthy human being in addition to NMDAR-Abs. All three 
patients had high titres of NMDAR-Abs as detected by CBA, and so we can 
presume that NMDAR-Ab concentration far exceeded that of any other 
antibody, especially at the high dilutions used in these experiments. However, 
to be certain that the effect on -power was NMDAR-Ab related, oscillating 
slices should be exposed to IgG from which the NMDAR-Abs have been pre-
absorbed. If the oscillation power in these slices followed a course similar to 
that seen in the vehicle/cIgG groups, it could be concluded that the effect seen 
here are due to NMDAR-Abs. 
Secondly, the mechanisms by which NMDAR-Abs might cause a decline in -
power have not been investigated. A number of intracellular recordings from 
pyramidal cells in both oscillating and non-oscillating conditions were obtained, 
but very few were of satisfactory quality and no reliable conclusions could be 
drawn from them. 
The effect seen in these experiments was small and confounded by the large 
variation in -power from one slice to the next as well as the natural decline in 
oscillation power over time in the mEC. It would have been better to use lower 
dilutions of IgG guided by normal IgG concentration in CSF and binding on CBA 
instead of relying on previous electrophysiological data obtained from the mEC 
with the attendant confounding factors mentioned above. Some indication of the 
validity of the results described above could be given by the detection of human 
IgG or its downstream effects in the slices used for electrophysiology and this 
will be the focus of the next chapter.
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5.1 Introduction 
NMDAR-Ab positive CSF has been shown to bind very strongly to the 
hippocampal neuropil (the areas of the hippocampus containing axons, 
dendrites and glial processes but not cell bodies (Dalmau et al., 2007; Irani et 
al., 2010b)). Binding is also present throughout the forebrain cortex, in the 
striatum and in the granule cell layer of the cerebellum, albeit much less 
intensely. This difference has been shown to be due to the high NMDAR 
content of the hippocampus (Moscato et al., 2014). Additionally, the staining 
pattern seen with patient CSF coincides with that obtained using commercial 
NR1 antibodies (Moscato et al., 2014), confirming it is due to NMDAR-Abs in 
the CSF. In the hippocampus, intense staining is present in both the medial and 
lateral blades of the molecular layer of the dentate gyrus, in the stratum oriens 
and throughout the molecular layers of the CA1-3 hippocampal subfields, with 
subtly reducing intensity in stratum radiatum and stratum lacunosum moleculare 
in CA3. The polymorph layer of the dentate gyrus (or hilus) is spared as are the 
pyramidal cell layers of CA1-3 (Dalmau et al., 2007; Irani et al., 2010b) This 
pattern is easily recognised and will be used in the coming sections to 
determine if NMDAR-Ab binding has taken place, although it should be 
appreciated that there are antibodies to other neuronal proteins that give similar 
staining patterns in the hippocampus. Immunohistochemically, AMPAR-Abs and 
GABAR-Abs can be differentiated from NMDAR-Abs by the differences in 
neocortical and cerebellar staining patterns. 
The binding pattern described above has been obtained by incubating thin 
sections (<10M) of both fixed and fresh frozen normal rodent brain tissue with 
patient CSF. Similar reactivity has also been demonstrated in the brains of mice 
exposed to NMDAR-Ab positive patient CSF by continuous 
intracerebroventricular infusion over two weeks (Planagumà et al., 2014) and 48 
hours following a single intraventricular injection of purified patient IgG (Wright 
et al., 2015b). NMDAR-Abs in patient CSF and serum bind to the surface of the 
cell membrane of cultured rodent live hippocampal neurons after 1 hour’s 
incubation, but binding in live rodent brain slices has not been reported. Only 
two published studies applying CSF or purified serum IgG from patients with 
NMDAR-Ab or VGKC-Ab encephalitis respectively to acute rodent brain slices 
exist (Lalic et al., 2011; Q. Zhang et al., 2012), and in neither was binding of 
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human IgG in the slices sought. To my knowledge, this is therefore the first 
attempt at developing a method to detect human IgG bound to rodent brain in 
the acute brain slice preparation commonly used in electrophysiology. 
5.2 Methods 
Sections for immunofluorescence were obtained from two sources. Firstly, the 
technique was learnt on horizontal naïve rat brain slices. Then, the slices from 
the electrophysiology (EP) experiments in chapter 3 were used. The 
immunofluorescence technique in fresh frozen tissue was based on protocols 
suggested by Dr P Pettingill of the Nuffield Department of Clinical 
Neuroscience, Oxford University. 
For the naïve brain slices, the PBS-perfused and snap-frozen brain of a male 
Wistar rat was used. On a cryostat, 10µm horizontal sections were prepared 
and collected on to slides and allowed to air-dry overnight before storing at -
20˚C. For staining, the slides were thawed for one hour at room temperature 
and blocked in 0.1 M Phosphate-buffered saline (PBS) with 10% normal goat 
serum (10% NGS/PBS) for one hour at room temperature. Sections were then 
incubated with NMDAR-antibody positive CSF diluted 1:10 in 3%-NGS/PBS or a 
commercial NR1 Ab (rat NMDAR1 aa. 660-811 recombinant protein, BD 
pharmingen) diluted 1:200 in 3%NGS-PBS overnight at 4˚C. Sections were 
washed three times in 300ml of PBS and specific IgG binding was detected 
using Alexa Fluor goat anti-human IgG secondary antibody (1:2000, Invitrogen, 
USA) for 1 hour at room temperature. Slides were washed three times in PBS, 
air dried and mounted with DAKO fluorescent mounting medium containing 
DAPI.  
For the sections obtained from EP experiments, slices were removed from the 
recording chamber by lifting the filter paper on which they were resting using 
forceps at the end of the experiments. They were placed on a second piece of 
rigid filter paper covered with a thin layer of OCT compound (Tissue-Tek) to 
keep them flat during the freezing process. This was plunged into liquid 
nitrogen-chilled isopentane and then stored at -80˚C until slicing. On a cryostat, 
12µm or 20µm sections were prepared (thickness depending on quality of 
frozen tissue and amount of tissue loss whilst slicing). The staining protocol was 
adjusted several times in order to optimize signal:noise ratios and cannot 
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therefore be summarized here. Briefly, the blocking step was either performed 
with 10% NGS/PBS or omitted. The AlexaFluor goat anti-human IgG secondary 
antibody (both 488 and 568 fluorescence bandwidth were used) was then 
applied to the slice at various dilutions and for different incubation periods. 
Slides were then washed three times for durations ranging from 30 seconds to 
10 minutes in PBS, air-dried, and mounted with DAKO fluorescent mounting 
medium containing DAPI. The exact protocol used will be described in the 
results section. 
The slides were then examined on a fluorescence microscope and pictures of 
areas of interest taken using the QCapture Pro Software (Qimaging, Canada). 
For experiments using fixed tissue, slices were fixed in 4% paraformaldehyde 
(PFA) immediately after EP experiments, and preserved in 4% PFA until IF was 
carried out (<1 week). On the day of IF, the slices were cryoprotected in 30% 
sucrose in PBS, then re-sectioned to 40m thickness on a freezing stage 
microtome. In some slices, antigen retrieval was carried out using just-boiled 
10mM Sodium Citrate at pH 6.00, and both the blocking step and incubation 
with secondary antibody were performed in the presence of 0.05% Tween for 
mild permeabilisation. The sections were examined by confocal microscopy. 
5.3 Results 
5.3.1 Naïve rat brain sections 
As horizontal hippocampal slices were used in the electrophysiological 
experiments described above, the binding pattern of NMDAR-Ab positive CSF 
in naïve horizontal rat brain sections was investigated in the first instance. 
Control slices incubated in 10% normal goat serum (NGS) only before adding 
the fluorescent secondary anti-human IgG antibody showed minimal non-
specific background staining only (see Error! Reference source not found. A). 
In sections exposed to patient CSF (1:10) binding was observed in the 
hippocampus in the predicted pattern (see Error! Reference source not 
found. B-D). The molecular layer of the DG was the most intensely stained 
area (Error! Reference source not found. C). Within the DG molecular layer, 
the inner third was more strongly labelled than the middle and outer third, 
consistent with unpublished observations from the neuroimmunology laboratory 
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in Oxford (Dr. P. Pettingill). No binding was detected in the DG hilus. The 
stratum oriens and molecular layers of the CA subfields were also strongly 
labelled, with more intense labelling at the borders of the stratum pyramidale 
(Error! Reference source not found. D). Some staining was also seen in the 
mEC and the cerebellum (Error! Reference source not found. Biii and E). 
Similar patterns were seen with the CSF from two patients with NMDAR-Ab 
encephalitis, and when sagittal rat brain slices were exposed to a commercial 
NR1 Ab, although permeabilisation with 1% Triton was required for the 
commercial antibody (see Figure 5.2). In unpermeabilised section, the 
commercial NR1 antibody bound to individual cell bodies in the cortex, the 
pyramidal layers of HPC, the granule cell layer and hilus of the DG. 
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Figure 5.1 NMDAR-Ab positive CSF binds strongly to the molecular layers of 
hippocampal (HPC) subfields and dentate gyrus (DG).  
A i-v shows the negative control naïve horizontal brain slices incubated with fluorescent 
anti-human IgG antibody. Only DAPI fluorescence is visible in the HPC and mEC. Ai 
mEC x10 – DAPI+anti-IgG,ii CA3 x10 – DAPI+anti-IgG,iii DG x10 – DAPI+anti-IgG. 
iv CA3 x20 – DAPI+anti-IgG, v DG x20 – DAPI+anti-IgG. B, C, D, and E show sections 
stained with patient CSF. Note the strong staining of the hippocampal neuropil (ml, so, 
sr) with sparing of the dentate gyrus hilus (h) (Bi, HPC x5 - DAPI+anti-IgG; Ci dentate 
gyrus x10, Di CA3 x20).Binding can also be seen in the mEC and cerebellum granule 
cell layer (gcl; Bii - mEC and cerebellum x5, Biii cerebellum x10). At larger 
magnification, the punctate cell-membrane stainingis better appreciated: Cii - DG 
x20, iii – DG x40 anti-IgG alone; Dii CA3 x40 anti-IgG alone; E - superficial mEC x20 
merge. GC: granule cells of DG; gcl: granule cell layer of cerebellum; h: hilus; ml: 
molecular layer; PC: pyramidal cell layer; so: stratum oriens; sr: stratum radiatum, WM: 
white matter. 
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Figure 5.2 Commercial NR1 antibody binding distribution is similar to that of 
patient antibodies but requires permeabilisation.  
Each row represents a different area of the brain. Cerebellar staining is shown in A, 
entorhinal cortex in B, dentate gyrus in C, and CA1-3 in D (Diii shows a x40 
magnification of CA3). Note that unlike patient CSF, the commercial antibody binds to 
cell bodies in CA3 pyramidal layer and DG hilus in addition to the neuropil. Scale bars: 
40m in x10 images (Cii and Dii), 20m in x20 images (Ai-Di and Aii and Bii), 10m in 
x40 images (Aiii-Diii). 
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5.3.2 Electrophysiology control slices 
In control EP slices (holding chamber or recording chamber but exposed to KA 
only) the results were not as clear as in the naïve horizontal sections. The 
background staining in the negative control sections appeared much stronger. 
In the sections incubated with patient CSF, the staining was much less bright 
and much “flatter”. The punctate pattern of staining was not seen at high 
magnification. The appearance of the neuropil was also less healthy: the 
surface of the sections appeared irregular with numerous small tears, giving it 
the appearance of cracked glass (see Figure 5.3). This was felt to represent 
freezing artefacts. This tissue damage is likely to be responsible for the high 
background in the negative control slices. 
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Figure 5.3 Patient CSF staining of slices used during electrophysiology 
experiments.  
Negative control slices are shown in Ai-iv. Note the uniform background staining (A, 
CA3 x20, i: anti-human IgG IF alone, ii: merged DAPI and IgG IF; DG x20, iii: anti-
human IgG IF alone, iv: merge with DAPI). Control EP slices incubated in patient CSF 
are shown in B-D. Low magnification images of the HPC and mEC (Bi-iii, x10, merged 
DAPI and IgG IF; Ci-iii corresponding anti-human IgG Ab IF only) show background 
staining only of the hippocampal neuropil. Higher magnification (x40) images of the 
same areas suggest there may be some specific NMDAR-Ab binding in the molecular 
layer of the DG in some sections (Dii, CSF 1:10) but not others (Diii, CSF 1:5). There 
does not appear to be any specific staining in CA3 (Di: CA3 x40, CSF 1:10)
  180
5.3.3 The search for human IgG in slices used in electrophysiology 
experiments 
Snap-frozen fresh tissue 
In the first instance, the same protocol as above was used to attempt detection 
of IgG in EP slices. As the effect on the staining of the blocking step was 
uncertain, some sections underwent a one-hour blocking step in 10% NGS prior 
to incubation with fluorescent anti-human IgG, whilst others were simply 
incubated in 1:2000 secondary antibody overnight at 4°C. 
For the patient IgG-exposed slices, a slice from a typical one-hour experiment 
as described in Chapter 4 was used. Briefly, this slice had been perfused with 
aCSF+KA containing 30µg/ml Pt3 IgG for one hour followed by a 30-minute 
wash in aCSF+KA. To investigate the effect of more prolonged exposure to 
patient IgG, a slice pre-incubated with 30µg/ml Pt3 IgG for 5 hours at room 
temperature and then placed on the EP rig and perfused with 10µg/ml Pt3 IgG 
for 3 hours at 32°C was also used. The control slice used had been stored in 
the holding chamber before being frozen and had therefore not been exposed 
to either KA or human IgG. 
There was no NMDAR-specific staining pattern comparable to the CSF staining 
described in section 5.3.1 in either section (see Figure 5.4 A). The presence of 
the blocking step did not seem to impact the staining, with similar non-specific 
background staining in the two groups of slices. 
The experiment was repeated with a short fixation step (3% formaldehyde for 2 
minutes) in half the sections prior to incubation with anti-human IgG antibody 
because of concerns that the washing steps following the incubation with 
secondary antibody might lead to loss of subtle NMDAR-specific staining. The 
secondary antibody incubation period was also shortened (30 minutes at room 
temperature) to reduce non-specific staining. Similar slices were chosen for the 
staining. Again, there was no NMDAR-specific staining in any of the patient IgG-
exposed sections, whether fixed or not (images not shown). In fact, non-specific 
background staining was brighter and more obtrusive in the sections that had 
undergone light fixation. 
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To prevent loss of bound antigen-secondary antibody complexes in the 
absence of fixation, the washes following the incubation in secondary antibody 
were shortened significantly to three thirty-second washes. The secondary 
antibody used was changed to a red-fluorescent goat anti-human IgG 
(AlexaFluor 568) as it was felt this may reduce the intensity of the background 
staining, and several dilutions of this antibody were trialled. 
Sections from a slice exposed to 30µg/ml Pt3 IgG for one hour (ca. 40% 
reduction in gamma-frequency oscillation power) and from a slice exposed to 
HC2 IgG 10µg/ml were incubated in 1:700, 1:2000 or 1:6000 Alexa Fluor 568 
goat anti-human IgG. No NMDAR-specific staining was detected in the Pt3-
perfused slices. The secondary antibody dilution did not appear to affect the 
intensity of the non-specific staining (see Figure 5.4 B). 
Finally, a very prolonged incubation in the secondary antibody was undertaken. 
Sections prepared from slices perfused with 30µg/ml Pt3 IgG and 10µg/ml HC1 
IgG were incubated for 72 hours at 4°C with fluorescent goat anti-human IgG at 
either 1:2000 or 1:6000 dilution. This also failed to detect any NMDAR-specific 
labelling in the patient IgG-perfused slices (see Figure 5.4 C). 
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Figure 5.4 No anti-human IgG antibody binding is present in snap-frozen slices 
from EP experiments.  
All images are from dentate gyrus unless otherwise indicated. The results of the 
standard protocol are illustrated in A: there was no NMDAR-Ab specific staining in 
slices exposed to pIgG for 1-5 hours, and removing the blocking step had no effect. 
Using a secondary antibody with a different excitation wavelength, varying the duration 
of incubation in 2Ab (both B), and prolonging incubation time (C) also had no effect. 
GC: granule cell layer of DG, H: hilus, ML: molecular layer. X40 magnification, scale 
bars 10m. 
  
Table 5.1 Summary of changes to standard immunofluorescence protocol and their effect 
Steps in IF protocol Basic Protocol Adaptations Reason Effect 
In control tissue from whole perfused fresh-frozen brain 
Slice thickness ≤10M 12-20 M To minimise tissue loss No difference in patient 
CSF binding pattern 
In EP slices 
Fixation None 3% PFA 1-2 minutes in 
some slices 
To reduce antigen loss  non-specific background 
Block 10% normal serum Not done in some slices To minimise steps 
preceding 2°Ab incubation 
No effect 
Washes PBS 10 minutes x3  to 30 seconds x3 To reduce antigen loss No effect 
Secondary antibody     
Dilution 1:2000 1: 700; 1:2000: 1:6000  dilution to improve 
detection of subtle binding 
dilution to reduce non-
specific binding 
No effect 
 
 
No effect 
Incubation Time Overnight at 4C 15 and 30 minutes at 
room temperature 
72 hours at 4C 
 duration to reduce non-
specific binding and  
temperature to reach 
equilibrium of antigen-
antibody reaction faster 
 duration to saturate 
antigen with antibody 
No effect 
 
 
 
 
No effect 
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Fixed tissue 
The quality of the tissue used for the immunofluorescence experiments is of 
paramount importance in obtaining valid results. As mentioned above, there 
was a clear difference in the quality of the sections obtained from the snap-
frozen whole brain of a naïve rat and the EP slices. The whole brain was much 
easier to slice and the sections displayed very little damage. On the other hand, 
the frozen EP slices were often not flat despite efforts and therefore difficult to 
re-section on the cryostat, resulting in tissue loss and tears. This “geographical” 
damage rendered the sections prone to presenting uneven staining patterns. 
Also there was often marked freezing artefact in the EP slices, presumably 
caused by the slices being frozen whilst wet (straight off the perfusion 
chamber). The artefact was not present in slices from the whole brain, the 
surface of which has remained relatively “dry” during the perfusion process. The 
freezing artefact gave the tissue an appearance like cracked glass and also 
resulted in irregular background staining. Whether human IgG could be 
detected in fixed tissue was therefore investigated, as fixation might circumvent 
both the tissue damage and loss caused by snap-freezing and subsequent 
cryostat slicing, and the possible loss of antigen during the IF process. Here, 
slices were fixed in 4% paraformaldehyde (PFA) immediately after EP 
experiments, cryoprotected in 30% sucrose, then re-sectioned to 40m 
thickness on a freezing stage microtome before being incubated with the anti-
human IgG antibody. The sections were examined by confocal microscopy.  
Using this technique, anti-human IgG binding was detected in scattered cells in 
cortex and hippocampus (see Figure 5.5 and 5.6). The binding appeared to be 
located in the cytoplasm of the cells. This staining was faint and present in both 
cIgG and pIgG-exposed slices but not in control slices (n=5 Pt3 IgG slices, n=3 
HC2 IgG). No clear pattern of binding was noted: the visual intensity of staining 
as well as the number of bound cells varied from section to section, but did 
occasionally appear brighter in cIgG-exposed slices (see Figure 5.7). No 
systematic analysis of binding intensity was undertaken as the staining was 
very subtle. The areas with the greatest density of cells with bound IgG were 
the perirhinal cortex and auditory cortex as well as the hilus of the dentate 
gyrus. Cells were less often detected in entorhinal cortex and pyramidal layers 
of the HPC. No cells were seen in the granule cell layer of the DG. This 
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distribution is unlikely to be related to the orientation of the slice in the perfusion 
chamber as this varied for each experiment and also would not explain the 
presence of bound cells in both peripheral (e.g. perirhinal cortex) and central 
areas of the slice (e.g. hilus of DG). Both antigen retrieval and lower dilutions of 
the secondary antibody (1:200) resulted in brighter staining, albeit in the same 
distribution as described above. The typical neuropil pattern of staining was not 
detected. No double-labelling was performed so the nature of the cells taking up 
human IgG is not known. 
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Figure 5.5 Intracellular binding of anti-human IgG antibody in EP experiment 
slices in fixed tissue.  
Unadjusted images are shown in A and corresponding enhanced images in B for 
clarity. Subtle staining of individual cells is visible in several areas of the neocortex and 
as well as pyramidal layer of HPC. Bound cells are present equally in neocortex 
sections from slices exposed to cIgG and pIgG; in HPC human IgG reactivity appears 
limited to slices exposed to pIgG. Magnification x63; scale bars 50m; mEC-medial 
entorhinal cortex, sPRc-superficial perirhinal cortex, CA3-Cornu Ammonis 3 subfield of 
HPC. 
A 
B 
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A 
B 
Figure 5.6 
Intracellular 
binding of anti-
human IgG 
antibody in EP 
experiment slices 
in fixed tissue.  
Unadjusted images 
are shown in A and 
corresponding 
enhanced images in 
B for clarity. Subtle 
staining of individual 
cells is visible in 
several areas of the 
neocortex and as 
well as pyramidal 
layer of HPC and 
hilus of DG. Bound 
cells are perhaps 
more prominent in 
sections from slices 
exposed to pIgG. 
Magnification x63; 
scale bars 50m; 
sPRc-superficial 
perirhinal cortex,  d-
lEC- deep lateral 
entorhinal cortex, 
DGh – dentate gyrus 
hilus, CA3-Cornu 
Ammonis 3 subfield 
of HPC. 
 
Figure 5.6 
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Figure 5.7 Brighter intensity of staining in cells in pIgG-exposed slices. Measurement of 
pixel intensity in a random selection of cells exhibiting intracellular binding of anti-
human IgG antibody reveals brighter staining in pIgG slices although this has not been 
performed systematically. Scale bar 50m.  
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5.4 Conclusion 
5.4.1 Remarks on fresh-frozen tissue IF 
No binding to human IgG was detected in slices snap-frozen immediately after 
EP experiments. As mentioned in Chapter 4, the IgG concentrations used in the 
EP experiments were low when compared to those used in studies describing 
the binding pattern of NMDAR-Abs in patient CSF or serum (Hughes et al., 
2010). 
Several methodological factors may influence the detection of subtle specific 
staining by immunofluorescence. The concentration of the antigen against 
which the secondary antibody is raised is obviously pertinent. The experience of 
the Oxford lab is that incubating control rodent brain section with CSF from 
patients with NMDAR-Ab encephalitis gives much stronger and more specific 
fluorescence patterns than using serum or purified IgG. This is probably related 
to the more propitious NMDAR antibody:total immunoglobulin ratio in CSF than 
serum. Whilst the IgG concentration in serum and CSF are around 10,000µg/ml 
and 25µg/ml respectively, that is a 400-fold difference, titration studies have 
shown that the NMDAR antibody concentration may only be around 10-fold 
lower in CSF than serum (Prof. A Vincent, personal communication). The 
smaller NMDAR antibody:total immunoglobulin ratio in the purified IgG used to 
perfuse the slices may mean that a smaller proportion of NMDAR in the EP 
slices are bound compared to control slices exposed to NMDAR-Ab-positive 
patient CSF.  
Several attempts at reducing background staining or antigen loss by varying the 
blocking step, the concentration and duration of incubation with secondary 
antibody, the duration of washes or introducing a brief post-fixation step all 
failed to reveal the presence of anti-human IgG in the EP slices. 
This may be because perfusion for one hour with relatively low concentrations 
of IgG was not sufficient to allow penetration of the antibodies into the slice and 
binding with NMDARs. Gamma-frequency oscillations are recorded by placing 
the tip of the recording electrode on the surface of the slice, causing as little 
damage to the tissue as possible, so that only slice surface binding should be 
required to see an effect on oscillation parameters. The other more likely 
explanation is that the lack of staining was related to the poor quality of the 
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fresh-frozen tissue used here. Indeed, there was significant freezing artefact 
and tissue loss in the sections obtained from re-sectioning the EP slices on a 
cryostat. This was associated with increased background staining and absence 
of the typical NMDAR-Ab binding pattern in slices exposed to patient CSF in 
comparison to sections from snap-frozen perfused whole-brain. 
5.4.2 Remarks on fixed tissue IF 
In slices re-sectioned from PFA-fixed EP tissue, human IgG was detected in the 
cytoplasm of individual cells in both pIgG and cIgG-exposed slices. This was 
not the pattern expected with NMDAR-Abs, which bind surface NDMARs. 
However, binding in the EP slices may not follow the pattern predicted by in 
vitro experiments due to cross-linking and internalisation of the antibody-antigen 
complex (Hughes et al., 2010; Mikasova et al., 2012). Nevertheless, the 
presence of human IgG in both pIgG and cIgG-exposed slices suggested this 
might also represent non-specific binding. 
Indeed, in addition to the NMDAR-Ab concentration and perfusion duration 
issues discussed above, another major barrier to detecting NMDAR-Ab binding 
in EP slices is the damage to the surface of each slice caused by the cutting 
process. Each EP slice has a layer of dead and damaged cells on both the rig-
contacting surface and the surface exposed to the perfusion medium. In order 
to reach and bind to NMDAR on live neurons in the slices, NMDAR-abs in the 
purified IgG would need to diffuse through these layers. It is likely that IgG 
binding to, and diffusion or uptake through, damaged cell membranes on the 
surface of the EP slices would take place. This would be detected by the anti-
human IgG secondary antibody in both pIgG- and cIgG-exposed slices, 
potentially concealing any specific NMDAR-Ab binding in the pIgG slices. 
Immunoglobulin uptake into neurons has not been extensively studied but 
recent studies have demonstrated this in neuronal cultures, organotypic slice 
cultures and human brain biopsy material (Hill et al., 2009; Geis et al., 2010; 
Congdon et al., 2013; Iffland et al., 2013). Hill et al. (2009) found IgG from 
healthy individuals in the dendrites and processes of cerebellar Purkinje cells 
after 4 hours of incubation and within the cell body cytoplasm and nuclei by 24 
hours in organotypic cultures of rat cerebellum. This did not affect the viability of 
the Purkinje cells. Other cell types in the cultures were not reported to 
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incorporate IgG. Congdon et al. (2013) demonstrated much faster neuronal IgG 
uptake, showing that maximal internalisation of IgG occurred within 30 minutes 
of incubation of organotypic hippocampal slice cultures prepared from 400m 
mouse hippocampus sections. The uptake was concentration-dependent, 
saturable and temperature dependent, with a significant reduction if the 
temperature was reduced to 4°C. However, the internalised IgG consisted 
mostly of specific antibodies targeting intracellular antigens (in this case Tau 
antibody in cultures from mice with high levels of intracellular tau). Intracellular 
control IgG was found in both wild-type and high-tau mice, but the levels were 
91% lower than those of tau antibody in slices from the high-tau line. The 
authors felt this might partly be related to more rapid clearance of unbound IgG 
out of neurons. Of note, about a third of the uptake was through damaged cell 
membranes, caused by sectioning the HPC into 400m sections. 
Similar results have been obtained by others (Geis et al., 2010; Greenlee et al., 
2014): IgG internalisation was seen with sera or purified IgG containing 
intracellularly-directed antibodies, and much less so with control IgG or serum 
from which intracellularly-directed antibodies had been pre-adsorbed. The 
antibodies targeting intracellular antigens in these preparations cannot have 
been preferentially internalised by an epitope-dependent mechanism, as the 
epitopes were internal and therefore invisible. It is therefore likely that targeted 
and untargeted IgG had both been taken up and the same mechanism of 
clearance of unbound internalised IgG had occurred. 
The relevance of the intracellular human IgG detected in EP slices is therefore 
still unclear. The nature of these cells remains to be determined, as does the 
role of cell membrane damage due to slicing. Other unanswered questions 
pertain to the epitope-specificity of the process: is the uptake at the level 
expected for control IgG internalisation in the studies above? Does it reflect 
retention of antibodies against cytoplasmic or nuclear antigens in the two 
samples? Of note, neither of the two samples had anti-nuclear antibodies. 
Visually, the intensity of staining appeared somewhat brighter in the pIgG slices 
although this was not examined systematically. 
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5.4.3 Further work 
It was not possible to detect human IgG in the NMDAR-Ab-specific pattern in 
the slices exposed to pIgG in EP experiments. Some intracellular human IgG 
was found in fixed and permeabilised slices exposed to pIgG and cIgG, but the 
functional relevance of this is unknown. This latter finding may be worth some 
further attention. The nature of the cells taking up the IgG could be determined 
using double-labelling studies and the functional consequence of IgG 
internalisation could be examined by Western blot analysis of NR1 content in 
the slices. However, at this juncture, a modest reduction in -power in the mEC 
in vitro and no definite NMDAR-Ab binding have been observed. It therefore 
seemed important to develop a method that would definitively deliver NMDAR-
Abs to the target tissue and allow enough time for receptor internalisation to 
take place. In the next chapter, the effect of intracerebral injection of pIgG on -
frequency oscillations in vitro 1-3 days after injection will be examined. 
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6.1 Introduction 
The acute exposure of rodent brain slices to NMDAR-Abs as performed in 
Chapters 4 and 5 did not result in unequivocal binding to NMDARs. There are 
several potential reasons for this finding. Firstly, the combination of the large 
size of immunoglobulin G molecules and the thickness of the slices (450m) 
may preclude sufficient diffusion of the antibodies through the slice in the space 
of a one-hour experiment. Secondly, the concentration of NMDAR-Ab in 10 or 
30g/ml purified IgG may well be too low to reveal the typical reactivity pattern 
seen in 10m section incubated with patient CSF at 1:10 dilution (especially 
relative to the much larger number of NMDAR in a 400m thick slice). Finally, 
rather than the surface binding detected by immunofluorescence in frozen 
slices, IgG internalisation may be taking place in the live rodent brain slices 
used in this study. An additional factor to contend with is the mechanism of 
action of the NMDAR-Abs in the acute slices. Whilst a subtle (19%) but 
significant amount of NMDAR internalisation has been observed in cultured 
hippocampal neurons incubated with highly dilute patient CSF (1:300) after two 
hours in one study (Mikasova et al., 2012), (but see Moscato et al. (2014) for 
contrast), these neurons have much better access to the NMDAR-Abs in the 
incubation medium than neurons in brain slices. Not only are cells more densely 
packed in the brain slice preparation, the cutting process damages cells on the 
surface of the slices so that any perfused agent has to diffuse through a layer of 
dead or unhealthy cells before reaching viable targets for its action. The 
occurrence of functionally significant internalisation over the one-hour period of 
perfusion in the acute experiments is therefore in question. Therefore, in order 
to provide more certain and more prolonged antibody delivery to the mEC, 
animals were subjected to a single intracranial injection of NMDAR-Abs in the 
form of patient’s purified plasma IgG.  
Several rodent passive transfer studies of autoimmune CNS disorders exist, 
showing variable and incomplete reproduction of clinical syndromes. Geis et al 
(Geis et al., 2010; Geis et al., 2012) showed that several intrathecal injections of 
IgG from patient with amphiphysin antibodies over 16 days resulted in stiffness, 
muscle spasms and anxiety in rats. Amphiphysin antibody binding to relevant 
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brain structures was also demonstrated. Shorter injection protocols have also 
shown promise, with a single intracerebroventricular injection of glycine-
receptor antibodies, in the form of IgG purified from the serum of patients with 
progressive encephalomyelitis with rigidity and myoclonus, resulting in anxiety-
like behaviours in mice (Carvajal et al., 2015). A single intrathecal injection of 
antibodies against the metabotropic glutamate receptor type 1 has also been 
shown to cause acute and reversible ataxia in mice with strong binding 
throughout the cerebellum (Sillevis Smitt et al., 2000). Finally, a single 
intracerebroventricular injection of NMDAR-Ab positive IgG decreased the 
seizure threshold of mice and was associated with significant NMDAR-Ab 
binding in structures surrounding the ventricle, including dentate gyrus and 
CA3, in the pattern expected for NMDAR-Abs 48 hours after the injection 
(Wright et al., 2014). 
It therefore seemed sensible to investigate whether a similar intervention in rats 
would lead to changes in -frequency oscillations in the mEC. 
Intracerebroventricular injections of pIgG and cIgG were performed in rats using 
increasing volumes of IgG, but no binding in structures adjacent to the ventricle 
was noted. Furthermore, the distance from the ventricle to the mEC is sizeable. 
Because of concerns that diffusion of the antibodies to the mEC would not 
occur even if larger volumes of IgG were used, intraventricular injections were 
abandoned in favour of direct intra-entorhinal injections.  
Direct intracerebral injection of IgG has also been shown to have both 
functional and behavioural effects in passive transfer models of CNS 
autoimmune diseases. Saadoun et al (2010) found that injections of aquaporin-
4 antibody-containing IgG with complement into one cerebral hemisphere 
caused axonal injury with myelinolysis after a single injection and full 
neuromyelitis optica lesions on the injected side after three injections. This was 
accompanied by preferential ipsilateral turning of the mice. Coesman et al 
(2003) delivered metabotropic glutamate type 1 receptor-antibody positive 
patient IgG to the flocculus of the cerebellum of mice by osmotic minipump and 
observed an eye movement disorder. Finally, acute infusion of NMDAR-Abs 
over five minutes into the prefrontal area of the rat neocortex has been shown 
to increase extracellular glutamate concentration within 30 minutes of infusion 
(Manto et al., 2010) consistent with disinhibition of excitatory neurons as seen 
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with NMDAR antagonists Moghaddam et al. (1997). This last finding in 
particular is of relevance to this study, as it suggests an effect on GABA-ergic 
inhibitory interneurons, which are essential in the generation of -oscillations. 
Indeed, if significant internalisation of NMDARs occurs in the mEC of animals 
injected with pIgG, one might predict reduced excitatory drive to these 
interneurons. This in turn would lead to less efficient recruitment to -
rhythmogenesis, and therefore less powerful oscillations. 
First, the distribution of human IgG following a single intra-entorhinal injection of 
patient or control IgG will be described. Then, effects on baseline -oscillations 
in entorhinal cortex and their NMDAR-sensitivity will be examined. Finally, 
NMDAR-mediated synaptic transmission will be investigated using sharp-
electrode intracellular recordings. 
6.2 Methods 
Male Wistar rats weighing 250-280g received a single intra-entorhinal IgG 
injection as described in Chapter 2. 5L of either pIgG or cIgG (undiluted, 
concentration around 12mg/ml for all samples used) was injected at a rate of 
0.250L/minute. A very small volume of fluorescent beads was co-injected to 
permit rapid localisation of the injection site both visually during EP experiments 
and for IF. Injections were carried out blinded for IgG type but in pairs so that 
the first the first cohort of rats received either Pt2 or HC2 IgG, and the second 
cohort received either Pt3 or HC1 IgG. 
Slices for electrophysiological experiments were prepared as previously 
described 1-3 days after the intra-entorhinal injection. Only slices containing a 
visible injection site in the mEC were used. Slices from the un-injected right side 
were used as controls. Entorhinal cortex -oscillations were generated by 
adding KA to the perfusion medium (aCSF) to a concentration of 400nM. Once 
oscillations had stabilised (power and frequency values in four consecutive 
recordings within 30 minutes changing by less than 20%), 50M D-AP5 was 
added to test the NMDAR sensitivity of the oscillations. 
For intracellular recordings, non-oscillating slices were used. Here, a bipolar 
stimulating electrode was placed in the most medial portion of the mEC in the 
same layer as the injection site. The position of the stimulating electrode was 
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adjusted so that the distance between the stimulating and recording electrode 
remained constant in each slice. Cells were identified from their 
electrophysiological properties and this was later matched to their 
morphological characteristics using biocytin immunocytochemistry. Baseline 
membrane properties were examined as well as the size of the NMDAR-
mediated component of evoked EPSPs. These were obtained by blocking other 
components of the membrane response to stimulation (AMPA/KA receptor-
mediated portion of EPSP blocked by 20M NBQX, GABAA and GABAB IPSPs 
following the EPSP blocked with 1M Gabazine and 1M CGP55845 
respectively). The cell membrane potential was held at -70mV during the EPSP 
recordings. Stimuli were delivered at 1Hz for 10 seconds for each stimulus 
voltage used (1, 2, 5, 7, 10, 12, 15 Volts) and the recording set up so that each 
one-second sweep was averaged with the previous sweeps so that a single 
averaged EPSP was obtained for each stimulus voltage. Peak amplitude (mV) 
and slope (mV/s) during the initial segment were measured. For EPSPs, once 
the stimulus was large enough to elicit a spike, it was no longer possible to 
reliably measure amplitude or slope and these EPSPs were excluded from the 
analysis. Occasionally, it was clear that spiking only occurred after 1 or only a 
few stimuli. In these cases, the stimuli were repeated individually and 
measurements were taken only when the stimulus was not followed by a spike. 
To determine the distribution of human IgG in the injected slices, slices were 
placed in 4% PFA immediately after an EP experiment. On the day of the IF 
procedure, the slice was cryoprotected in 30% sucrose, re-sectioned on a 
freezing-stage microtome, washed and then incubated with anti-human IgG 
antibody overnight, before being mounted in DAPI-containing fluorescent 
mounting-medium and coverslipped. For colocalisation studies, primary 
antibodies to CAMKII, PV, calretinin, calbindin, somatostatin, GAD 67 and 
GABA were used before incubation with appropriate secondary antibodies as 
well as anti-human IgG Ab. 
6.3 Results 
6.3.1 Accuracy of injection and surgical complications 
In total 62 male Wistar rats weighing 250-280g received a single intracerebral 
injection into the left mEC. The first two animals were injected with FITC-
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conjugated dextran (molecular weight (m.w.) 500000 Da; compared to IgG: 
m.w. 150000 Da) to examine the extent of diffusion of large molecular weight 
molecules in brain in vivo. Both animals received 10L at a rate of 250nL/min. 
One animal did not recover from anaesthesia and it was felt that the large 
volume of the injection may have caused pressure on the brainstem and thus 
reduced respiratory drive. After this, the injection volume was first reduced to 3 
L and then increased to 5L in all experimental animals, as this was well 
tolerated. The animals responded well to being returned to their home-cage 
post-operatively and no aggressive behaviour towards cage-mates was noted. 
No obvious change in behaviour and no visible seizures occurred whilst the 
animals were observed (during examinations and during cage-cleans and cage-
changes by animal housing unit staff). Mild weight loss took place in the day or 
two following surgery in half the animals, but this did not exceed 10% of pre-
surgery body mass and recovered in those animals not killed before post-
operative day 2. 
Figure 6.1 shows the distribution of FITC-dextran dye in the brain following a 
single intra-entorhinal injection on the left. This image is from the brain of the 
animal that died during the procedure and thus was not perfused with PBS prior 
to removal of the brain. Despite the blood vessels, a yellow discoloration of the 
whole ventro-caudal pole of the forebrain can be seen on the left. In the insets 
are images taken during slicing of the brain of the animal that survived the 
procedure. Here, the yellow discolouration caused by the FITC-conjugated 
dextran can again be seen with the naked eye. It is present throughout the 
medial portion of the mEC where the injection is sited and spreads laterally 
along the white matter separating the HPC and neocortex. 
The injection was misplaced in four of the 56 animals whose brains were used 
in EP or IHC experiments. In two animals no injection site was visible and in 
another two, it was too rostral, either in the subiculum or in the white matter 
separating the cortex and hippocampus. These four animals were excluded 
from the study. In the remaining 54 animals, the location of the injection site 
within the entorhinal cortex varied, presumably because of variation in the size 
of each individual rat. The position of the injection varied both along the medio-
lateral axis and rostro-caudal axis (i.e. layer of mEC) but all animals in which 
the injection was sited within the mEC were kept in the study. For -oscillation 
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assessments, recordings were made in layers II and III only, irrespective of the 
layer in which the injection site was found. For intracellular recordings, the 
electrode was placed as close as possible to the injection site. 
6.3.2 Detection of human IgG in injected rat brains 
NMDAR-Ab negative control IgG bound to individual neurons and neuropil 
surrounding the injection site one to three days after injection, but no binding 
and no fluorescent beads were detected on the un-injected side (Figure 6.1). In 
five of nine animals studied, anti-human IgG immunofluorescence was present 
as a faint rim around the injection site, extending radially by about 20-30 μm. 
Occasionally, faintly labeled cell bodies were also visible near the injection site 
(see Figure 6.1 Cii). In one animal (day 3 post injection), such faintly labeled cell 
bodies were seen further afield as well. In two animals no anti-human IgG 
binding could be detected. In a further two animals strong anti-human IgG 
reactivity was detected around the injection site with some strongly bound cell 
bodies within 20-30 μm from the injection site and some weakly labeled cells 
further afield (e.g. Figure 6.1 Di and ii). 
A similar pattern of binding was detected in slices from animals injected with 
pIgG (Figure 6.2). There were no beads and no fluorescence in the uninjected 
side (see Figure 6.2 C). Anti-human IgG antibody fluorescence was present as 
a rim around the injection site in nine of the ten animals studied. In one rat, no 
anti-human IgG was detected by IF. In six animals the reactivity was faint, and 
accompanied by faintly stained cells extending up to 50m from the injection 
site (Figure 6.2, Ai-iii), as well some faintly stained cells further afield (in three 
animals, e.g., in deeper layers of the mEC and in one case in the subiculum 
below the mEC, see Figure 6.3). In the remaining three animals (of note, these 
had all received Pt3 IgG), brightly stained cells could be seen around the 
injection site and also extending down below the injection site into the deeper 
cortical layers. These cells had the appearance of neurons, with visible apical or 
basal dendrites. These dendrites were also moderately brightly stained and 
could be followed as they extended into the superficial layers of the mEC 
(Figure 6.2 B).  
A number of brains were not used for EP experiments, but were snap-frozen 
after PBS perfusion. No difference in staining pattern between fixed tissue and 
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fresh-frozen tissue was noted, confirming that the reactivity seen in fixed slices 
was not due to fixation of unbound antigen. Also, no differences in distribution 
of human IgG in brains examined at days 1 to 3 could be detected in either 
cIgG or pIgG-exposed animals. 
Overall, the intensity of human IgG antibody-binding appeared highest in 
sections from pIgG-exposed animals, although this difference was entirely 
attributable to the binding pattern seen in Pt3-exposed slices. Similarly, labelled 
dendrites were only seen in Pt3 IgG slices. In all other slices, variable intensity 
of binding in the area immediately surrounding the injection site was noted. 
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Figure 6.1 cIgG binds to individual neurons and neuropil surrounding the 
injection site.  
Injection of large molecular weight fluorescent dye (A) suggested good diffusion 
throughout the mEC. In most animals receiving cIgG, anti-human IgG fluorescence is 
present as a faint rim extending 20-30m around the injection site (B and C, Bi x10 
with inset showing injection in layer 3 mEC, yellow= fluorescent beads, Bii x40, Ci x20 
with inset showing injection in layer 1 (white arrow)) with occasional faintly stained cell 
bodies nearby (Cii, x40). In some animals the anti-human IgG fluorescence was very 
strong with intensely stained cell bodies around the injection site (Di, layer 1 injection 
site (outer aspect of mEC to left of photograph)) as well more weakly stained cells 
further afield (Dii – x40 of cells in layer 2 lateral to injection site). No human IgG was 
detected in the un-injected side of the brain (layers 1-4 mEC, Ei DAPI x10, ii anti-
human IgG x10, iii merge). 
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Figure 6.2 pIgG binds to cell bodies and neuropil surrounding the injection site. 
In most animals with pIgG injections, the anti-human IgG fluorescence is weak (Ai x20, 
with inset showing injection site in LII/III. Stained cells are visible around and below the 
injection site (Aii and iii, x40). In a few animals intense immunofluorescence can be 
seen in cells surrounding the injection site and extending below into deeper cortical 
layers (Bi, x10 with inset showing injection site in LII/III, ii and iii are x20, iv-vi are x40). 
Biv and v show bound axo-dendritic trees of the these neurons extending towards the 
brain surface with strong binding in layer I. vi illustrates the rapid decline in binding as 
distance from binding site increases. No human IgG is detected in the un-injected mEC 
(Ci-vi, i-iii are x10 and iv-vi are x40, i+iv are DAPI, ii+v are anti-human IgG IF, iii+vi are 
merge). Scale bars: 50m on x10 images, 10m on x20 and x40 images. 
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Figure 6.3 pIgG binds to cells distant from injection site and axo-dendritic tree of 
cells near injection site. 
In some animals, faintly stained cells could be detected over 100ms away from 
injection site, as in A, where moderately bright IF can be seen within 50m from the 
injection in layer 2 of mEC (i) and faintly stained cells were seen in the subiculum (ii) 
and molecular layer of DG (iii), indicated by red and blue rectangle respectively on the 
inset in Ai. Axons and dendrites running towards the superficial layers of the mEC are 
also bound near the injection site (Aiv, x40). Images in B show the same phenomenon 
in an animal with very faint anti-human IgG fluorescence after pIgG injection into layer 
3 mEC.
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6.3.3 -frequency oscillations in brain slices sub-acutely exposed to 
NMDAR-Abs 
Baseline -oscillation characteristics 
KA perfusion (400nM) generated -oscillations in 123 slices from 24 animals 
injected with either pIgG or cIgG. To compare the characteristics of -
oscillations in pIgG and cIgG brains, the peak power, area power and frequency 
of -activity were recorded one hour after addition of KA to the perfusion 
medium. This time point was chosen as oscillation power and frequency had 
been observed to peak around this time in previous experiments. Oscillations 
with a peak power greater than 100V2/Hz were excluded from the analysis as 
outliers. Seventy-two of the slices were from the left side of the brain (injected 
side) and 51 from the un-injected right side. Pt2 (n=21 left-sided slices from 6 
rats) and Pt3 IgG (n=21 left-sided slices from 7 rats) were used as a source of 
NMDAR-Abs, and both HC1 (n=16 left-sided slices from 6 rats) and HC2 (n=14 
left-sided slices from 5 rats) as cIgG. For controls, slices from the un-injected 
right side of the brain dissected at the same level as the left-sided slices used 
(n=26 from pIgG brains, 12 rats; n=25 from cIgG brains, 10 rats), as well as 6 
slices from two naïve animals were used. Experiments were carried out blinded 
to the nature of the IgG used in each animal. From here, left-sided slices from 
pIgG brains will be referred to as pIgG slices, left-sided slices from cIgG brains 
as cIgG slices and right-sided slices as control slices. There was no statistical 
difference between right-sided slices from pIgG and cIgG brains in peak power 
(unpaired t-test, t(21) = 0.2925, p=0.77), area power (t(21) = 0.697, p=0.49), or 
frequency (t(21) = 1.446, p=0.16). 
The first cohort of rats received either Pt2 (n=21 slices from 6 rats) or HC2 IgG 
(n=14 left-sided slices from 5 rats, see Table 6.1 and Figure 6.4 A-C). Peak 
power in pIgG slices was lower than in control slices but not cIgG slices. There 
was also a trend towards lower area power in pIgG slices than control slices. 
There was no difference in oscillation frequency between the three groups. 
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Table 6.1 mEC -oscillation parameters in slices from animals exposed to Pt2 
IgG, HC2 IgG and control slices 
 pIgG 
(median 
± IQR) 
cIgG 
(median 
± IQR) 
Control 
(median 
± IQR) 
Kruskal-
Wallis H
P Dunn’s 
MCT* 
P 
Peak 
power 
V2/Hz 
3.6 ± 
2.34-
13.24 
11.2 ± 
3.99-
38.9 
10.94 ± 
6.35-
32.87 
7.022 0.03 pIgG 
vs. 
control 
0.035 
Area 
power 
V2/Hz.kHz 
0.143 ± 
0.057-
0.32 
0.324 ± 
0.116-
0.833 
0.343 ± 
0.134-
0.977 
5.843 0.054 pIgG 
vs. 
control 
0.066 
Frequency 
Hz 
45.86 
±12.79$ 
45.80 
±11.92$ 
48.11 
±11.06$ 
F(2, 55) 
= 0.253§ 
0.777   
* multiple comparisons test;   $ Mean ± standard deviation:  § one-way ANOVA 
Visual inspection of the pooled power spectrum obtained by averaging the 
power spectrum at 1 hour of KA perfusion for each Pt2 IgG slice revealed a 
wider spread of frequencies at half-maximal power (31.74 Hz) than in HC2 IgG 
slices (25.64Hz) or control slices (23.5Hz, see Figure 6.4 B and D), raising the 
possibility of diminished synchrony, although it was not possible to investigate 
this further due to time constraints. 
The second cohort of rats received either Pt3 (n=21 slices from 7 rats) or HC1 
IgG (n=16 slices from 6 rats, see Table 6.2 and Figure 6.4 D and E). Peak 
power in pIgG slices was larger than in control slices but not cIgG slices. There 
was no difference in area power between pIgG slices and either cIgG or control 
slices however. There was no difference in oscillation frequency between the 
three groups. 
Table 6.2 mEC -oscillation parameters in slices from animals exposed to Pt3 
IgG, HC1 IgG and control slices 
 pIgG 
(mean 
± SD) 
cIgG 
(mean ± 
SD) 
Control 
(mean ± 
SD) 
ANOVA 
F 
P Tukey’s 
MCT* 
P 
Peak 
power 
V2/Hz 
29.62 ± 
19.58 
21.06 ± 
15.25 
15.79 ± 
12.78 
F(2, 62) 
= 4.582 
0.014 pIgG vs. 
control 
0.01 
Area 
power 
V2/Hz.kHz 
0.561 ± 
0.443 
0.568 ± 
0.408 
0.281 F(2, 
63)= 
2.613 
0.081   
Frequency 
Hz 
53.94 
±5.81 
52.91 
±6.79 
55.58 
±5.3 
F(2, 63) 
= 1.150 
0.323   
* multiple comparisons test 
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The apparent effect of subacute exposure to pIgG was therefore to disrupt -
power in one cohort and potentiate it in the other (see Figure 6.4). When the 
two cohorts were combined (Figure 6.5 Ai-Ci), these effects cancelled each 
other out so that there were no differences in peak power, area power or 
frequency of mEC -oscillations between groups (see Table 6.3). 
Table 6.3 mEC -oscillation parameters in slices from animals exposed to 
grouped pIgG, grouped cIgG and control slices 
 pIgG 
(median ± 
IQR) 
cIgG 
(median ± 
IQR) 
Control 
(median ± 
IQR) 
Kruskal-
Wallis H 
P 
Peak power 
V2/Hz 
13.24 ± 
3.59-32.38 
14.22 ± 5.95-
38.54 
13.00 ± 
6.35-26.84 
0.494 0.78 
Area power 
V2/Hz.kHz 
0.234 ± 
0.110-0.514 
0.394 ± 
0.145-0.871 
0.309 ± 
0.140-0.535
2.135 0.344 
Frequency 
Hz 
49.99 
±10.56$ 
49.59 
±10.03$ 
52.21 
±9.12$ 
1.354§ 0.508 
$ Mean ± standard deviation:  § one-way ANOVA F 
As mentioned above, the location of the injection site within the mEC varied 
because of the size of each animal. The immunofluorescence studies above 
demonstrated generally limited diffusion of the IgG around the mEC. Thus, 
NMDAR-Abs injected into the deep layers (layers IV-VI mEC) may not have 
reached the -generating fast-spiking interneurons in LII of the mEC. Baseline -
oscillation power and frequency from pIgG slices with a superficial injection (LI-
III, n=24 pIgG exposed slices) and a deep injection (LIV-VI, n=16 pIgG slices) 
were therefore compared (see Table 6.4 and Figure 6.5 Aii-Cii). There were no 
differences in peak power, area power, or frequency between slices with 
superficial or deep injection sites. 
Table 6.4 Baseline -characteristics in pIgG slices (grouped Pt 2 and 3 slices) by 
layer of injection site 
Location of 
injection site 
LI-III (n=24) Layer IV-VI 
(n=16) 
Mann-
Whitney U 
P value 
Peak Power 
V2/Hz 
(median±IQR) 
16.34 ± 5.18-
38.92 
10.88 ± 3.82-
21.27 
164 0.448 
Area Power 
V2/Hz.kHz 
(median±IQR) 
0.34 ± 0.108-
0.654 
0.224 ± 
0.127-0.482 
175 0.644 
Frequency Hz 
(mean ± SD) 
52.16 ±7.15 50.81 ±9.82 t(38)= 0.506§ 0.616 
§ unpaired t-test 
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Similarly, increasing time from injection was felt to potentially diminish any effect 
caused by the NMDAR-Abs because of active clearance of IgG. However, there 
were no differences in power or frequency in pIgG slices prepared 1 to 3 days 
after injection (Table 6.5 and Figure 6.5 Aiii-Ciii). 
Table 6.5 Baseline -characteristics in pIgG slices (grouped Pt2 and 3 slices) by 
days since injection 
Day after 
injection 
Day 1 (n=4) Day 2 (n=16) Day 3 (n=17) P value 
Peak Power 
V2/Hz 
(median±IQR) 
10.27 
±2.97-69.44 
10.08 
±3.44-17.99 
17.89 
±5.35-37.39 
0.3 
Kruskal-Wallis 
(H=2.403) 
Area Power 
V2/Hz.kHz 
(median±IQR) 
0.305 
±0.067-1.463 
0.275 
±0.093-0.482 
0.214 
±0.113-0.534 
0.99 
Kruskal-Wallis 
(H=0.028) 
Frequency Hz 
(mean ± SD) 
46.84 
±8.89 
49.00 
±8.8 
54.35 
±6.78 
0.09 
ANOVA (F(2, 
34)=2.569 
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Figure 6.4 Differential effect of Pt2 and Pt3 IgG on -oscillation power in mEC 
after subacute exposure. 
Peak power (Ci, median ±IQR (box) ±min-max (whiskers)) but not frequency (Ciii, 
mean ±SD) was reduced in slices from animals injected with Pt2 IgG compared to 
control slices, whereas it was increased in animals injected with Pt3 IgG (Ei, mean 
±SD), with no effect on frequency (Eiii). In both cases, there were no differences when 
compared to HC IgG. Traces in A are illustrative examples of extracellular field 
n= 25 n= 14 n= 21 
n= 21 n= 16 n= 25 
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recordings in slices from brains injected with HC2 IgG (green) or Pt 2 IgG (red), and a 
control slice from the right-side of an injected brain (black). Note the latter trace 
appears somewhat less rhythmical. B and D show the average power spectrum (solid 
line ± SD in dashed line) obtained from 1-minute recordings done 1h after the start of 
KA perfusion in each group of brain slices (Pt2 IgG: B dark red n=21 slices; HC2: B 
dark green n=14 slices; control slices from Pt2+HC2 brains: black n=25; Pt3 IgG: D red 
n=21 slices; HC1: D green n=16 slices; control slices from Pt2+HC2 brains: black 
n=25). 
 
Figure 6.5 Subacute exposure to pIgG has no effect on -oscillation 
characteristics. 
When the results from the two cohorts of injected animals (Pt2 and HC2 IgG + Pt3 and 
HC1 IgG) are pooled, no effect on  power or frequency is detected (Ai to Bi, median ± 
IQR (box) ± min-max (whiskers). The absence of changes after subacute exposure to 
pIgG (n=42 slices from 13 rats) was not related to the location of the injection (Aii peak 
power, Bii area power versus location of injection: median ± IQR; Cii frequency vs. 
location of injection: mean ± SD) or the number of days since the injection (Aiii peak 
power, Biii area power vs. number of days after injection: median ± IQR; Ciii frequency 
vs. days after injection: mean ± SD). cIgG: n= 30 slices from 11 rats, control: n= 50 
slices from 24 rats). 
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Response to NMDAR antagonism 
Next, sensitivity to NMDA receptor antagonism was investigated. Diminished 
response to NMDAR antagonism might be expected in slices from animals 
exposed to NMDAR-abs for 24-48 hours, as significant internalisation of surface 
and synaptic NMDARs should have occurred after 12 hours (Moscato et al., 
2014). The selective and competitive NMDAR antagonist D-AP5 at the standard 
concentration of 50M was used to test this hypothesis. 
D-AP5 (50M) was added to the perfusion medium once oscillations had 
stabilised as described in Chapter 4, and washed out after 40 minutes. 
Stabilisation occurred in 19 slices from pIgG brains (9 slices from 6 animals 
injected with Pt2 IgG, and 10 slices from 6 animals injected with Pt3 IgG), 14 
slices from cIgG brains (6 slices from 4 animals injected with HC2 IgG, and 8 
slices from 4 animals injected with HC1 IgG), and 20 naïve slices (14 slices 
from the un-injected side of the brain of experimental animals and 6 slices from 
naïve animals). This constitutes just less than half the slices exposed to KA in 
each group, which compares well with previous experience with naïve brain 
slices.  
D-AP5 caused a non-significant reduction in peak power in the three groups of 
slices (see Table 6.6). Area power was reduced significantly, but only in the 
pIgG slices. Frequency decreased significantly in the three groups of slices with 
D-AP5 perfusion. There was no effect of IgG treatment on the changes seen in 
any of these parameters (2-way ANOVA; frequency: IgG type F(2, 50)= 2.284, 
p=0.112; area power: IgG type F(2, 50)= 0.676, p=0.513; peak power: IgG type 
F(2, 50) =0.433, p=0.651, see Figure 6.6).
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Table 6.6 Response to D-AP5 in slices from animals exposed to pIgG, cIgG and 
control slices 
Reduc
-tion 
in: 
pIgG 
(mean 
± SD) 
cIgG 
(mean 
± SD) 
Control 
(mean ± 
SD) 
Two-way 
ANOVA F 
P Tukey’s 
MCT* 
P 
Peak 
power 
% 
26.54 
±46.88 
6.33 
±70.64 
14.62 
±63.76 
F(2, 100)= 
2.876 
0.061   
Area 
power 
% 
23.55 
±34.62 
7.069 
±56.21 
15.35 
±40.97 
F(2, 100)= 
4.249 
0.017 pIgG 
baseline 
vs. D-
AP5 
<0.05 
Freq-
uency 
% 
13.10 
±10.66 
22.07 
±11.52 
16.93 
±15.10 
F(2, 100)= 
61.12 
<0.00
01 
baseline 
vs. D-
AP5 all 
groups 
<0.00
01 
* multiple comparisons test 
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Figure 6.6 There is no effect of IgG treatment on sensitivity to NMDAR 
antagonism in oscillating slices. 
D-AP5 induced a reduction in power and frequency of -oscillations in superficial mEC 
in slices from animals sub-acutely exposed to pIgG or cIgG and in control slices as 
expected (Bi-iii). Example field potential recordings from a Pt2 IgG slice before addition 
of D-AP5 (black), after addition of D-AP5 (red) and after D-AP5 washout (grey) are 
shown in Ai with corresponding power spectra in ii, illustrating the small decline in 
power and frequency, which partially recovers. Unlike earlier pharmacological 
experiments, the reduction in power was not significant (except area power in pIgG 
slices, Bii). However, the nature of the injected IgG does not affect the magnitude of 
the reduction (C). 
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6.3.4 NMDAR synaptic function in animals sub-acutely exposed to 
NMDAR-Abs 
Although -oscillations in the mEC and other cortical areas are clearly sensitive 
to pharmacological blockade or genetic alterations of NMDAR (Cunningham et 
al., 2006; Middleton et al., 2008; Carlen et al., 2011), no direct evidence for 
NMDAR dysfunction in slices exposed to NMDAR-Abs can be obtained from 
extracellular field recordings of -oscillations. There is little doubt that NDMAR-
mediated drive to fast-spiking parvalbumin positive interneurons is an essential 
component of -rhythmogenesis (Middleton et al., 2008; Carlen et al., 2011). To 
determine if NMDAR-mediated synaptic transmission is disrupted in animals 
exposed to NMDAR-Abs would require intracellular recordings from such fast-
spiking interneurons. The contribution of NMDAR-mediated drive to the phasic 
output of these cells during -oscillations could then be quantified in the 
presence and absence of NMDAR-Abs. However, finding interneurons using 
sharp microelectrodes and obtaining sufficiently long recordings are both 
difficult. Patch-clamping techniques, which allow visualisation of the neurons in 
slices, and more recently optogenetic systems allowing stimulation or inhibition 
of selected interneuron subtypes can circumvent these issues, but were not 
available for this study.  
It is possible to obtain indirect evidence of a specific effect on interneurons by 
examining the IPSPs invading excitatory principal cells during -rhythms. A 
reduction in their size and synchrony concomitant with a decline in local field -
power would suggest that the latter is related to the former, especially in the 
presence of unchanged EPSPs in the recorded principal cell. 
Since no effect on -oscillation power or sensitivity to pharmacological NMDAR 
blockade was found in the mEC of rats having received a local NDMAR-Ab 
injection, it was futile to look for any of these changes during -oscillations in 
these animals. Instead, a simple direct assay of NMDAR function in cells near 
the injection site was used. There is no evidence to suggest that NMDAR-Abs 
bind preferentially to NMDAR on interneurons (Moscato et al., 2014); although 
the reduction in -oscillations with NMDAR antagonists is a result of a specific 
effect on fast-spiking interneurons, this is a reflection of their essential role in 
generating this rhythm and their much higher sensitivity to NMDAR antagonism 
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compared to pyramidal cells (Grunze et al., 1996). If NMDAR-Abs were able to 
bind and cause the internalisation of NMDARs in principal cells near the 
injection site, a reduction in the NMDAR-mediated component of evoked EPSPs 
might result. This was investigated using sharp intracellular electrode 
recordings from neurons near the injection site in slices prepared from animals 
exposed to either cIgG or pIgG. Because of time constraints, few good quality 
recordings from neurons in naïve animals were obtained, but where possible 
will be shown as well. 
Cell characterisation and inclusion criteria 
Recordings were obtained from a total of seventeen cells. Nine were stellate 
cells and 8 were pyramidal cells. The nature of the cells was determined based 
on electrophysiological characteristics and then confirmed post-hoc by 
immunohistochemistry of biocytin-filled cells (see Figure 6.7). Stellate cells are 
the most numerous cell type in layer II of the mEC and can be recognised 
electrophysiologically by their response to depolarising and hyperpolarising 
current pulses (Alonso and Klink, 1993): the membrane potential peaks and 
then sags to a steady-state level (Figure 6.7 B). If suprathreshold depolarising 
current steps are given, firing occurs early due to the peak in membrane 
potential (Figure 6.7C). Other characteristics include a marked depolarising 
afterpotential (DAP) following each action potential, a shorter action potential 
duration than pyramidal cells, and the presence of an intrinsic membrane 
potential oscillation in the theta range (Figure 6.7 A) (Alonso and Klink, 1993). 
Pyramidal cells, on the other hand, have a much subtler current-induced sag, 
and firing after threshold depolarisation occurs late due slowly rising membrane 
potential. DAPs are very small if visible at all and no subthreshold oscillatory 
activity of the membrane potential is visible (Alonso and Klink, 1993).  
Three cells had to be excluded from the analysis because the stimulating 
electrode was misplaced, usually too far from - and in a deeper layer than - the 
recording electrode. This resulted in no or only minuscule EPSPs being 
recorded even with high stimulation power. For 2 cells, only baseline 
characterisation was available, the cells being lost before the stimulation 
protocol was commenced. These 2 cells were included in the intrinsic 
membrane properties analysis. Thus, a total of 5 pyramidal cells (2 cIgG and 3 
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pIgG) and 7 stellate cells (5 cIgG and 2 pIgG) were available for evoked EPSP 
analysis (see Table 6.7). 
Table 6.7 Summary of recorded cells included in intrinsic membrane properties 
and evoked EPSP analysis. 
Cell 
type 
cIgG pIgG 
 Injection 
location 
Day 
post-
injec
tion 
Excluded from 
EPSP/ 
comment 
Injection 
location 
Day 
post-
injec
tion 
Excluded from 
EPSP/ 
comment 
Pyrami-
dal 
cells 
LII mid-
mEC 
1  LII lateral 
mEC 
1  
 LII/III mid-
mEC 
1 Only 
characterisation; 
stimulating 
electrode 
misplaced 
LII mid-
mEC 
1 Only 
characterisation 
available 
 L6 medial 
mEC 
2  LIII mid-
mEC 
1  
   LIV-V mid-
mEC 
2  
   LVI lateral 
mEC/WM 
3 Completely 
excluded: 
injection 
location and 
stimulating 
electrode 
misplaced 
Stellate 
Cells 
LIII lateral 
mEC 
1  LII lateral 
mEC 
1  
LIII mid-
mEC 
1  LII mid-
mEC 
1 Only 
characterisation 
available 
LV lateral 
mEC 
2  LII mid-
mEC 
1  
LIII 
medial 
mEC 
3     
LIV 
medial 
mEC 
3     
L2 3 Only 
characterisation; 
stimulating 
electrode 
misplaced 
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Intrinsic membrane properties 
Pyramidal cells 
There were no differences in either resting membrane potential (RMP) or firing 
threshold (FT) between the cIgG (n=3) and pIgG (n=4) exposed cells or naïve 
cells (n=3, see Figure 6.8). RMP was -58.83 ±12.35mV in naïve cells, -63.50 ± 
7.4 mV in cIgG-exposed rats and -67.5 ± 4.8 mV in pIgG-exposed rats (one-way 
ANOVA F(2, 7)=0.933, p=0.437). FT was -51.17 ±3.33mV in naïve cells, -54.17 
± 1.44 mV in cIgG exposed slices and -56.75 ±3.40 mV in pIgG exposed slices 
(F (2, 7)= 1.065, p=0.111). 
There was also no difference in membrane input resistance (Rin) between the 
three groups of cells (one-way ANOVA: naïve 80.24 ±48.41 M, cIgG 115.5 
±13.00 M, pIgG 93.29 ±43.20 M, F(2, 7)=0.633, p=0.56). 
Inter-spike interval (ISI) at firing threshold however, was longer in cIgG-exposed 
cells and naïve cells than pIgG-exposed cells with significant differences 
between each group (median ± IQR: naïve 0.676 ±0.55-0.89s, n=221 APs; cIgG 
0.897 ±0.48-1.688s n=174 APs; pIgG 0.318 ±0.228-0.5705s n=456 APs, H = 
58.80, p<0.0001; Dunn’s multiple comparisons test p<0.01 for each 
comparison). 
To further investigate this apparent difference in firing rate, input-frequency 
curves were constructed by counting the number of APs on each depolarising 
step from 0.1 to 0.4 nA for each cell. This is a more controlled method for 
examining firing rate and thus excitability as the membrane potential is 
controlled. There was no difference between groups in the number of APs on 
each step (2-way ANOVA, effect of size of depolarising current F(3, 108)= 
53.16, p<0.0001, effect of antibody treatment F(2, 108)= 0.289, p=0.75). 
The change in membrane potential (MP) in response to injection of a brief 
current step (IV curve) differed significantly between the groups, with a greater 
change in membrane potential at each step in cells from slices exposed to cIgG 
compared to pIgG, but greater change in pIgG cells compared to naïve cells 
suggesting these differences are related to random sampling error caused by 
the small number of cells in each group (2-way ANOVA: effect of step size 
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F(6,102) = 16811, p <0.0001; effect of IgG type F(6, 102) = 9.81, p =0.0023, 
Sidak’s post-hoc multiple comparisons p<0.001 for each step). 
Stellate cells 
Recordings from only two naïve stellate cells were obtained, and so the results 
from these are not included in the analysis below, but they are shown on the 
graphs in Figure 6.9 for completeness. 
RMP and FT were similar in the cIgG and pIgG exposed cells. RMP was -61.78 
±7.14 mV in cIgG-exposed cells and -65.00 ±2.65 mV in pIgG-exposed cells 
(cIgG n=6, pIgG n=3; unpaired t-test t(7)=0.734, p=0.487, see Figure 6.9). 
Naïve cell RMP was -72.00 ± 1.41 mV (n=2). Firing threshold was -60.95 ±2.12 
mV in cIgG exposed slices and -58.33 ±3.51 mV in pIgG exposed slices 
(unpaired t-test t(7)=1.426, p=0.197). Naïve cell FT was -63.75 ±1.06 mV. 
There was also no difference in membrane Rin between cIgG and pIgG cells 
(unpaired t-test: cIgG 75.00 ±17.69 M, pIgG 76.71 ±9.61 M, t(7)=0.152, 
p=0.88). Rin of naïve stellate cells was 71.25 ±30.27 M. 
In contrast to pyramidal cells, ISI at firing threshold was longer in pIgG-exposed 
cells than cIgG-exposed cells (median ± IQR: cIgG 0.269 ±0.192-0.462 s, 
n=218 APs from 6 cells; pIgG 1.194 ±0.602-2.157s, n=82 APs from 3 cells; 
Mann-Whitney test, U = 2358, p<0.0001). Naïve cell ISI at FT was 0.096 
±0.072-0.12 s. When the input-frequency data were examined, there was also 
an effect of antibody treatment on number of APs per 100ms step (2-way 
ANOVA: effect of step size F(3, 100)= 86.27, p<0.0001; effect of antibody 
treatment F(1, 100)= 6.15, p=0.015), but this was only present at the 0.2nA step 
(uncorrected Fisher’s least significant difference test: 0.2nA step cIgG vs. pIgG 
t(100)=2.014, p=0.047; p>0.05 at 0.1, 0.3 and 0.4 steps). 
The IV curve of the stellate cells differed significantly between the two groups, 
with a greater change in membrane potential at most steps in cells from slices 
exposed to pIgG compared to cIgG (2-way ANOVA: effect of step size F(8,207) 
= 11042, p <0.0001; effect of IgG type F(1, 207) = 4.78, p =0.03, Sidak’s post-
hoc multiple comparisons test p<0.001 for -0.3, -0.2, 0.2, 0.3, 0.4 steps; p>0.05 
for -0.4, -0.1 and 0.1 steps). Note that this is the opposite as the difference seen 
in pyramidal cells. 
  219
 
Figure 6.7 Cell type identification by electrophysiological and morphological 
characteristics. 
Stellate neuron (i) and pyramidal neuron (ii) action potentials are shown in A. The 
distinct DAP of stellate cells is indicated by the black arrowhead. Insets show the slow 
intrinsic membrane oscillation present in stellate cells but absent in pyramidal cells 
(APs truncated). The membrane response to hyperpolarising and depolarising current 
injections is shown in B. The peak (black arrow) and sag (grey arrow) becomes more 
pronounced with the magnitude of the input in stellate cells (i), but is absent in 
pyramidal cells (ii, AP truncated). The response to a longer depolarising step (C, APs 
truncated) demonstrates the characteristic early firing with rapid accommodation of 
firing rate in stellate cells in contrast to the later firing (see also Bii, 0.2nA step) with 
minimal accommodation in pyramidal cells. Examples of biocytin-filled recorded cells 
are shown in D. Note the extensive lateral dendritic arborisation of the stellate cell (i). 
Unfortunately, only one filled pyramidal cell was successfully stained and little 
anatomical detail is visible. The injection site is indicated by white arrows. 
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Figure 6.8 Intrinsic membrane properties of naïve, cIgG and pIgG exposed 
pyramidal neurons. 
There was no difference in resting membrane potential (RMP, A), firing threshold (FT, 
A) or input resistance (B) between the three groups, although membrane potential 
change to incremental 0.1nA current injections (I-V curve, C) appeared larger in cIgG 
cells. However, the IV curve of pIgG cells was steeper than that of naïve cells. 
Interspike interval (ISI, s) at FT is shown in Di and Dii. There appeared to be a 
significant difference with higher firing rates in pIgG cells, but this was not borne out 
when membrane potential was controlled (Diii). 
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Figure 6.9 Intrinsic membrane properties of naïve, cIgG and pIgG exposed 
stellate cells. 
There was no difference in resting membrane potential (RMP, A), firing threshold (FT, 
A) or input resistance (B) between the pIgG and cIgG cells, although membrane 
potential change to incremental 0.1nA current injections (I-V curve, C) appeared larger 
in pIgG cells at the larger current steps. Interspike interval (ISI, s) at FT is shown in Di 
and Dii. There appeared to be a significantly lower firing rate in pIgG cells, and this was 
also present when membrane potential was controlled (Diii). Only two naïve stellate 
cells were recorded; the values obtained are shown above but were not included in 
statistical analysis.  
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Evoked EPSP analysis 
EPSPs were elicited in the presence of 20μM NBQX, 1μM CGP55845, and 1μM 
Gabazine to block the AMPAR-mediated component of the EPSP and any 
contribution of GABA-mediated inhibition to the shape of the EPSP. To confirm 
that the resultant EPSP were wholly NMDAR-mediated, D-AP5 (50M) was 
added to the perfusion medium and the stimulation protocol repeated. As 
expected, EPSPs were completely abolished (Figure 6.10). 
Pyramidal cells 
EPSPs were obtained from 2 cIgG, 3 pIgG and only one naïve pyramidal cells 
at stimulus voltages from 1-25V. The 1 and 2 V stimuli rarely gave rise to a 
visible membrane potential deflection. A complete data set is only available for 
stimuli of 5,7, and 10V. 
On average, EPSP peak amplitude and slope were greater in cIgG cells than 
pIgG cells (Figure 6.11 A and B). However, the number of cells in each group is 
very small and the variability within groups was large, such that it is not possible 
to interpret this difference. An ANOVA showed, as expected, that it did not 
reach statistical significance (2-way ANOVA for peak amplitude: effect of 
stimulus size F(3, 11) = 1.57, p =0.25; effect of IgG type F(1,11) = 0.617, p 
=0.45. 2-way ANOVA for slope : stimulus F(5, 17) = 2.17, p =0.11; IgG F(1, 17)  
=2.89, p =0.11). 
Stellate cells 
EPSPs were obtained from 4 cIgG, 2 pIgG and no naive stellate cells at 
stimulus voltages from 1-25V. The 1 V stimulus rarely gave rise to a visible 
membrane potential deflection. A complete data set is only available for stimuli 
of 1, 2, 5, and 7V. 
On average, EPSPs peak amplitude and slope were greater in cIgG cells than 
pIgG cells at each stimulus (Figure 6.11 C and D). However, the number of cells 
in each group is very small and the variability within groups was large, such that 
interpreting this difference is difficult. An ANOVA showed the difference did not 
reach statistical significance (2-way ANOVA for peak amplitude: effect of 
stimulus size F(3, 16) = 3.750, p =0.033; effect of IgG type F(1,16) = 0.923, p 
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=0.35. 2-way ANOVA for slope : stimulus F(3, 16) = 2.48, p =0.099; IgG F(1, 
16)  =0.267, p =0.613). 
Large depolarisation events 
Occasionally, a stimulus would be followed by a large and/or prolonged 
depolarisation event, usually after a stimulus larger than that of a magnitude 
sufficient to cause spiking had been exceeded. These large depolarisation 
events were seen in both pyramidal and stellate cells and in both pIgG and 
cIgG injected animals. The duration, area under the curve and coastline of 
these events were compared to determine if NMDAR-abs had any effect on the 
characteristics of the events by altering the excitability of the cells. 
Pyramidal cells 
Pyramidal cells appeared relatively resistant to producing large or prolonged 
depolarisation after stimulation, with one of two cIgG and one of three pIgG-
exposed cells exhibiting this behaviour. In both cells, the events consisted of a 
large membrane depolarisation superimposed with multiple action potentials. 
There was progressive failure of action potential repolarisation, leading to a 
large depolarisation of membrane potential. If spike repolarisation was 
completely abolished, as in the cIgG cell in the top panel of Figure 6.12, a 
rhythmic membrane potential oscillation became apparent on the depolarised 
membrane plateau. It is not possible to compare the two events statistically, but 
they appeared of similar duration and coastline. 
Stellate cells 
All the stellate cells recorded exhibited prolonged depolarisations with repetitive 
firing upon suprathreshold stimulation (Figure 6.12). In some cells, this occurred 
only with large stimuli, e.g. above 20V, but in others, this was present at low 
voltage stimulation on the first of ten stimuli only. Figure 6.12 shows the first 
depolarisation event recorded from each stellate cell (the characteristics of the 
events did not change markedly within cells as stimulation voltage increased), 
and summarises the events’ characteristics. 
The events were highly heterogeneous with some events displaying failure of 
spike repolarisation and consequent marked membrane depolarisation with 
intrinsic membrane oscillations as seen in the pyramidal cells, whilst others 
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consisted of smaller recurrent membrane depolarisations triggering firing of a 
single spike or a small cluster of APs. Finally, some had features of both of the 
above. Statistical comparison seemed inappropriate in view of the small number 
of events and the heterogeneity. Of note, the events in the pIgG-exposed 
stellate cells appeared longer than in their cIgG counterparts (1.53 ±0.69s vs. 
0.852 ±0.146s), suggesting perhaps an inhibition deficit. In contrast, the 
coastline of the pIgG cell events was smaller, indicating the events were less 
complex despite their longer duration. 
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Figure 6.10 EPSP characterisation and response to D-AP5. 
A - EPSPs were recorded by electrically stimulating neurons at a set distance from the 
recording electrode (black arrow, Ai) using a bipolar electrode (white arrow, Ai). The 
injection site can be seen as a red dot in LII/III of mEC (Ai). The NMDAR-mediated 
component of the EPSP was isolated by adding 1M Gabazine and CGP55845 to 
block GABAR-mediated inhibition and 20M NBQX to block AMPA/KA receptor 
mediated excitation (schematic in ii). The peak amplitude and slope of the EPSP was 
then measured (iii). The NMDA-R mediated nature of the resultant EPSPs was 
confirmed by perfusing a slice with D-AP5, causing the remaining EPSPs to be 
abolished (B). Ci-iv demonstrate the complete absence of EPSPs once NMDARs have 
been blocked in both stellate cells(i and iii) and pyramidal cells (ii and iv). 
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Figure 6.11 EPSPs recorded in pyramidal and stellate cells from cIgG brains are 
larger than those recorded from pIgG slices. 
Example recordings from pyramidal cells (Ai and ii) and stellate cells (Ci and ii) 
illustrate the larger EPSPs evoked in cIgG than pIgG cells (increasing stimulus 
intensity illustrated by darker grey response). Average values (±SEM) for peak 
amplitude (Bi and Di) and slope (Bii and Dii) show the large variability in EPSP size 
between cells. No statistical comparison has been performed (pyramidal cIgG n=2 Ai 
and B, pyramidal pIgG n=3 Aii and B (naïve pyramidal n=1); stellate cIgG n=4 Ci and 
D, stellate pIgG n=2 Cii and D). 
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Figure 6.12 Large depolarisation events elicited by suprathreshold stimulation of 
pyramidal and stellate cells. 
Pyramidal cell events are shown in the first row and stellate cell events below this. 
Events in cIgG cells occupy the left panel and those in pIgG cells the right panel. Most 
events consist of repeated small depolarisation, which trigger one or more APs. In 
some cells, spike repolarisation fails and a plateau depolarisation is reached where 
intrinsic membrane oscillations are visible (e.g. cIgG pyramidal cell and 5 and 15V 
stellate cIgG cell.  
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6.3.5 Histological findings in mEC sub-acutely exposed to NMDAR-
Abs 
Nature of the cell bodies containing internalised IgG 
Anti-human IgG antibody binding was detected in slices from both cIgG and 
pIgG brains used during EP experiments, as described in section 6.3.2. The 
binding seemed to be within the cytoplasm of the cells, and occasionally also 
along the axo-dendritic tree of presumed neurons, albeit this only appeared to 
be the case for pIgG brain sections. The nature of these cells was investigated 
using double-labelling for intracellular proteins specific to neuron subtypes of 
interest. Unfortunately, the double-staining process led to significant loss of anti-
human IgG antibody binding, such that it was difficult to confirm double-staining. 
Co-localisation with excitatory principal cells 
Antibodies against the  isoform of calcium/calmodulin-dependent protein 
kinase II (CAMKII) were used to label excitatory principal neurons. CAMKII is 
exclusively expressed in excitatory neuronal populations in rodent cerebral 
cortex and hippocampus (Liu and Murray, 2012).  
PIgG and cIgG injections did not appear to disrupt excitatory cell distribution in 
any of the slices examined (Figure 6.13). Colocalisation of human IgG with 
CAMKII was seen in slices from 2 animals only, both having received Pt3 IgG. 
In both these animals, the injection was located superficially in LI/II and human 
IgG binding within cells was visible in LII, where CAMKII positive excitatory 
neurons are located. In other animals the human IgG-positive cells and CAMKII-
positive cells did not appear to colocalise (Figure 6.13 and Figure 6.14). 
However, in these animals the pIgG injection was situated in slightly deeper 
layers (II and III) and the IgG-bound cells tended to cluster below the injection 
site (Figure 6.15). 
Co-localisation with inhibitory interneurons 
No co-localisation was seen with Parvalbumin, GABA or GAD67 (Figure 6.16). 
Co-localisation with interneurons of subtypes other than parvalbumin was not 
directly investigated in view of the results with GABA and GAD67. It is 
noteworthy that both GABA and GAD67 immunofluorescence was often weak 
and that human IgG binding was less marked in double-stained slices. 
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Furthermore, bleed-through of the interneuron marker immunofluorescence into 
human IgG immunofluorescence occurred, increasing the difficulty of 
interpreting the results. 
Effect of IgG injection on Parvalbumin-positive interneuron numbers 
A reduction in the number of parvalbumin-positive interneurons in the cerebral 
cortex and hippocampus following chronic pharmacological NMDAR blockade 
or partial genetic NMDAR ablation has been noted in several animal models of 
schizophrenia.(Keilhoff et al., 2004; Rujescu et al., 2006; Gandal et al., 2012) 
Parvalbumin-positive cell bodies in the mEC of injected rats were therefore 
counted and compared to the number on the uninjected side. Cells were 
counted in the whole mEC in order to avoid spurious results caused by variation 
in size of the injection site and expressed as number of cells/mm2. There was 
no difference in the number of PV-positive cell bodies in the whole mEC of the 
naïve (n=16) or cIgG (n=8) and pIgG (n=8) injected slices (mean ± SD: naïve 
53.91 ±12.05 cells/mm2, cIgG 42.52 ±22.34 cells/mm2, pIgG 42.00 ±23.67 
cells/mm2, ANOVA: F(2, 28)=1.624, p= 0.215). There were also no differences 
between cIgG and pIgG slices when LII, LIII and the deep layers (V and VI) 
were considered separately, although there were significantly more PV-positive 
cells in LIII of uninjected slices (naïve 25.12 ±4.69 cells/mm2, cIgG 16.84 
±11.27 cells/mm2, pIgG 17.10 ±10.42 cells/mm2, ANOVA: F(2, 28)= 3.465, p= 
0.045; Uncorrected Fisher’s Least Significant Difference test t(28)=2.211, 
p=0.035 naïve vs. pIgG, t(28)= 2.059, p=0.049 naïve vs. cIgG) presumably 
because of the absence of tissue disruption/damage related to the injection 
(Figure 6.17)
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Figure 6.13 cIgG and pIgG do not disrupt excitatory cell distribution in mEC and 
cIgG does not co-localise with CAMKII. 
Top row (x40) shows an injection of cIgG into layer II of mEC (1 day after injection). 
The DAPI and CAMKII merge show very limited disruption of the excitatory cell 
distribution in layer II at the site of the injection. The second (x20) and third (x20 and 
x40) rows show a similar pattern of apparently even excitatory cell distribution very 
surface 
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LIII 
LIII LIV‐V 
LII LIII LIV LII LIII LIV LIII 
LIII 
LIV‐V 
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close to pIgG injection sites (fluorescent beads in third row). The bottom panel shows 
human IgG and CAMKII binding in cIgG slices. Few cells with bound anti-human IgG 
antibody are present, but they do not co-localise with CAMKII (e.g. circled cells in 
middle row). Injection sites indicated by arrows. Layers 1-6 indicated by notation LI to 
LVI. 
 
 
Figure 6.14 Co-localisation of pIgG and CAMKII is occasionally seen. 
Human IgG and CAMKII co-localisation was seen in two animals only (see top row 
(x20) and second row (x40 of top row). In other animals the cells with human IgG 
binding and CAMKII-positive cells did not appear to colocalise (bottom two rows). 
However, in these animals the pIgG injection was situated in slightly deeper layers (II 
and III) and the human IgG-positive cells tended to cluster below the injection site, 
where fewer CAMKII positive cells were seen. In one animal, there was marked 
dendritic binding (bottom row). The labeled dendrites appeared to contact CAMKII-
positive cells in LII and III, where CAMKII-negative IgG-bound cells were also present 
(see merge panel). 
LII 
LI 
LII 
LIII LIV‐V 
LIII 
LII 
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Figure 6.15 Human IgG-positive cells appear to be located in a different layer to 
the CAMKII-positive cells in pIgG slices 
In this animal, the pIgG injection was located in LII of the mEC (see inset in first row). 
CAMKII-positive excitatory cells are seen around and just below the injection site 
(yellow fluorescent beads). Photographs in the bottom row are taken below the 
injection site (injection towards top right of pictures). The bottom of layer III is denoted 
by the presence of CAMKII-positive cells. Below this is layer IV or lamina dissecans. 
The human IgG-bound cells appear to be within layer V and have labelled dendrites 
that extend upwards towards layer III. The human IgG-positive cells are not CAMKII 
positive.
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Figure 6.16 human IgG does not co-localise with inhibitory interneuron markers. 
The top panel shows Parvalbumin immunofluorescence with PV-positive cells present 
in the proximity of pIgG (top) and cIgG (bottom row) with no colocalisation with human 
IgG antibody. GABA-positive cells are much more numerous than PV cells as they 
comprise other interneuron subtype as well. No colocalisation is seen. For both PV and 
GABA, some bleedthrough of immunofluorescence into the human IgG channel has 
occurred. The white arrowheads in the bottom panel denote cells used as landmarks in 
the higher magnification insets. 
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Figure 6.17 There is no reduction in Parvalbumin-positive interneurons in slices 
from animals sub-acutely exposed to NMDAR-Abs. 
Example microphotographs of mEC sections stained for PV are shown in A. Ai shows 
the apparently normal distribution of PV-positive cells around pIgG and cIgG injection 
sites. A lower magnification image in Aii shows the normal distribution of PV-positive 
interneurons in mEC and HPC, with intense staining related to dendritic arborisation in 
LII of mEC and throughout the pyramidal layers of the HPC. The deeper layers of MEC 
as well as the peri-rhinal cortical areas have less intense staining. PV-positive 
interneurons were less numerous in both cIgG and pIgG injected brain slices compared 
to the contralateral un-injected, slice but there was no difference between the two 
treatment groups. 
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6.4 Discussion 
6.4.1 The distribution of human IgG in rodent brain slices after 
injection 
The diffusion and binding pattern of the injected human IgG was not as widely 
distributed as expected. Neuropil staining by anti-human IgG antibody was only 
detected within 50m of the injection site and yet FITC-conjugated dextran dye, 
with a molecular weight far surpassing that of IgG molecules (500 kDa versus 
150 kDa) was detectable throughout the mEC and within the ipsilateral lateral 
ventricle 24 hours after injection. Moreover, contrary to expectations, most of 
the binding of human IgG that was seen appeared to be intracellular and very 
faintly stained cells were sometimes noted some 100-200 m away from the 
injection site, suggesting that some sub-detection threshold diffusion had taken 
place. In a small minority of pIgG-injected animals axo-dendritic localisation of 
human IgG appeared quite prominent. 
This reactivity pattern contrasts with that seen in mice having received a single 
injection of 10L purified pIgG, where strong binding of anti-human IgG 
antibody was observed in the molecular layers of the dentate gyrus, CA1 and 
CA3, as predicted by NR1 subunit immunofluorescence, up to 48 hours after 
injection with no intracellular binding (Wright et al., 2015b). In that study, anti-
human IgG immunofluorescence following healthy control IgG injection was 
minimal and limited to the injection site. 
Antibody diffusion after direct intracerebral injection in vivo has only very 
recently received attention (Daniel J. Wolak et al., 2015). The authors showed 
that non-targeted IgG diffusion in the extracellular space (ECS) of rat neocortex 
is reduced by a factor of ten compared to that in a free medium and is much 
slower than that of other large molecules such as transferrin (80 kDA). This is in 
agreement with older studies showing that an antibody against amyloid- 
remained localised to the injection site for up to one week with little binding of 
amyloid- plaques not in the immediate vicinity of the injection (Wilcock et al., 
2003). 
A number of factors influence the diffusion of molecules through the ECS of the 
brain (D. J. Wolak and Thorne, 2013). The size of the molecule is of course 
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important, as ECS width has been measured at around 40-60nm, but other 
factors such as hindrance by non-specific binding to cellular or extracellular 
matrix constituents, cellular obstacles and electrical charge all play a part. 
Binding to Fc receptors was shown to play a significant part in hindering 
antibody diffusion in rodent brain ECS, as adding excess Fc fragments or 
unlabelled antibody increased the diffusion of fluorescently labelled antibody 
(Daniel J. Wolak et al., 2015). Fc receptors are present on most cell types in 
the central nervous system, including astrocytes, oligodendrocytes, microglia, 
neurons and brain capillary endothelial cells (Okun et al., 2010). Some non-
specific binding is therefore likely to have taken place after the injection. 
Assessing the distribution of binding using NMDAR-Fab fragments may clarify 
this. 
Furthermore, IgG removal from brain is rapid. Y. Zhang and Pardridge (2001) 
found that IgG efflux following a single intracortical injection had a half-time of 
48 minutes, considerably faster than the egress of a 70 kDA dextran used as 
control, the levels of which remained essentially unaltered over the 90-minute 
experiments. Similar rapid elimination has been demonstrated after intra-
cisternal antibody infusion in rats, with an antibody CSF half-life of 24 minutes in 
the early phase and 12.8 hours in the late phase, leaving 0.1% of the initial 
antibodies in the CSF at 90 minutes (O'Hear and Foote, 2006), although some 
medium-term survival of antibody occurred by diffusion into brain parenchyma 
after administration into CSF. The rapid efflux from brain parenchyma found by 
Y. Zhang and Pardridge (2001) was nearly entirely mediated by Fc receptors, 
most likely situated on the abluminal membrane of brain capillary endothelium, 
as the addition of unlabelled Fc, intact IgG, but not Fab abolished the efflux. 
The presence of intracellular human IgG in the slices in this study is consistent 
with the findings of studies described in Chapter 5, which demonstrated 
internalisation of intracellular antigen-targeted but also non-targeted or healthy 
control IgG into neurons (Hill et al., 2009; Geis et al., 2010; Congdon et al., 
2013; Iffland et al., 2013). As both control and patient IgG appeared 
intracellularly located, it is likely that a portion of the uptake occurred through 
non-specific Fc receptor binding, rather than through binding to the NMDA 
receptors. 
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In view of the limited diffusion and rapid elimination of IgG in brain, the 
restricted and inconsistent binding seen here is perhaps less surprising than the 
striking NR1-like distribution of immunofluorescence after single 
intracerebroventricular injection of NMDAR-Ab positive IgG in mice. CSF 
turnover rate is high in rodents, occurring up to 12 times per day in rats, and 
elimination of antibodies via choroid plexus cells is also expected. However, 
both Daniel J. Wolak et al. (2015) (2mg/ml) and Y. Zhang and Pardridge (2001) 
used much lower IgG concentrations than either this study (5L of IgG at 
around 12 mg/ml, so total 60 g administered) or in Wright et al. (2015b)(10µL 
at around 25mg/ml, so 250g of IgG). Y. Zhang and Pardridge (2001) 
determined that addition of 1.5 g unlabelled non-specific IgG completely 
blocked labelled IgG efflux, such that it is plausible that the much higher IgG 
concentrations used in the Oxford study could have saturated the Fc receptor-
mediated efflux mechanism and therefore prolonged the half-life and diffusivity 
of NMDAR-abs following ventricular injection.  
A reduction in NMDAR-Ab titre in the IgG preparations used over time may also 
be relevant. Indeed, immunofluorescence intensity and distribution deteriorated 
over consecutive mouse cohorts in the Oxford study (personal communication, 
Dr S. Wright, NDCN, Oxford University). The IgG administered during 
intracerebral injections in this study had been prepared one (Pt 3 IgG) to two (Pt 
2 IgG) years previously. If NMDAR-Ab concentration in the IgG decreased over 
that time, the likelihood of obtaining neuropil staining in the NR1 pattern would 
be much lower, whereas non-specific internalisation would still be present. 
The co-localisation studies were rather unsuccessful and did not resolve the 
nature of the cells taking up the IgG. Co-localisation with CAMKII, a marker of 
excitatory cortical neurons, could only be ascertained in slices from two animals 
that had received Pt3 IgG injections. The distribution of the stained cells in 
these sections was striking however: as well as being present around the 
injection site, the human IgG-positive cell bodies clustered vertically below the 
injection site into the deeper layers. Processes assumed to be apical dendrites 
travelled vertically up towards layer II, reminiscent of the columnar-like 
arrangement of the entorhinal cortex, where dendrites and axons of layer III and 
V pyramidal cells gather into bundles that travel up towards the superficial 
layers, separating layer II cells into islands (Ikeda et al., 1989; Witter and 
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Moser, 2006). These columns are thought to mediate connectivity between 
deep and superficial layers of the mEC. Although it was encouraging that no co-
localisation was detected in slices from animals with cIgG injections, it is 
noteworthy that anti-human IgG antibody immunofluorescence was lost in the 
double-staining process. Additionally, co-localisation with microglia, astrocytes 
and oligodendrocytes was not investigated. These cells also express FC 
receptors and microglial uptake of foreign IgG would be expected (Okun et al., 
2010). 
Even if IgG uptake occurred mostly in neuronal cells, the functional effect on 
surface or total NMDAR levels was not assessed here. Reduction in surface 
NMDARs would be expected in order for network or single cell effects to take 
place, as demonstrated by the lack of effect of incubation with Fab fragments or 
short incubation with patient CSF on surface NMDAR density and NMDAR-
mediated currents in cultured hippocampal neurons (Moscato et al., 2014). No 
difference in total NR1 was found 22 or 46 days after a single 
intracerebroventricular injection of patient IgG or control IgG in mice (Pettingill, 
2013), but a reduction in surface NR1 protein concentration was noted in the 
hippocampi of mice receiving a 14-day infusion of patient CSF (Planagumà et 
al., 2014) with accompanying memory deficits and anhedonic behaviours. On 
the other hand, 48 hours after a single injection of 10L of patient IgG (Wright et 
al., 2015b), there was no apparent NMDAR loss, despite increased seizure 
susceptibility in the mice, which correlated with the amount of IgG bound to the 
hippocampus. 
6.4.2 Network activity in brain slices from animals sub-acutely 
exposed to NMDAR-Abs 
No effect on -oscillation power or frequency, or sensitivity to NMDAR 
antagonism was noted, and the lack of effect did not appear to be related to 
either variability in injection location or time elapsed since antibody 
administration. This was probably due to the restricted diffusion of antibodies 
directly injected into the mEC and rapid clearance described above. 
Additionally, no effect on the number of PV-positive interneurons was seen 
here, in contrast to studies of chronic NMDAR hypofunction in rodents (Keilhoff 
et al., 2004; Rujescu et al., 2006; Gandal et al., 2012). 
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As can be seen in Figure 6.17, although the number of PV-positive interneurons 
in layer II of the entorhinal cortex is quite low (16.58 ± 5.75 cells/mm2), 
especially in comparison to the excitatory principal cells, the axonal arborisation 
is dense, and it is known that multiple interneurons synapse onto individual 
principal cells and provide recurrent inhibitory synapses onto other interneurons 
(Jones and Buhl, 1993). Even if successful binding of NMDAR-Abs and 
consequent internalisation of NMDARs in the small areas where neuropil and 
cell body binding was seen is assumed, this is unlikely to reduce NMDAR-
mediated drive to a sufficient number of PV-positive interneurons to disrupt -
rhythmogenesis. 
6.4.3 NMDAR-mediated synaptic function in slices from animals 
sub-acutely exposed to NMDAR-Abs 
Intrinsic membrane properties of neurons such as resting membrane potential 
and apparent input resistance, are generally determined by permeability to ions, 
chiefly Na+, K+, and Cl -, and this in turn correlates to the number of open ion 
channels in the cell membrane. These ion channels are generally voltage-gated 
and not related to glutamate or GABA receptors. A change in these properties 
in the presence of NMDAR-Abs would therefore not be expected unless there 
was a toxic effect on the membrane from the IgG. Furthermore, NMDARs are 
usually quiescent at normal resting membrane potentials, as both ligand binding 
and depolarisation of the cell membrane are required to open the ion channel 
and remove the Mg2+ block. The contribution of NMDARs to baseline excitatory 
neurotransmission is therefore small. 
Some statistically significant differences in intrinsic membrane properties of 
neurons in animals administered cIgG or pIgG were found however. Firing rate 
appeared higher in pIgG-exposed pyramidal cells although this was not 
confirmed by the input-frequency curve, and slower in pIgG-exposed stellate 
cells. Surprisingly, although resting membrane potential and input resistance 
were similar, the change in membrane potential to increasing magnitude current 
steps were different in cIgG and pIgG cells, albeit in opposing direction for the 
two cell types. The validity of these differences is questionable in view of the 
low number of cells in the analysis. Additionally, the differences in I-V curve 
may be a consequence of the analysis method: the response to each current 
step was measured three times in each neuron and the average and standard 
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deviation (which was always very small) for each step were pooled for all the 
neurons in each category. This resulted in a much smaller standard deviation at 
each step than if a single value from each neuron had been used, in which case 
the inter-neuron standard deviation would have been calculated rather than a 
pool of the intra-neuron standard deviation. The IV curve shape, that is the 
magnitude of change in membrane potential resulting from different current 
steps, is related to voltage-sensitive ionic conductances in the cell membranes 
and not to neurotransmitter receptor activity, such that it is difficult to reconcile 
the changes seen here in pIgG cells with what is known about the 
electroresponsiveness of stellate and pyramidal cells in the entorhinal cortex 
(Klink and Alonso, 1993). 
The reduction in pIgG stellate cell firing rate appears somewhat more robust, as 
it was confirmed by the input-frequency results, where membrane potential is 
controlled. Again, it is difficult to envisage a simple explanation for this. A 
reduction in firing rate could result from an increase in the inhibition: excitation 
ratio experienced by the cell. Cells in layers II, III, and V of mEC are exposed to 
continuous spontaneous excitation through tonic glutamatergic activity (Berretta 
and Jones, 1996; Greenhill et al., 2014): This is mostly AMPA receptor driven 
although there is evidence for both spontaneous discrete pure NMDAR 
activation and mixed spontaneous AMPA and NMDAR synaptic activity, more 
frequent in deeper layers.  
Internalisation of NMDARs might lead to a reduction in excitation, thus 
increasing the inhibition: excitation ratio. However, such an explanation is too 
simplistic, as it does not take into account the effect of antibodies on NMDARs 
on inhibitory cells, and probably exaggerates the role of NMDAR-driven 
excitation in the firing of principal cells. In fact, spontaneous inhibition 
dominates synaptic responses in all layers of the mEC, with increasing 
inhibition-to-excitation ratios from layer V to layer II (Greenhill et al., 2014). 
Layer II interneurons with extensive axonal and dendritic arborisation in layers I 
and II have powerful NMDAR-mediated activation relative to the faster AMPA 
receptor-driven response (Jones and Buhl, 1993), such that an NMDAR-related 
change in the inhibition: excitation ratio at individual layer II stellate cells will 
more likely reflect alterations of inhibitory tone. Internalisation of NMDAR on 
interneurons would predict a reduction in inhibition, which should lead to the 
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opposite effect on firing rate. The situation is made yet more complex because 
the link between spontaneous miniature synaptic activity and firing rate is not a 
given: firing rate appeared related to network connectivity rather than intrinsic 
excitability in one study of the mEC (Quilichini et al., 2010) and high layer II cell 
firing rates in the mEC have been recorded in vivo despite the dominant 
inhibition seen both in spontaneous and evoked synaptic responses (see 
discussion in Jones (1994)). 
The small number of cells from which EPSPs were obtained precluded 
statistical analysis and prevents firm conclusions from being drawn, but 
encouragingly, the trend appears to be in the hypothesised direction with, on 
average, smaller evoked NMDAR-mediated EPSPs in stellate and pyramidal 
cells from slices exposed to pIgG. Stimulation paradigms such as the one used 
here have been shown to elicit monosynaptic NMDAR responses, so that a 
reduction in EPSP amplitude will likely relate directly to NMDAR content or 
activity at the synapse (Jones, 1994). Here, other sources of excitation and 
inhibition have been removed pharmacologically so that the generally elevated 
synaptic inhibition discussed above is not relevant. 
The large depolarisation events resulting from supra-threshold stimulation in 
stellate cells resembled the epileptiform discharges seen in vitro after 
pharmacological blockade of GABAA and GABAB-mediated inhibition (Jones, 
1994). GABAA and GABAB inhibition is blocked in these slices, but the 
epileptogenic potential of this intervention is mitigated by the concurrent 
inhibition of fast excitatory transmission through AMPA and KA receptors. 
Instead, these events only occurred when electrical stimulation depolarised the 
recorded cell sufficiently to remove the NMDAR Mg2+ block and promote action 
potential firing, thus circumventing the AMPAR block. The greater degree of 
depolarisation, as indicated by the area under the curve, and the greater 
complexity of the response being related to a higher number of membrane 
NMDAR in the cIgG stellate cells is an attractive hypothesis, but cannot be 
verified by the data obtained here. Similarly, the depolarisation events recorded 
in pyramidal cells strongly resembled reported epileptiform paroxysmal 
depolarising events that emerge during early network synchronisation induced 
by loss of GABAA inhibition, and the same mechanism as above can 
presumably be invoked. Layer III and layer V pyramidal neurons are very 
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susceptible to producing these network-driven discharges, presumably because 
of the lower inhibition: excitation ratio found in these layers, but also because of 
the relatively high probability of recurrent connections between pyramidal cells 
in these layers (Dhillon and Jones, 2000). The recurrent excitatory postsynaptic 
potentials recorded at these connection are AMPA and NMDAR-mediated. The 
relative resistance of pyramidal cells in this study to producing these 
epileptiform discharges was therefore somewhat surprising, but it is important to 
remember that the experiments were not set up in such a way as to study this 
phenomenon and a number of other factors may have affected the outcome, 
such as distance between recording and stimulating electrode and tissue 
disruption due to the injection. 
6.4.4 Further work 
This chapter describes an attempt at establishing a passive transfer model that 
would allow investigation of the effects of NMDAR-abs on NMDAR-mediated 
transmission. Because the IgG injections were intra-entorhinal, the model was 
always going to be very limited and there was no expectation that it would result 
in any of the clinical features of NMDAR-Ab encephalitis. Unfortunately, this 
model was marred by limitations related to immunoglobulin availability and 
binding within brain matter after a single intracerebral infusion. The lack of effect 
of pIgG injections on -oscillations is therefore likely to be a result of the 
limitations of this particular model rather than an indication that NMDAR-abs are 
not pathogenic. The encouraging preliminary intracellular NMDAR-mediated 
EPSP recording results and the findings in Chapter 4 support this view. 
To validate the use of this model, it would be important to determine whether 
the NMDAR-Ab injection was associated with a reduction in surface or total 
NMDARs. Without this key information, the link between the injections and any 
electrophysiological changes recorded can only be surmised. Along this line, it 
would also be important to determine if the IgG uptake seen in these slices is 
into microglia or neurons. 
However, the low diffusivity of antibodies through brain extracellular space 
(Daniel J. Wolak et al., 2015) and rapid clearance into blood by reverse 
transcytosis (Y. Zhang and Pardridge, 2001) would suggest that a single 
intracerebral injection is not the ideal model to study the effect of NMDAR-Abs 
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on network or single-cell activity. A more prolonged infusion of a relatively high 
IgG concentration (or addition of Fc fragments to patient IgG to saturate the Fc 
receptor-mediated efflux mechanism) seems like a more reliable method to 
obtain significant binding of NMDAR-Abs and some functional effect on NMDAR 
density has already been demonstrated using this technique (Planagumà et al., 
2014). 
Finally, effects of NMDAR-Abs at the single cell level, where factors that may 
introduce variability such as fluctuations in cell membrane potential can be 
controlled, need to be firmly established before progressing to investigating 
changes in network activity. This could be achieved using sharp microelectrode 
intracellular recordings as done here or by patch-clamp recordings. Obtaining 
sufficient recordings from interneurons may remain a challenge, but animal 
models with reduced NR1 expression on PV-positive interneurons (Korotkova et 
al., 2010) or optogenetic systems that allow selective stimulation or inhibition of 
PV-positive interneurons (Sohal et al., 2009) may circumvent this issue. 
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7.1 Overview 
NMDAR-Ab encephalitis is a recently identified disorder that raises many 
unanswered issues in terms of the best diagnostic tests, the mechanisms of 
antibody-induced disease, and the best treatment strategies. The work reported 
here first compared four different assays used for the detection of NMDAR-Abs 
in patients with suspected NMDAR-Ab encephalitis. The rest of the Thesis 
describes the acute and sub-acute effects of exposure to NMDAR-Abs from 
patients with NMDAR-Ab encephalitis on -frequency oscillations in the medial 
entorhinal cortex of rats. Entorhinal cortex oscillations were chosen as a model 
of a cognitively relevant rhythm that relies partly on normal NMDAR function 
(Cunningham et al., 2006).  
7.2 What is the most accurate diagnostic assay for the 
detection of NMDAR-Abs? 
For serum samples, the study undertaken as part of this thesis confirmed the 
high sensitivity of the live cell-based assay developed by Oxford (l-CBA, 
sensitivity 100%) but highlighted its low specificity (28.57%), limiting its 
usefulness as a single test for the presence of relevant antibodies in serum. 
The specificity of the l-CBA is likely to be underestimated in this study because 
of the deliberate over-representation of patients with known non-immune 
pathology and positive NMDAR-Abs by l-CBA.  
Several methods for improving l-CBA specificity have been suggested, including 
addition of a control step in positive samples to detect co-localisation with a 
commercial NR1 antibody, and performing a further study of the addition of CSF 
assays to serum testing. Addition of a more specific assay, such as IHC, which 
was found to be 100% specific and 85.71% sensitive, would also be helpful 
although this may not distinguish well between different CNS antibodies, in 
particular NMDAR, GABABR, and AMPAR antibodies. Indeed, the pattern of 
binding in the hippocampus for these three antigens is very similar (Dalmau et 
al., 2008; Lai et al., 2009; Lancaster et al., 2010). AMPAR-Ab and GABABR-Ab 
binding in the cortex, basal ganglia, and in particular in the cerebellum differ 
markedly from that of NMDAR-Abs (Lai et al., 2009; Lancaster et al., 2010), and 
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should therefore allow differentiation of the antibody when there is discrepancy 
between CBA and IHC result.  
It is important to note that the use of the terms sensitivity and specificity is 
somewhat premature here. The sensitivity and specificity of a diagnostic test 
can only be assessed in the presence of a gold standard for diagnosis, and this 
is not yet available for NMDAR-Ab encephalitis, although clinical criteria are 
expected to be published soon (A. Vincent, personal communication). The 
results of this study have been expressed as sensitivity and specificity for each 
test for practical purposes, although it may have been more correct to report 
only preliminary true-positive, true-negative, false-positive and false-negative 
rates. The diagnosis for patients included was classified by the treating 
physician as “definite”, “probable”, “possible”, and “unlikely” NMDAR-Ab 
encephalitis based on their experience and also using a diagnostic aid (see 
Appendix B) we prepared for this purpose. The robustness and reliability of this 
classification is therefore arguable, and has not been validated. 
For a definite diagnosis, the patient had to meet the following criteria: one of 
inflammatory CSF or teratoma; three of psychiatric symptoms, dysautonomic 
features, movement disorder, or seizures and/or EEG epileptiform 
abnormalities; and two of the five following additional features (encephalopathy, 
altered consciousness, improvement with immunotherapy or tumour removal, 
MRI changes, or tumour other than teratoma). The fallibility of these criteria is 
exemplified in the discussion of the clinical history of patient 3 in Appendix B, 
and further work to improve these and test their validity would be required. 
Insufficient samples were available to determine the sensitivity and specificity of 
the assays studied for CSF, and to examine whether NMDAR-Abs are present 
in all patients with NMDAR-Ab encephalitis, and thus if CSF testing should be 
preferred to serum testing. 
The commercial antibody detection kit developed by Euroimmun (Euf-CBA) had 
the lowest sensitivity (74.04%) but high specificity (92.86%), rendering it of 
limited usefulness. This finding contrasts with those reported by Wandinger et 
al. (2011), but is in keeping with previous unpublished experience at the Oxford 
Neuroimmunology laboratory. The poor sensitivity is unlikely to be due to 
problems with the execution of the assay or interpretation of the results in this 
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study as some serum samples with negative Euf-CBA scores scored highly on 
at least two of the other methods. It may be related to a factor intrinsic to the 
assay such as the over-fixation of the cells used to allow durability. 
The fixed cell based assay used in Barcelona (f-CBA) also requires combination 
with IHC and testing of CSF to be useful (Gresa-Arribas et al., 2014) and 
therefore offered no additional advantage over l-CBA in this study. It had lower 
sensitivity (71.43%) but higher specificity (85.71%) than l-CBA. 
Overall, combining IHC with l-CBA, and paying particular attention to IHC 
results when there is a discrepancy in results, may be the most accurate 
diagnostic assay approach. L-CBA has advantages over f-CBA for serum 
samples, as it is faster to perform, and f-CBA is associated with marked non-
specific background staining of all cells on the coverslip and also a lower 
density of cells on the coverslip. It is not possible to state whether CSF testing 
is necessary for the accurate diagnosis of NMDAR-Ab encephalitis from this 
study. 
The degree of discordance between assays in this study was surprisingly high. 
The design of the study and the time available to perform it did not allow 
investigation of the causes of this. The amount of antigen available for the 
NMDAR-abs to bind might be one relevant factor, and the assay with the most 
NR1 protein would be predicted to be the most sensitive. The amount of NR1 
protein in each preparation could be assessed using Western blot, and is likely 
to be higher in the CBAs than in IHC due to virally-driven expression of NR1 
(and NR2B). Fixation and permeabilisation are also likely to impact the amount 
of NR1 protein in the CBAs. However, contrary to expectation, IHC was more 
sensitive than both l-CBA and Euf-CBA. Additionally, end-titres were highest 
with IHC. The good sensitivity and los threshold of detection of IHC for both 
serum and CSF is thus still difficult to explain. It is worth noting that the 
discordance among assays was much more marked for serum samples than 
CSF, suggesting that non-specific binding plays a role in the discrepancies 
between assays. 
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7.3 Improving the NMDAR-ab assay comparison study 
One significant limitation of the comparison study performed here is the fact that 
the Barcelona f-CBA could only be approximated. Indeed, the permeabilisation 
step as well as the dilutant used for the samples and the washes had to be 
altered in order to reduce background staining with serum and obtain usable 
result. The Barcelona laboratory presumably does not experience the same 
level of background staining, as this would render their assay difficult to 
interpret and less time efficient, both essential qualities for a diagnostic test. A 
preferable approach would therefore have been for the Barcelona group to 
perform the f-CBA and IHC and score the results as part of a collaboration, 
such that their results could be compared with the results of the l-CBA 
performed at Oxford and the Euf-CBA performed as per Euroimmun 
instructions. 
The ideal comparison study should also be performed prospectively rather than 
retrospectively as done here, and a control group should be included 
comprising healthy controls, patients with other types of autoimmune 
encephalitis, and non-immune pathologies. 
7.4 Insights into the neurobiological impact of NMDAR-Abs 
Anterograde amnesia and other cognitive deficits occur early in NMDAR-Ab 
encephalitis and persist throughout the illness. They are likely to result from 
impaired function of the hippocampus and parahippocampal region, including 
the entorhinal cortex (Zola-Morgan et al., 1994), which lies at a critical juncture 
between the hippocampus and sensory cortices. The vast majority of cortico-
hippocampal inputs pass through the entorhinal cortex and an intact entorhinal 
cortex is required for correct encoding of spatial context in the hippocampus (Lu 
et al., 2013), and learning and retention of spatial tasks (Steffenach et al., 
2005). During the course of this thesis, memory impairments have been 
demonstrated in mice exposed to NMDAR-Abs intracerebroventricularly after a 
single injection (Pettingill, 2013) and prolonged infusion (Planagumà et al., 
2014). In both studies the performance of mice on memory tasks improved after 
cessation of administration of antibodies. Planagumà et al. (2014) were able to 
demonstrate parallel memory deficits and recovery and reduction followed by 
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recovery of total and synaptic NMDAR cluster density in the hippocampus of 
mice exposed to NMDAR-Abs.  
In view of the proposed mechanism of action of NMDAR-Abs being 
internalisation and degradation of cross-linked surface NMDAR, these findings 
would suggest a link between the NMDAR-mediated transmission and the 
memory deficits described. However, no study so far has satisfactorily 
examined the neural mechanisms underlying these changes or established a 
clear deficit of NMDAR-mediated transmission in neuronal networks. 
To establish whether NMDAR-Abs affect NMDAR-mediated neurotransmission, 
and in particular, if the function of NMDAR on parvalbumin-positive interneurons 
is altered, we examined the power and frequency of -frequency oscillations in 
the mEC of rats.  
7.4.1 Findings from acute application experiments in vitro 
Acute exposure to NMDAR-Abs by perfusion of live entorhinal-hippocampal 
brain slices with purified IgG from three patients with NMDAR-Ab encephalitis 
for one hour resulted in a reduction in -oscillation power, which persisted 
despite washout. No change in frequency was noted. Smaller declines in -
power were seen in naïve slices exposed to vehicle only, slices exposed to 
healthy control IgG, disease control IgG containing VGKC-Abs, and NMDAR-Ab 
Fab. The decreases in these groups of controls slices were very similar, 
suggesting that although there is an attrition in the population taking part in 
oscillatory activity over time in brain slices, the larger reduction in slices 
exposed to patient IgG is likely to be due to the NMDAR-Abs.  
No specific extracellular binding of patient IgG to the brain slices used in 
electrophysiological experiments was detected. Both patient and control IgG 
could be detected in the cytoplasm of individual cells in all regions of the slices, 
indicating that some IgG internalisation had occurred during the 1-hour 
electrophysiology experiments. It is unclear whether this is relevant to the 
electrophysiological findings, as some degree of non-specific IgG uptake by 
neurons is expected (Hill et al., 2009; Geis et al., 2010; Congdon et al., 2013; 
Iffland et al., 2013; Greenlee et al., 2014), particularly in brain slices where 
membrane damage to superficial cells is prevalent. 
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7.4.2 Findings from rats administered NMDAR-Abs intracerebrally 
To determine if more marked effects could be obtained by prolonged exposure 
to NMDAR-Abs, the spontaneous activity and pharmacologically induced -
oscillations in slices from animals having received an intracerebral injection of 
concentrated NMDAR-Abs were examined. No epileptiform or rhythmic activity 
was noted in pharmacologically unchallenged slices, suggesting there was no 
widespread loss of inhibition or toxicity from the IgG. There were no changes in 
power or frequency of -oscillations and no differences in the sensitivity to 
NMDAR antagonism in the mEC of rats having received a single intra-entorhinal 
injection of patient IgG up to three days previously. It is worth noting that the 
two patient IgG samples used produced opposite effects on -power however, 
with lower baseline power in animals administered Pt2 IgG and higher power in 
those given Pt3 IgG, raising the possibility that Pt3 IgG had lost activity over 
time. Evoked NMDAR-mediated excitatory post-synaptic potentials in pyramidal 
and stellate cells surrounding the injection site also appeared smaller in animals 
exposed to NMDAR-Abs in Pt2 IgG, although only a small number of cells was 
available for this analysis. Human IgG was detected in a small area around the 
injection site and within cells in close proximity. In two patient IgG-treated 
animals this reactivity appeared brighter and was present in several cells below 
the injection site, which also stained positive for CAMKII, identifying them as 
excitatory neurons. No co-localisation with markers of inhibitory interneurons 
and no reduction in the numbers of parvalbumin-positive cells were detected 
however, in keeping with the lack of change in -oscillation parameters. 
7.5 Strengths and weaknesses 
All in all, the results are not unequivocal. Patient IgG was able to reduce -
oscillation power and appeared to also diminish the NMDAR-mediated 
component of evoked synaptic responses. Both these findings support the 
presence of a reduction in inhibitory tone in functional cortical networks 
exposed to NMDAR-Abs. Using the reduction in the magnitude of the evoked 
NMDAR-mediated synaptic response in pyramidal and stellate cells as evidence 
supporting a reduction in inhibitory tone may seem counter-intuitive, but it is 
worth remembering that during physiological activity, the inhibition:excitation 
ratio is strongly in favour of inhibition. Interneurons in the entorhinal cortex and 
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other cortical areas are highly sensitive to NMDAR antagonism (Jones and 
Buhl, 1993; Homayoun and Moghaddam, 2007; Middleton et al., 2008; Carlen 
et al., 2011), and it is conceivable that if an antibody-mediated reduction in the 
NMDAR-mediated component of evoked responses is present in principal cells, 
it is also present in interneurons, where it will have much more dramatic effects 
on network activity and oscillatory rhythms. 
Several limitations of the techniques used in this study may have impacted the 
magnitude of the changes recorded. In the acute exposure experiments low 
NMDAR-Ab concentrations were used, compounding the likely slow and 
incomplete diffusion of antibodies through the slices. It is also not clear if 
incubation with NMDAR-Abs for one hour is sufficient to allow significant binding 
and internalisation of NMDAR. The findings of Mikasova et al. (2012), who 
demonstrated significant levels of internalisation after two hours in neuronal 
cultures, and of Congdon et al. (2013), who found that maximal neuronal IgG 
uptake had occurred within 30 minutes of incubation in hippocampal 
organotypic slice cultures, would suggest that at least some degree of specific 
binding and internalisation is possible within the duration of our experiments. 
This may also explain the lack of recovery in -oscillation power during the 
washout phase. 
In the subacute exposure experiments, the diffusion of patient IgG around the 
injection site was noted to be limited, even in animals examined three days after 
the injection. This is in keeping with the slow diffusion of IgG through brain 
extracellular space (Daniel J. Wolak et al., 2015) and rapid elimination of IgG by 
transcytosis after intraparenchymal injection (Y. Zhang and Pardridge, 2001). A 
single intraparenchymal IgG injection may therefore not have provided 
sufficiently prolonged and widespread exposure to NMDAR-Abs within the mEC 
to cause obvious network changes. 
One of the features of NMDAR hypofunction models of schizophrenia is 
reduced inhibition-to-excitation balance with, in particular, lower numbers of 
parvalbumin-positive interneurons (Gandal et al., 2012). Pyramidal neuron 
excitability is increased in NR1 knock-down mice in the hippocampus (Gandal 
et al., 2012) and in the prefrontal cortex of rats treated with an NMDAR 
antagonist (Homayoun and Moghaddam, 2007). In keeping with the essential 
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role of inhibitory activity by PV+ fast-spiking interneurons in the generation of -
oscillations, stimulus-evoked -oscillations are also impaired in NR1 knock-
down mice (Gandal et al., 2012) and mice with NR1 deletions from PV+ 
interneurons (Carlen et al., 2011). Whether a similar link exists between Ab-
mediated reduction in NMDAR and preferential deficits in inhibition remains 
unresolved, but is supported by our findings of reduced -power and NMDAR-
mediated evoked synaptic responses (see above). The early occurrence of 
seizures in NMDAR-Ab encephalitis supports the possibility of relative inhibition 
impairment although it is also possible that early inflammatory and possibly 
destructive histopathological changes in NMDAR-Ab encephalitis could mediate 
this. More recently, an increased susceptibility to seizure following PTZ 
administration was found in mice given a single bolus of NMDAR-Ab-positive 
IgG compared to mice receiving control IgG (Wright et al., 2015a). No increase 
in apoptosis markers had been noted in these animals, and although direct 
measures of neuronal excitability were not performed, it is therefore likely that 
the seizures reflected an impairment of inhibition. Moscato et al (Moscato et al., 
2014) have reported similar degrees of internalisation of NMDAR on excitatory 
and inhibitory neurones in hippocampal neurone cultures and also found that 
the amplitude and frequency of miniature inhibitory post-synaptic currents 
(mIPSCs) were similar in cultured hippocampal neurones treated with patient or 
control CSF for 24 hours. Instead, the density of inhibitory synapses onto 
excitatory neurons was reduced, which the authors considered to be a 
homeostatic response to the lower NMDAR concentration at synapses.  
However, using mIPSCs as a measure of GABA-ergic neurotransmission is 
misleading. mIPSCs are recorded in the presence of tetrodotoxin, a Na+ 
channel blocker that blocks action potentials generation. mIPSCs are caused by 
quantal release of neurotransmitter rather than action potential-mediated 
mechanisms, and therefore do not estimate use-dependent GABA release. A 
reduction in synaptic NMDAR content in interneurons might be expected to 
cause a reduction in principal cell inhibition when glutamate is present to 
activate glutamatergic synapses but not in the resting state when there is 
minimal input to interneurons (note that mIPSCs were recorded in the presence 
of an AMPAR antagonist). This is supported by the findings of Li et al (Li et al., 
2002), who showed that the NMDAR antagonist MK-801 reduced the frequency 
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and amplitude of spontaneous and evoked IPSCs in pyramidal cells in the 
posterior cingulate and retrosplenial cortices, but had no effect on mIPSCs, 
such that the effect of MK-801 on interneurons relied on action potential 
dependent mechanisms. 
In this study, the use of -oscillations and evoked responses in brain slices 
circumvented these issues by providing functional networks with endogenous 
glutamate in which to observe use-dependent physiologically relevant 
responses. A significant excess reduction in -power in the mEC was found 
after slice perfusion with patient IgG compared to control IgG. This would be in 
keeping with a greater effect on PV+ fast-spiking cells, whose activity 
synchronises principal cell firing in -oscillations, however no direct proof of this 
is available at present. No reduction in PV+ interneurons was found in the 
injected animals and evoked IPSPs were obtained in too few cells to allow 
meaningful comparison. Proof would require intracellular recordings ideally from 
interneurons to examine the nature and strength of NMDAR and AMPAR-driven 
synaptic inputs, or from principal cells, where the pattern of invading IPSPs and 
EPSPs could be scrutinised to determine relative deficits. 
7.6 Future studies 
A number of studies would need to be carried out to explain and complete the 
findings in this thesis. Firstly, -oscillation recordings in the presence of patient 
IgG from which NMDAR-Abs have been pre-absorbed would be required to 
confirm the effect seen in this thesis is NMDAR-Ab related. Secondly, the 
mechanisms underlying the reduction could be investigated using intracellular 
recordings as described above. Finally, an effect on surface NMDAR density or 
synaptic content would need to be demonstrated. This is likely to be complex in 
brain slices were techniques based on surface protein biotinylation have been 
shown to be unreliable (Grosshans et al., 2002a; Grosshans et al., 2002b). 
Future studies should be performed using a more reliable method of antibody 
delivery to the brain parenchyma, such as prolonged infusions. The effect of 
antibodies at a single-cell level should also be firmly established before moving 
on to network activity although both mediums are important to develop an 
understanding of the neurobiological mechanisms underlying temporal lobe 
dysfunction in NMDAR-Ab encephalitis. Studies using optogenetic activation on 
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specific neuronal subtypes such as PV+ interneurons and genetic models such 
as mice lacking NR1 expression in PV+ interneurons are likely to be useful in 
that endeavour. 
NMDAR-Ab binding detected immunohistochemically in rodent brain slices is 
strongest in the hippocampus due to the high concentration of NMDAR in this 
brain region (Moscato et al., 2014). This in itself is likely to be indicative of its 
importance in memory and learning. Long-term infusion of CSF from patients 
with NMDAR-Abs into the cerebral ventricles of mice has been shown to cause 
intense NMDAR-Ab deposition in the hippocampus (Planagumà et al., 2014). 
This region therefore seems to be a strong candidate for assays of the effects of 
NMDAR-abs on NMDAR-dependent synaptic transmission and network activity.  
After the submission of this thesis, a further study demonstrating just such an 
effect was published (Planaguma et al., 2016), closing the gap between 
reduced surface NMDAR loss and behavioural changes in the partial animal 
model described above (Planagumà et al., 2014). In their (2016) study, the 
authors replicated their work showing memory impairments paralleling the 
course of NMDAR-Ab deposition in the hippocampus of mice receiving an 
intracerebral infusion of CSF from patients with NMDAR-abs. They also 
performed slice electrophysiology experiments ex vivo examining LTP in the 
hippocampus. They found that short-term plasticity, assayed using a paired 
pulse protocol, was similar in animals receiving patient or control CSF, 
indicating that pre-synaptic transmitter release probability was unaffected. 
However, LTP as indicated by an increase in the slope of the evoked field 
EPSP in CA1, was markedly reduced in animals having received patient CSF 
compared to control CSF.  
LTP at the Schaffer collateral-CA1 synapses is NMDAR-dependent, and a 
mouse model with NR1 loss restricted to the CA1 area of the hippocampus has 
previously demonstrated absent CA1 LTP and selectively impaired spatial 
memory (Tsien et al., 1996). It is therefore very likely that the antibody-mediated 
reduction in surface and synaptic NMDAR content demonstrated by Planaguma 
et al. (2016) throughout the hippocampus of the mice receiving patient CSF was 
responsible for the LTP deficit in these mice. 
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Additionally, they elegantly demonstrate the first potentially relevant non-
immune-based translational therapeutic strategy. Indeed, Mikasova et al. (2012) 
had shown that the interaction between NMDAR and Ephrin B2 receptors was 
weakened by NMDAR-abs, leading to removal of NMDARs from the synapses 
and subsequent internalisation. Activating Ephrin B2 receptors using Ephrin B2 
prevented the loss of NMDARs. Indeed, Ephrin B2 receptors are felt to stabilise 
and cluster NMDAR at excitatory synapses. Planaguma et al. (2016) added 
Ephrin B2 to the CSF infused in half the mice receiving patient and control CSF, 
and found that this prevented the memory impairment, the reduction in surface 
and synaptic NDMAR density and the loss of LTP. Although translating such a 
finding for use in the human disease will require much more work, including 
developing a fuller animal model of NMDAR-Ab encephalitis, it is an 
encouraging example of hypothesis-led laboratory discoveries finding practical 
and potentially therapeutic applications. 
7.7 Summary 
Publication of the results of the studies undertaken as part of this thesis are 
planned as follows: 
7.7.1 Assay study 
 Poor agreement between assays for serum sample results 
 Good agreement when using CSF 
 Performance of assays calculated using available clinical data (data 
collection still on-going, as is comparison of assays using a larger cohort 
of samples) shows: 
o Good performance of IHC with satisfactory “sensitivity” and 
excellent “specificity”  
o L-CBA also has good sensitivity, but at the expense of specificity 
o Euf-CBA has good specificity at the expense of sensitivity 
o Overall all tests require careful interpretation if performed using 
serum, in the light of clinical details and laboratories using Euf-
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CBA should send away negative samples for re-testing on IHC 
and a CBA at a reference laboratory. 
7.7.2 Electrophysiology 
 Patient IgG reduces -oscillation power in acute slices in the mEC but not 
hippocampus 
 Further experiments using a lower dilution on IgG will hopefully confirm 
this and allow construction of a dose-response curve 
 At present, no mechanistic explanation for this effect is available but it is 
likely to be related to NMDAR internalisation in the slices. 
 The results of the intracerebral injection studies will not be included in the 
publication, as the model did not appear to result in sufficient antibody 
binding to NMDARs. 
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Appendix A Clinical details of patient samples used in this 
thesis 
Patient 2 
Patient 2 was a 25-year-old woman who developed headache and non-specific 
flu-like symptoms with a sore throat one week before becoming confused, 
disorientated and febrile. There also appeared to be intermittent anisocoria. 
Over the following 24 hours, the confusion worsened and was accompanied by 
anxiety and paranoid thoughts. She was admitted to hospital and started on 
antiviral therapy and antibiotics, as well as antiepileptic medication. 
Lumbar puncture revealed a lymphocytosis with 120 lymphocytes per mm3. 
CSF protein was modestly raised. Extensive virological investigations were 
negative. Over the next two days she became increasingly agitated and 
displayed catastrophic thinking. This was promptly followed by somnolence and 
reduced responsiveness. On the 6th day of her admission, she responded only 
to pain and MRS score was 5. She was also diagnosed with a pulmonary 
embolism, which was treated with anticoagulation on a high dependency unit. 
Brain imaging with MRI showed bilateral hippocampal signal change. 
On the 7th day of admission, she developed periodic grimacing movements. 
EEG showed no evidence of epileptiform activity during these however. 
Abdominal distension was also noted. 
As there had been no response to antiviral treatment with acyclovir, ganciclovir 
and ribavirin and viral PCR studies had been negative, anti-neuropil antibodies 
were looked for and NMDAR-Abs were detected. Imaging of chest, abdomen 
and pelvis with CT showed no abnormalities. 
On day 10 of admission she developed excessive secretions from nose and 
mouth. 
Pulsed intravenous methylprednisolone was commenced on day 25 of the 
illness, followed by high-dose oral prednisolone. She also received a course of 
intravenous immunoglobulin but failed to respond. An ovarian teratoma was not 
found, but she eventually underwent oophorectomy on day 160 of the illness as 
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she had failed to respond to treatments. She died on day 190, having remained 
at MRS 5 during the entire course of her illness. 
Patient 3 
Patient 3 initially presented in 2006 at the age of 15 with an acute onset of 
frequent complex partial seizures, visual hallucinations, agitation with 
aggressive outbursts, intermittent drowsiness and reversal of sleep-wake cycle. 
There was high signal in the right insular cortex on brain imaging with MRI and 
a CSF lymphocytosis with normal protein and glucose. EEG revealed diffuse 
slow wave activity over the right hemisphere. CSF PCR studies were negative 
for herpes viruses. Treatment with intravenous acyclovir and anticonvulsants 
did not lead to any improvement and she was therefore given a course of 
intravenous immunoglobulin for a presumptive immune-mediated encephalitis. 
Seizures and agitation settled, but she continued to be significantly cognitively 
impaired. 
She re-presented in 2009 with a 4-day history of acute agitation, auditory 
halllucinations, reversal of sleep-wake cycle, and impulsive behaviours. No 
seizures or focal neurological signs were noted. Brain imaging with MRI and 
CSF studies were normal. CSF viral PCR studies were negative. EEG findings 
were similar to her previous admission with mild slowing over the right 
hemisphere but no epileptiform activity. 
On this occasion, NMDAR-Ab encephalitis was suspected and the diagnosis 
was confirmed on serum assay. No teratoma was detected using CT scanning 
of chest, abdomen and pelvis as well as pelvic ultrasound. 
She received intravenous immunoglobulin and high dose oral prednisolone with 
little benefit initially. She started to improve after plasma exchange. Slow 
improvement continued after this with a progressive decline in NMDAR-Ab 
level. She was treated with azathioprine as a steroid-sparing agent from 2010. 
There have been no further relapses, and she slowly recovered to a score of 
96/100 on the Addenbrooke’s cognitive examination. She is currently working 
full-time and is no longer on immunosuppressing medication, but she continues 
to have a low positive NMDAR-Ab titre. 
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Appendix B Clinical decision aid devised for the assay 
comparison study 
Table B.1 Features required for a clinical diagnosis of NMDAR-Ab encephalitis 
CORE FEATURES SPECIFIC FEATURES ADDITIONAL FEATURES 
Inflammatory CSF Psychiatric symptoms 
 
Encephalopathy 
Teratoma Dysautonomic features Altered consciousness (form 
stupor to coma) 
 Movement disorders Improvement with 
immunotherapy/tumour removal 
 Seizures and/or EEG 
epileptiform abnormalities 
MRI alterations 
  Tumour other than teratoma 
DIAGNOSIS Core features Specific features Additional 
Features 
DEFINITE 1/2 3/4 2/5 
PROBABLE 1/2 <3 2/5 
 or   
 0 3/4 2/5 
POSSIBLE 1/2 1/4 <2 
 or   
 0 2/4 2/5 
UNLIKELY 0 <2 Irrelevant 
For example, patient 2 above would score 1/2 on the core features 
(inflammatory CSF) and 3/4 on specific features (psychiatric symptoms, 
movement disorder, and dysautonomic features all present). She had 3 of the 5 
additional features (encephalopathy, altered consciousness, and MRI 
abnormalities). She therefore qualifies for a definite clinical diagnosis of 
NMDAR-Ab encephalitis.  
For patient 3, both episodes need to be considered together in order for a 
probable diagnosis to be made. When both episodes are considered together, 1 
of the 2 core features were present (inflammatory CSF; first episode), as were 2 
of the 4 specific features (psychiatric symptoms and seizures), and 3 of the 5 
additional features (encephalopathy, improvement with immunotherapy, and 
MRI abnormalities). In this case, the presence of autoimmune encephalitis was 
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strongly suspected from the course of the first episode. The second episode 
was characterised by encephalopathy and psychiatric features, which on their 
own would be insufficient for anything above a possible NMDAR-Ab 
encephalitis diagnosis. However, the presence of a previous episode with 
clearer encephalitic features and the patient’s age and sex, render any other 
diagnosis very unlikely.
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